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1 Summary 
 
Hematopoietic stem cell transplantation (HSCT) is a commonly used therapy in patients with hematopoietic 
disorders, when confentional chemotherapy is no possible treatment or has not been effective. The main 
complication after HSCT besides relapse is graft-versus-host disease (GVHD), where immunocompetent 
donor T cells can recognize recipient cells as foreign through differences in their human leukocyte antigens 
(HLA) and thus start an immune reaction against the recipient. GVHD leads to tissue damages, whereas 
thymus, secundary lymphoid tissues, skin, liver and intestine are primarily affected, and can also cause death. 
Thus, it is of interest to diagnose GVHD as soon as possible to be able to start an early treatment and to 
prevent a further progress of the disease. Nowadays GVHD is diagnosed only on clinical symptoms. 
The aim of our study is to find molecular markers for diagnosing and predicting GVHD before symptomes 
occur as well as to be able to ameliorate the outcome of HSCT in further studies by downregulating GVHD 
development through influencing regulatory molecules. 
In our study 76 patients with a median age of 45, who applied allogeneic HSCT were included. Leukemia and 
myeolodysplastic syndromes (MDS) were the most common diagnosed diseases in those patients. Bone 
marrow stem cells (BMSC) and peripheral blood stem cells (PBSC) were the main stem cell sources used for 
HSCT, whereas only 7 patients applied cord blood stem cells (CBSC) as graft. We analyzed the gene 
expression levels of IFN-γ, IL-10, IL-18, ICOS, Foxp3, FuT7 and B7-int in CD4+ and CD8+ T cells before 
HSCT and at different timepoints after HSCT as well as the donors’ gene expression levels with real time 
quantitative-PCR (RQ-PCR) and measured also the donors’ and patients’ (different timepoint occassions) 
cytokine protein levels of IFN-γ, IL-10, IL-18, IL-12, IL-17 and IL-23 in the plasma with enzyme-linked 
immunosorbent assay (ELISA). The gene expression and protein plasma levels were analyzed to find a 
correlation between those levels and the appearance of GVHD. 
In conclusion, IFN-γ could be used as a predicting molecular marker for aGVHD development, whereas IL-
18, Foxp3, FuT7 and ICOS are possible diagnostic markers. Higher IFN-γ plasma levels (> 200 pg/ml) at the 
day of HSCT (p = 0.009) are correlated with a decreased aGVHD outcome, whereas IL-18 plasma levels are 
increased at the onset day of aGVHD (p < 0.001). Foxp3 (p = 0.005 – 0.020), FuT7 (p = 0.001 – 0.023) and 
ICOS (p = 0.005 – 0.029) gene expression levels are enhanced at different timepoints after HSCT in case of 
GVHD. 
IFN-γ may be a key cytokine which production intervention could probably lead to a reduced occurrence of 
aGVHD. 
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2 Aim of the study 
 
The overall aim of the study is to find a correlation between cytokine plasma levels as well as T cell gene 
expression levels and the appearance of GVHD after HSCT. 
Some specific aims are: 
• To predict GVHD before symptoms occur. 
• To be able to start an earlier treatment of GVHD through molecular diagnostic markers, thus 
ameliorating the survival rate after HSCT. 
• To find key cytokines and regulatory molecules in GVHD that theoretically could be influenced to 
downregulate the occurrence of GVHD. 
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3 Introduction 
 
     3.1 Preface 
 
In our study patients with different hematopoietic disorders applied hematopoietic stem cell transplantation 
(HSCT) as treatment. Thus an overview of HSCT and its complications focusing on graft-versus-host disease 
(GVHD) and the main appearing hematopoietic diseases is given in the following section. Furthermore the 
measured genes and cytokines that may play a crucial role in the development of GVHD are explained. 
 
 
     3.2 Hematopoietic Stem Cell Transplantation (HSCT) 
 
The first bone marrow transplantation (BMT) was accomplished in 1939. The idea was to cure aplastic 
anemia by injecting human bone marrow cells to the patient which should lead to reestablishing of a normal 
blood cell level. But it was without success (Léger and Nevill, 2004). In 1957 Thomas Donnall, who got the 
Nobel Prize for his work, ran the first BMT on a leukemia patient, who got irradiated before the 
transplantation. The BMT led to newly matured blood cells, but the patient died in the end (Barkholt and 
Ringdén, 2004; Thomas, et al., 1959). Georges Mathé succeeded BMT to patients, whose bone marrow was 
damaged due to a reactor accident and have recovered their own bone marrow after transplantation. Through 
further studies Thomas Donnall improved BMT and its break through came in the 1970s through the 
identification of the human leukocyte antigens (HLA) system, leading to transplantations of HLA receptor-
identical donors (Barkholt and Ringdén, 2004; Gatti, 1968). 
Nowadays HSCT is applied to many patients with hematological malignancies, non-malignant bone marrow 
disorders and genetic diseases associated with abnormal hematopoiesis and function (Uzunel, 2003). The 
term BMT is meanwhile less commonly used and often replaced through HSCT, because bone marrow is not 
the only stem cell source used in transplantations nowadays. The aim of the transplantation is that the 
abnormal hemolytic system is restored with the healthy donor system as donor cells are taking over the blood 
cell production.  
HSCT is divided into allogeneic, autologous and syngeneic transplantations. Allogeneic implies that the stem 
cells are taken from a not genotypical ident donor, like a HLA-ident sibling or a HLA-like donor (Barkholt 
and Ringdén, 2004; Léger and Nevill, 2004). In the case of an autologous HSCT the patient gets its own stem 
cells, which were taken before conditioning and properly manipulated. The main risk factor of autologous 
HSCT is that tumor cells remain after their abatement. But finding a HLA-matched donor for allogeneic 
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HSCT can be complicated. HLA-identical siblings are only available in about 30% of the cases. HLA-matched 
unrelated donors (MUD) are disposable with a 60-90% probability depending on the patient’s origin. A 
syngeneic HSCT is done very rarely, because a monozygotic twin is needed as donor. A huge advantage is 
though that no immunosuppression is needed (Barkholt and Ringdén, 2004). 
 
 
          3.2.1 Conditioning 
 
Conditioning is a pre-transplantation treatment with two main aims: the elimination of the cancer cells and 
the suppression of the immune system, so that the graft will be engrafted and not rejected (Barkholt and 
Ringdén, 2004; Léger and Nevill, 2004; Uzunel, 2003). There are different types of conditioning regimes. If the 
recipient is in quite good health, showing no comorbidities, do not have a fast proceeding disease, and is 
neither too old (>60 years) nor a young child, the myeloablative conditioning is generally the method of 
choice (Barkholt and Ringdén, 2004; Léger and Nevill, 2004; Sala-Torra et al., 2008). In this conditioning 
regime chemotherapy (with high-dose cyclophosphamide application) with or without combination of total 
body irradiation (TBI) is applied (Barkholt and Ringdén, 2004; Fefer et al., 1974; Léger and Nevill, 2004). In 
case of hematological malignancies it is important that the abnormal cells are eliminated, reached through 
chemotherapeutic agents that inhibit cell proliferation and through radiotherapy, whereas the bone marrow 
that will be replaced by the donor’s one, is usually additionally irradiated. Accessorily the immune system has 
to be restrained via conditioning, like in non-malignant hematological diseases, so that the stem cell 
transplant will not be rejected (Barkholt and Ringdén, 2004; Léger and Nevill, 2004; Storb and Thomas, 1983; 
Thomas et al., 1975). TBI can also be fractioned into different sub-irradiations, leading to a higher total dose 
rate in the end, which is seen to minimize the risk for severe complications in some diseases, but not in 
leukemia (Barkholt and Ringdén, 2004). 
If the patient’s conditions are not appropriate to the myeloablative conditioning, like in case of higher age or 
organ failure, a milder form, the so-called non-myeloablative or reduced-intensity conditioning (RIC) is 
adopted (McSweeney and Storb, 1999; Sala-Torra et al., 2008; Slavin et al., 1998, Welniak et al., 2007). The aim 
of this method is that not all tumor cells are getting destroyed through the conditioning, using “lower doses of 
cytoreductive treatments and incorporating more directed immunosuppressive agents” (Welniak et al., 2007) 
(Barkholt and Ringdén, 2004; Mohty et al., 2005; Sala-Torra et al., 2008). The remaining malignant cells 
should be eliminated by the donor’s stem cells. 
If the patient suffers from a severe immunodeficiency, no conditioning is needed, because the immune system 
is not able to reject the transplant (Barkholt and Ringdén, 2004).  
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          3.2.2 Stem Cell Sources 
 
There are three main stem cell sources used for HSCT: bone marrow that is either taken from the spinal cord 
or the pelvic bone, peripheral blood and umbilical cord blood (UCB) (Gluckman et al., 1997; Kurtzberg et al., 
1996; Welniak et al., 2007). Nowadays the stem cell harvesting from peripheral blood is more common than 
the ”direct aspiration from the bone marrow” (Léger and Nevill, 2004). For peripheral blood stem cell (PBSC) 
harvesting the donor has to be treated with hematopoietic growth factors, granulocyte colony-stimulating 
factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF), respectively so that the stem 
cells proliferate and circulate into the periphery (Barkholt and Ringdén, 2004; Léger and Nevill, 2004; Schmitz 
et al., 1995). The stem cells can then be isolated from the donor’s blood via their CD34 surface marker 
(Barkholt and Ringdén, 2004). A big advantage of the peripheral blood as stem cell source is that neutrophils 
and platelets recover faster after the engraftment as with bone marrow or cord blood HSCT, and more stem 
cells can be gained (Bensinger et al., 1993; Welniak et al., 2007). It is better if more stem cells can be 
transplanted, because the engraftment will be faster and the risk for rejection or infections is lowered (Deeg et 
al., 1985; Paulin et al., 1987). Umbilical cord blood as stem cell source has the advantage that it can act as a 
more tolerant immune system, because it is more immature, leading to a lower GVHD risk but otherwise to 
an enhanced rejection that is maybe due to the low cell amount (Gluckman et al., 1997; Kurtzberg et al., 1996; 
Wagner et al., 1995). In the 1990s umbilical cord blood was only used in children, based on its low stem cell 
amount, but nowadays it is also applied in adults by transplanting two cord bloods from unrelated donors or 
by in vitro expansion of cord blood cells (Léger and Nevill, 2004; Laughlin et al., 2004).  
The transplanted stem cells ”home to the bone marrow” (Léger and Nevill, 2004) in the patient, where they 
start to re-establish the hematopoiesis. During the time period from conditioning to engraftment, when a 
normal blood cell amount and immunoreconstitution is reached, the recipient’s immune system is very 
weakened and coincides with an enhanced infection risk that is diminished by antifungal and antiviral 
prophylaxis (Barkholt and Ringdén, 2004; Léger and Nevill, 2004). Until the immune system is fully recovered 
with normal T and B cell activity it takes about one year (Lum, 1987).  
 
          3.2.3 Complications 
 
The most common complications relating to HSCT are GVHD, relapse and graft failure or rejection, but also 
”organ damage, blood vessel damage, cataracts, secondary cancers and death” (Barkholt and Ringdén, 2004) can 
occur (Uzunel, 2003). Organ and cell damage is often due to conditioning, whereas secondary cancers can 
occur, if not all malignant cells have been deleted leading to metastasis forming and tumor cell dissemination. 
A high risk factor of stem cell transplanted patients is their impaired immune system that can cause severe 
infections, which can lead to death (Welniak et al., 2007). Most infections are effected by host’s own 
microorganisms and the activation of herpes simplex virus (HSV) or cytomegalovirus (CMV) (Barkholt and 
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Ringdén, 2004). 
Host-versus-graft (HVG), or rejection is a disease, where the immune reaction is caused by remaining 
recipient immune cells that can recognize the graft leading to graft rejection, occurring at about 10% of HSCT 
(Uzunel, 2003). Different host cells like “NK cells, NKT cells, γδ T cells, and/or CD4+ and CD8+ T cells” 
(Welniak et al., 2007) recognizing donor’s HLA can mediate rejection (Haraguchi et al., 2005, Welniak et al., 
2007). Graft rejection is primarily seen by transplants of MUDs and T cell-depleted grafts (Welniak et al., 
2007).  
Relapse, where the disease recurs after applied HSCT, appears more frequently in autologous than in 
allogeneic HSCT, because the positive graft-versus-leukemia (GVL) effect is missing (see page 13). But relapse 
can also occur after allogeneic HSCT. In case of early relapse the mortality rate is high, whereas patients with 
later relapse may undergo additional chemotherapy with second HSCT, although the outlook for a long-term 
survival is also low in this relapse group, due to the toxicity of a further treatment (Mortimer et al., 1989; 
Radich et al., 1993; Uzunel, 2003). 
 
 
     3.3 Graft-versus-host disease (GVHD) 
 
GVHD, an analogous disease to rejection, is the ”main reason for transplant-related mortality (TRM)” (Uzunel, 
2003) and thus the major hindrance for a positive HSCT outcome (Anderson et al., 2008; Fujimori et al., 
2000; Uzunel, 2003). GVHD occurs, when immunocompetent graft T cells differ from the recipient’s minor 
histocompatibility antigens (MiHAs) or HLA and thus can recognize them as foreign and start an immune 
reaction against the recipient (Ferrara, 2007; Krenger et al., 1997; Reddy and Ferrara, 2003). The recipient 
cells are destroyed by this immunological reaction and its immune system is suppressed through conditioning 
and thus cannot innitate an immune response against the allogeneic donor cells (Abbas and Lichtman, 2003: 
p.388) 
Different factors can lead to a higher risk for developing GVHD. Higher age (>50 years) of the donor or 
recipient, disparities in the HLA-locus or the MiHAs between donor and recipient and also specific host 
alleles in the HLA-locus play crucial roles in GVHD development (Bross et al., 1984; Kollman et al., 2001; 
Rowe et al., 2006; Welniak et al., 2007). Male recipients with female donors have a higher risk for developing 
chronic GVHD (cGVHD) due to disparities between MiHAs encoded on the Y and X chromosomes, whereas 
they have a lower risk for relapse that is probably due toa positive influence on the GVL effect (Miklos et al., 
2004; Randolph et al., 2004). Such well characterized MiHAs that are encoded by genes on the Y chromosome 
and induce T cell response through female transplants are for example dead box RNA helicase Y (DBY), 
ubiquitously transcribed tetratricopeptide repeat gene, Y-linked (UTY) and drosophila fat-facets related Y 
gene (DFFRY) (Miklos et al., 2004; Vogt et al., 2000; Wang et al., 1995). A female donor, who was immunized 
through an earlier blood transfusion or pregnancy against these antigenes, increases the risk for cGVHD in a 
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male recipient accessorily (Bross et al., 1984; Miklos et al., 2004; Rowe et al., 2006). 
Different conditionings as well as “the tissue source, purity and number of donor immune cells that are infused” 
(Welniak et al., 2007) can affect the development of GVHD too (Barkholt and Ringdén, 2004). If killer 
immunoglobulin-like receptors (KIR) that can recognize HLA-alleles and its ligand exhibit disparities 
between donor and recipient and through the KIR’s influence on NK cell activity GVHD, rejection, and also 
the positive graft-versus-tumor (GVT) effect can be affected (Davies et al., 2002; Farag et al., 2006). In UCB 
more differences in MiHAs between donor and recipient occur than in HLA-identical related bone marrow 
grafts, but although the risk for severe GVHD is lower. This may be explained through two effects that on the 
one hand cord blood stem cells (CBSC) are not that mature, thus not that affective against recipient’s antigens 
and on the other hand MiHAs act as targets for GVT activity (Barker et al., 2001; Goulmy et al., 1983; 
Takahashi et al., 2007). 
 
          3.3.1 The Positive GVL/GVT Effect 
 
A positive effect of GVHD can be the occurrence of GVL/GVT. Cytotoxic donor T and NK cells can react 
against leukemia or malignant cells that remained after conditioning leading to their elimination (Barkholt 
and Ringdén, 2004; Robertson and Ritz, 1990). TNF-related apoptosis-inducing ligand (TRAIL) that can 
induce caspase-8-dependent apoptosis is seen to be important for the positive GVL/GVT effect (Reddy and 
Ferrara, 2003). If the patient survives GVHD the probability for relapse is very low due to GVL/GVT (Weiden 
et al., 1981). Studies are going on with the aim to prevent the GVHD development but to maintain the 
positive GVL effect of donor T cells to elevate the patients’ survival rate (Dazzi et al., 2000; Mackinnon et al., 
1995). 
 
               3.3.2 Acute and Chronic GVHD 
 
GVHD can be distinguished in two different diseases, acute and chronic GVHD (Welniak et al., 2007).  
Acute GVHD (aGVHD) normally appears within the first 100 days after transplantation. The first organs that 
are affected are the thymus and secondary lymphoid tissues, the skin, the liver and the intestine, whereas also 
the lung can be affected (Ferrara, 2007; Welniak et al., 2007). aGVHD occurs in about 40% of HLA-identical 
siblings and in about 80% of unrelated donor transplants (Léger and Nevill, 2004). Four grades (I-IV) with 
different strength can occur, whereas grade III and IV leads to a death rate of 80%. The reason for death is 
often a consequence of both conditioning and GVHD that cause immunosuppression and can therefore lead 
to infections with opportunistic pathogens (Ferrara, 2007; Przepiorka et al., 1995). A TH1 type immune 
response (IL-12, IL-2, IFN-γ) has been seen to be the main trigger in the development of aGVHD, but also 
TH2 donor T cells are involved in its development (Mohty et al., 2005; Reddy and Ferrara, 2003). It is still 
debated how a restriction towards TH1 or TH2 cell response contributes to the outcome of GVHD (Murphy et 
 14 
al., 1998). IL-12 induces TH1 cells leading to monocytes and macrophages activation whereby inflammatory 
cytokines “such as tumor necrosis factor-α (TNF-α), IL-1 and IL-6” (Mohty et al., 2005) are produced. This 
cytokine storm can lead to the development of aGVHD (Reddy and Ferrara, 2003). But early polarization of 
donor T cells to TH1 cells by host cytokines can also extenuate aGVHD, as has been shown in mice so far 
(Brok et al., 1993; Reddy and Ferrara, 2003).  
It is quite well understood how GVHD arise. Its pathophysiology is classified into three main stages (Krenger 
et al., 1997; Welniak et al., 2007). The pathophysiology of GVHD is shown in figure 1. The first stage primes 
the immune response triggered by aftereffects of the conditioning that lead to host tissue damage and 
distribution of pro-inflammatory cytokines, primarily TNF-α and IL-1 (Ferrara, 2007; Krenger et al., 1997). 
The released cytokines activate host and donor antigen-presenting cells (APCs) and “upregulate costimulatory 
molecules (B7/CD28 and CD40/CD40L)” (Welniak et al., 2007). 
Through this step the second stage is induced, where the donor T cells get activated in secondary lymphoid 
tissues, primed through donor or host APCs (cross-presentation) by presentation of HLA and MiHA 
mismatched antigens (Ferrara, 2007; Krenger et al., 1997, Matte et al., 2004). If dendritic cells, the main APCs, 
do not get stimulated through inflammatory cytokines no T cell activation occurs leading instead to tolerance 
(Reddy and Ferrara, 2003). In the second stage the activated donor T cells primarily produce type I cytokines 
like IL-2, a T cell growth factor, and IFN-γ (Krenger et al., 1997). If IL-2 binds to CD25 (IL-2R α-chain), T 
cells produce more IFN-γ and IL-4, B and NK cell proliferation is enhanced as well as anti-apoptotic protein 
B cell lymphoma-2 (Bcl-2) is induced (Abbas and Lichtman, 2003, p.265). IFN-γ can increase GVHD 
development through its induction of inflammatory cytokines and nitric oxide (NO) (Teshima and Ferrara, 
2002). A converse effect of IFN-γ on GVHD is debated in the discussion (see below). 
In the third stage activated and differentiated donor T cells distribute phagocytes stimulating cytokines and 
migrate to GVHD target tissues, where T cells and stimulated mononuclear phagocytes, especially NK cells 
damage the tissues (Ferrara, 2007; Krenger et al., 1997; Welniak et al., 2007). Through tissue damage further 
inflammatory cytokines, like TNF-α, IL-1, IL-2 and IFN-γ are produced leading to enhanced homing of T 
cells, neutrophils and monocytes to target tissues (Reddy and Ferrara, 2003; Welniak et al., 2007). The 
destruction of the tissue in the effector stage, when GVHD is already developed, occurs via two main 
pathways. Mismatches in the HLA-A, -B or -C genes lead to lysis of the cells through the perforin/granzyme 
pathway by CD8+ cytotoxic T cells (CTLs), whereas HLA-D mismatches cause GVHD by CTL lysing cells 
through the Fas/FasL pathway (Ferrara, 2007; Pinkoski et al., 2000). TNF-α is essential in the effector stage of 
aGVHD, by upregulating alloantigen presentation through activating dendritic cells, by inducing 
inflammatory cytokines and by its induction of apoptosis and necrosis (Krenger et al., 1997; Laster et al., 
1988). Besides tissue damage “transmission of infectious agents, consecutive multi-organ failure and death” 
(Rieger et al., 2006) are the main consequences of GVHD (Rieger et al., 2006). 
30-50% of the patients, who survive the first 3 months after HSCT, develop cGVHD (Barkholt and Ringdén, 
2004). They are not obliged to have a previous aGVHD (80% have developed aGVHD), but it heightens the 
risk for cGVHD development as well as increased donor or recipient age and transplantation of not T cell- 
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depleted grafts (Atkinson et al., 1990; Barkholt and Ringdén, 2004; Storb et al. 1983). It is believed that “new T 
cells produced after the donor’s bone marrow has engrafted in the patient may cause cGVHD” (Barkholt and 
Ringdén, 2004). The first organs that are affected by cGVHD are skin, lungs, eyes and mucosa, but also 
exocrine glands, gastrointestinal tract and serous membranes are targeted (Aractingi et al., 1996; Higman and 
Vogelsang, 2004; Welniak et al., 2007). cGVHD has the characteristics of autoimmune diseases that are linked 
to a damaged thymus due to conditioning and/or aGVHD and/or upper age (Teshima and Ferrara, 2002; 
Welniak et al., 2007). The development and progress of cGVHD are not fully understood, but it is known that 
cGVHD is connected with the formation of auto-antibodies, “the expansion of auto-reactive recipient CD4+ T 
and B cells” (Pinkoski et al., 2000), as well as reduced donor anti-host CTL activity (Via and Shearer, 1988). 
 
 
Figur 1: Pathophysiology of GVHD (Welniak et al., 2007) 
APC, antigen-presenting cell;  GVHD, graft-versus-host disease; GVT, graft-versus-tumor; IFN, interferon;  NK cell, natural killer cell; 
PMN, polymorphonuclear cell; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand 
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 3.3.3 Prophylaxis and Treatment 
 
There are different treatments for GVHD and its prophylaxis. Cyclosporine A, that acts as an 
immunosuppressor by inhibiting lymphocyte proliferation and the production of IL-2 and IFN-γ, with or 
without the combination of methotrexate that inhibits cell proliferation and growth, thus is also useful for the 
elimination of remaining tumor cells, are mainly used as GVHD prophylaxis after the transplantation (Léger 
and Nevill, 2004; Storb et al., 1989; Welniak et al., 2007). Instead of cyclosporine A and methotrexate also 
other immunosuppressors like antithymocyte globulins (ATG), tacrolimus or rapamycin are in common use, 
which all downregulate T cell activation and proliferation (Armand et al., 2008; Grosskreutz et al., 2003; 
Sehgal, 1998; Welniak et al., 2007). 
ATG is very commonly used in combination with the conditioning regime, because it reduces the appearance 
of graft rejection and GVHD. ATG is a polyclonal antibody that leads to T cell-depletion in vivo, thus depletes 
engrafted donor T cells as well as host T cells and can also induce apoptosis of B cells, NK cells and 
monocytes, whereas hematopoietic stem cells (HSC) are not affected by ATG (Bacigalupo, 2005; Grüllich et 
al., 2009; Simpson, 2003; Waller et al., 2003). ATG is also seen to have a positive effect on engraftment and 
have anti-leukemic activity against certain leukemia forms (Grüllich et al., 2009). 
In case of strong conditioning cyclosporine A is applied in combination with corticosteroids, like 
prednisolone, that also impair T cell proliferation and inhibit an inflammatory response (Forman et al., 1987). 
Whereas mycophenolate mofetil (MMF), another immunosuppressor, which inhibits T and B cell 
proliferation and also enhances engraftment, is used at transplantations with RIC (Barkholt and Ringdén, 
2004; Forman et al., 1987; Mohty et al., 2007).  
In high risk patients T cell-depletion of the graft can be used before the transplantation to suppress its 
reaction against the host cells and reduce GVHD development. 15% of patients with T cell-depleted grafts 
compared to 50% without T cell-depletion develop GVHD. But a T cell-depleted graft has also disadvantages, 
as it increases the incidence of infections, graft rejection or relapse (Bross et al., 1984; Krenger et al., 1997; 
Simpson, 2003). There are better results regarding rejection, if only CD8+ T cells are depleted or if ATG is 
applied (Barkholt and Ringdén, 2004; Simpson, 2003). 
As described above, the development of aGVHD is triggered by tissue damage through the distribution of 
pro-inflammatory cytokines. To decrease the risk for GVHD tissue damage is reduced through the 
application of cytoprotective agents like fibroblast growth factor-7 (FGF-7), IL-11 or keratinocyte growth 
factor (KGF) and also through reduced conditioning (Teshima and Ferrara, 2002; Welniak et al., 2007). It has 
been shown that “TNF-α blockade during conditioning can delay the onset of aGVHD and decrease the 
incidence of severe diseases” (Krenger et al., 1997). 
As mentioned before, it is more common to use stem cells derived from peripheral blood for HSCT nowadays 
leading to a better neutrophil and platelet recreation, but the blood cells that have to be mobilized through G-
CSF or GM-CSF are seen to cause a longer GVHD duration, if the disease appears, comparing to bone 
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marrow as stem cell source (Sala-Torra et al., 2008; Welniak et al., 2007).  
Many researches are going on to protect patients from the development of GVHD, but if the disease is not 
preventable, good treatments have been established. aGVHD is normally treated with high-dose 
corticosteroids, thus inhibiting an inflammatory response and reducing the aGVHD reaction. It has a success 
rate of about 40% (Léger and Nevill, 2004; Ferrara, 2007). But also other immunosuppressiva are used for the 
treatment of aGVHD like cyclosporine A or the T cell-depleting ATG (Barkholt and Ringdén, 2004; Martin et 
al., 1990). CMV can be activated through the use of corticosteroids and thus ganciclovir, an antiviral 
medication that prevents CMV infections is additionally applied as prophylaxis in case of aGVHD and 
cGVHD (Léger and Nevill, 2004). Different antibiotics are also administered for preventing diverse infections. 
cGVHD is as well as aGVHD treated with different immunosuppressiva like steroids and cyclosporine A. To 
get cGVHD under control in high risk patients the use of thalidomide that decreases TNF-α secretion and is 
anti-inflammatory as well as lymph node irradiation is common (Barkholt and Ringdén, 2004).  
 
 
          3.3.4 Probably Relevant Cytokines and Molecular Markers in GVHD 
 
               3.3.4.1 Preface 
 
It is still not fully understood which cytokines play a dominant role in the development of GVHD. Previously 
it has been considered that TH1 cytokines that are involved in a cell-mediated immune response would trigger 
an alloreactive T cell response against the recipient and therefore leading to more GVHD development. TH2 
cytokines have been suggested to be immunosuppressive and thus believed to inhibit GVHD (Krenger and 
Ferrara, 1996). These findings could on the one hand be confirmed in some preclinical and clinical projects 
(Krenger et al., 1995; Williamson et al., 1997), but on the other hand contrary results have been seen both in 
murine models and patients’ studies, where TH1 cytokines could protect from GVHD development and TH2 
cytokines have augmented the GVHD outcome (Blazar et al., 1995; Sykes et al., 1990). 
We were interested in studying different gene expression levels in CD4+ and CD8+ T cells as well as plasma 
levels of diverse cytokines that are likely to be involved in the development of GVHD in a huge number of 
stem cell transplanted patients looking for a correlation between TH1 and TH2 cytokine levels and the 
appearance of GVHD. It is not easy to diagnose and distinguish between GVHD-associated and infectious 
inflammations, thus a molecular marker would be helpful for diagnosing GVHD and starting an early 
treatment. Furthermore an intervention in the cytokine system could help to diminish the risk for the 
development of GVHD. 
The gene expressions and plasma levels of the characteristic pro-inflammatory TH1 cytokines IFN-γ and IL-
18 were measured with real time quantitative-polymerase chain reaction (RQ-PCR) and enzyme-linked 
immunosorbent assay (ELISA), respectively. Additionally the plasma level of the pro-inflammatory cytokine 
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IL-12 was analyzed with ELISA. The typical immunosuppressive cytokine IL-10 was analyzed at gene 
expression and protein level. Furthermore ICOS, Foxp3, FuT7 and B7-int gene expressions as well as the IL-
17 and IL-23 protein expressions were studied.  
The different cytokines and molecular markers are described in detail below. 
 
 
               3.3.4.2 Interferon-γ (IFN-γ) 
 
IFN-γ is also known as type II or immune interferon due to its important role in preventing and controlling 
infectious diseases. It acts as a pro-inflammatory cytokine. IFN-γ is mainly secreted by TH1 CD4+ cells, CD8+ 
T cells, γδ T cells, NK cells, and NKT cells after an inflammatory activation leading to cell-mediated immune 
response whereas mainly macrophages but also NK cells,  neutrophils and CTLs get activated and proliferate 
(Abbas and Lichtman, 2003, p.268 et seq.; Chen and Liu, 2009; Ikeda et al., 2002). IFN-γ inhibits IL-4 
synthesis and TH2 cell proliferation by what it blocks a humoral immune response. During adaptive immune 
response CD4+ T cells and CD8+ T cells are the primarily IFN-γ producing cells. T cells get stimulated 
through antigens or IL-12 and IL-18 (pathway via signal transducers and activators of transcription 4 
(STAT4) and NF-κB) to produce IFN-γ (Ikeda et al., 2002). NK cells are activated by tissue macrophages 
recognizing bacterial products and producing TNF-α and IL-12 at low levels to produce IFN-γ. IFN-γ itself 
stimulates macrophages (as the initial macrophage-activating factor) leading to more TNF-α and IL-12 
production ending up in a positive feadback loop with more IFN-γ production and additionally, IFN-γ 
enhances its own mRNA expression (auto-amplification loop) (Ikeda et al., 2002; Young and Hardy, 1995). 
TH1 cells increase the IL-12 production by stimulated APCs and keep the IL-12 receptor β-chain expression 
on CD4+ T cells up through their IFN-γ distribution (Ikeda et al., 2002). IFN-γ increases the antigen 
presentation through its upregulation of class I and II MHC gene expressions (Chen and Liu, 2009; Chesler 
and Reiss, 2002). Given that IFN-γ activates antiviral mechanisms by fending microbial infections it controls 
the immune system at many different sites. IFN-γ influences the cell cycle through growth and apoptosis, 
plays and important role in ”leukocyte trafficking and leukocyte endothelial interactions and in immune 
regulatory functions” (Chen and Liu, 2009) such as supporting TH1 cells and repressing TH2 cells development. 
It modulates the antigen processing and inhibition capacity of TH17 cells and has an inhibitory effect on the 
generation of memory T cells (Chen and Liu, 2009; Ikeda et al., 2002; Young and Hardy, 1995). It have been 
shown in mice models that IFN-γ plays a part in T cell homeostasis by erasing activated CD4+ and CD8+ T 
cells through apoptosis. (Badovinac et al., 2000; Refaeli et al., 2002). 
IFN-γ suppresses immunoglobulin G1 (IgG1) and IgE production (induced by IL-4) and on the contrary 
enhances Ig2A synthesis (induced by lipopolysaccharide (LPS) or IL-2), although it does not cause class-
switching. IFN-γ has both repressive and stimulatory effects on B cells by inhibiting LPS-induced 
proliferation of naive B cells, but acting anti-apoptotic on mature B cells and promoting their differentiation. 
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IFN-γ is suppressive for hematopoietic progenitor cells, but it enhances their development in combination 
with IL-3 and stem cell factor (Young and Hardy, 1995). It depends very on in which cytokine combinations 
IFN-γ occurs. For example IFN-γ acts as a ”survival factor for committed human erythroid and myeloid 
progenitor cells in the absence of other cytokines” (Young and Hardy, 1995). IFN-γ has been seen to inhibit graft 
rejection (Chen and Liu, 2009), but also the opposite effect has been observed, where ”donor T cells 
responding to host alloantigens release IFN-γ and IL-2” (Moore et al., 2001), both belonging to the TH1 
cytokines. Through IFN-γ release pro-inflammatory macrophages and NK cells get activated. Those can then 
be triggered by gut bacteria or by latent infections. As a result inflammatory cytokines and active nitrogen 
intermediates are ejected, which lead to tissue damage (Moore et al., 2001). It has been observed that 
autoimmune responses can be inhibited by IFN-γ through the induced development of regulatory T cells 
(Tregs) (turning CD4+CD25- into CD4+CD25+ Tregs) leading to an upregulated T effector cell apoptosis (Chen 
and Liu, 2009). As mentioned before cGVHD has characteristics of autoimmune diseases. 
IFN-γ that is composed of 4 exons and 3 introns is coded on chromosome 12. The functional protein appears 
as a non-covalent homodimer (34KDa), whereas two IFN-γ polypeptids are antiparallel associated (Chen and 
Liu, 2009; Ikeda et al., 2002; Young and Hardy, 1995). The IFN-γ receptor consists of a α-chain that is coded 
on chromosme 6 and a β-chain, coded on chromosome 21. The α-chain is constantly expressed, the β-chain at 
very low levels on those cells which can react to IFN-γ (Chen and Liu, 2009; Ikeda et al., 2002). As shown in 
murine studies, TH1 cells lack the β-chain leading to no response in contrast TH2 cells express the β-chain and 
have a total response to IFN-γ that blocks their proliferation (Bach et al., 1995; Pernis et al., 1995). 
IFN-γ binds to two α - and two β -chains. The α -chain is responsible for ligand binding and trafficking 
through the cell, whereas the β -chain is needed for signaling. Signaling occurs via the janus kinase-signal 
transducers and activators of transcription (JAK-STAT) pathway, inducing caspase-1 and Fas/FasL, which are 
IFN-γ/STAT1 dependent genes. STAT1 leads also to a basal caspase-1 expression in certain cells without IFN-
γ (Ikeda et al., 2002). Caspase-1 turns IL-1β into an active form leading to an inflammatory cytokine (Abbas 
and Lichtman, 2003, p.254). 
 
 
               3.3.4.3 Interleukin-12 (IL-12) 
 
IL-12 is an interleukin that is important for the interaction between innate and adaptive immunity and acts as 
an early pro-inflammatory cytokine. IL-12 controls inflammatory and infectious innate immune response as 
well as the persistence and initiation of the adaptive immune response. IL-12 is mainly distributed by 
phagocytic cells (monocytes, macrophages, neutrophils), B cells and dendritic cells, but also by mast cells, 
keratinocytes and skin Langerhans cells (Colombo and Trinchieri, 2002; Trinchieri, 1995; Watford et al., 
2003). In combination with infectious agents IL-12 stimulates the IFN-γ production of NK cells and T cells, 
dendritic cells and macrophages leading to phagocytic cells and CTLs activation, and inflammation primarily 
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in the innate immune response (Colombo and Trinchieri, 2002; Trinchieri, 1995). 
Microbial products can induce IL-12 production in two different ways, through toll-like receptor (TLR) 
signaling and through CD40-CD40L binding (T cell-dependant manner). IL-12, which is an antogonist to IL-
4, mainly acts on T and NK cells via enhancing their proliferation, IFN-γ production and cytotoxic activity 
(CTLs and NK cells), and polarizing T cells into TH1 cells leading to cell-mediated immunity and distribution 
of IFN-γ and IL-2 (Trinchieri, 1995; Watford et al., 2003). IL-12 has a further positive effect in combination 
with CD28 ligand expression on APC, on T cell receptor (TCR)/CD3 stimulation during antigen presentation 
leading to T cell proliferation and IFN-γ production. IL-12 additionally induces the production of TNF-α, 
macrophage colony-stimulating factor (M-CSF), IL-3, IL-8 and IL-2 by T and NK cells (Trinchieri, 1995).  
In combination with IL-18 IL-12 upregulates the expression of IL18R on TH1 cells and acts on macrophages, 
dendritic cells and B cells via enhancing the IFN-γ production in those cells and also in APCs (Lotze et al., 
2002; Kashiwamura et al., 2002; Watford et al., 2003). IL-12 indirectly induces its own production, because 
IFN-γ positively regulates the IL-12 production, against it IL-10, IL-11, IL-13 as well as IFN-α and -β inhibit 
the IL-12 production (Watford et al., 2003). ”IL-12 increases IL-2-induced proliferation of activated T cells but 
mostly inhibits IL-2-induced proliferation of NK cells” (Trinchieri, 1995). IL-2 provides the proliferating effect 
that IL-12 has on activated T cells (Trinchieri, 1995). 
IL-12 is a heterodimeric cytokine containing a disulfid-linked IL-12p35 subunit (α-chain) and a IL-12p40 
subunit (β-chain). The subunits’ protein expression is regulated independently, because the IL-12p35 subunit 
is coded on chromosome 3, whereas IL-12p40 is coded on chromosome 5. The IL-12p40 subunit can also 
appear as a free monomer or a homodimer (p402), but their functions are unknown (Colombo and Trinchieri, 
2002; Watford et al., 2003). ”The p40 gene is regulated at the level of transcription and is highly inducible by 
microbial products” (Watford et al., 2003). The p40 promoters bind many transcription factors, such as NF-κB, 
interferon regulatory factor-1 (IRF-1) and c-Rel. p35 is in contrast to p40 regulated transcriptionally as well as 
translationally. The p35 gene is constantly synthesized at low levels in unstimulated cells and in most cell 
types and its translation is stimulated through LPS. If a co-expression of both subunits occurs in the same cell, 
the biologically active p70 heterodimer is built (Trinchieri, 1995; Watford et al., 2003). 
The IL-12R is primarily expressed on activated T cells and NK cells, but also on dendritic cells. Resting T cells 
do not express IL-12R and only TH1 cells express both subunits. The receptor, which has three binding sides, 
is composed of the IL-12Rβ1 subunit binding to IL-12p40 and the IL-12Rβ2 subunit binding to IL-12p35 
(Colombo and Trinchieri, 2002; Trinchieri, 1995; Watford et al., 2003). Both subunits are necessary for a 
high-affinity binding and the β2 subunit is essential for the signal transduction. The receptor subunits occur 
as dimers or oligomers on the cell surface. The signal transduction pathway takes place through a 
JAK2/STAT4 signaling (only IFN-γ and IL-12 activate STAT4) (Colombo and Trinchieri, 2002). The 
transcription factor for the IL-12Rβ2 subunit, T-box expressed in T cells (T-bet) is induced by IFN-γ 
(Watford et al., 2003). 
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               3.3.4.4 Interleukin-18 (IL-18) 
 
IL-18 is like IL-12 a pro-inflammatory cytokine, has also an IFN-γ-inducing factor and plays an important 
role in the ”transition from innate to adaptive immunity” (Lotze et al., 2002) as in the defense against tumors 
and infections (Lotze et al., 2002; Kashiwamura et al., 2002). IL-18 is expressed in many cell types as in 
macrophages, dendritic cells, keratinocytes (in the differentiating skin cells), intestinal epithelial cells and in 
different non-immune cells in tissues with rapid cell proliferation, where its expression is not clearly 
understood yet; maybe IL-18 is involved in tissue regeneration and repair there (Kashiwamura et al., 2002). 
IL-18 induces both TH1 and TH2 cytokines and is therefore part of the destructive and compensatory 
pathways depending on its interaction with other cytokines (Kashiwamura et al., 2002; Nakanishi et al., 2001). 
In the presence of antigen and IL-12 it provides IFN-γ, TNF-α and IL-1 production (TH1 cytokines) leading 
to distribution of ”NO and reacitve oxygen intermediates” (Kashiwamura et al., 2002) by macrophages and 
neutrophils disturbing microbial pathogens and also tissues, whereas IL-18 provides IL-4, IL-5, IL-10 and IL-
13 (TH2 cytokines) and prostanoids, like prostaglandin E2 (PGE2) secretion, in absence of IL-12, but 
supported through IL-2 and/or IL-3 (Kashiwamura et al., 2002; Min et al., 2004; Nakanishi et al., 2001). 
Prostanoids affect the production of cytokines, such as IL-12. Through TH2 cytokine distribution T and NK 
cells secret IL-13 leading to suppression of inflammatory cytokines, like IFN-γ and IL-12. To induce a TH2 cell 
response IL-18 probably has to induce the cyclooxygenase 2 (Kashiwamura et al., 2002). TH2 cytokines are 
anti-inflammatory and therefore IL-18 is maybe involved in tissue repair and regeneration. IL-18 increases 
NK cell and CD8+ T cell perforin-dependent cytotoxicity independently of IL-12. Additionally IL-18 can 
induce GM-CSF, IL-1β and IL-8, whereas IL-8 leads to neutrophil infiltration (Kashiwamura et al., 2002).  
IL-18 belongs to the IL-1 cytokine family and is similar to their “molecular structure, processing and signaling” 
(Reddy et al., 2003). However, IL-18 is located on another chromosome, on chromosome 11 and not on 
chromosome 2, like the other IL-1 homologous cytokines. Macrophages and dendritic cells store and produce 
IL-18 as a precursor form (pro-IL-18 with 24kD), which has to be processed by caspase-1 (IL-1β-converting 
enzyme) to allow its secretion and to form a fully function cytokine (18kD) (Lotze et al., 2002; Kashiwamura 
et al., 2002). It is unknown how caspase-1 gets triggered, but it is known, that NO directly inactivates it. 
Caspase-1 and IL-18 do both have promoter regions with ”the consensus sequence for IRF-1 and IFN consensus 
sequence binding protein” (Kashiwamura et al., 2002). Therefore, interferons probably control the induction 
and processing of IL-18 as well. Without caspase-1 the Fas/FasL system is involved in the processing of IL-18 
(Kashiwamura et al., 2002).  
The IL-18 gene is assembled of seven exons, whereas exons 1 and 2 are non-coding. There are 2 promoters 
lying upstream exons 1 and 2 that both have a NF-κB recognition sequence. The IL-18 gene lacks a RNA-
destabilizing element that may be the reason for a long-lasting IL-18 production in inflammatory reactions. 
Different transcription factors are activated through IL-18. NF-κB can be activated through myeloid 
differentiation primary response gene 88 (MyD88) and TNF receptor-associated factor 6 (TRAF6) leading 
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among others to IFN-γ production. Its mitogen-activated protein kinase (MAPKinase) activation is involved 
in the activation of NK cells and also the transcription factors activator protein-1 (AP-1) and nuclear factor of 
activated T cells (NFAT) can be activated via IL-18 (Kashiwamura et al., 2002). The heterodimeric IL-18R, 
located on chromosome 2, is composed of a ligand-binding α-chain (IL-18Rα/IL-1 Rrp) and an associating β-
chain (IL-18Rβ/AcPL) (Reddy et al., 2003; Sims, 2002). TH1, but neither TH2 nor naive T cells express IL-18R, 
which is induced by IL-12 leading to fast IL-18 response and IFN-γ production. NK cells constitutively 
express IL-18R leading to a fast enhancement of their cytolytic activity through binding of IL-18 
(Kashiwamura et al., 2002; Watford et al., 2003). 
 
 
               3.3.4.5 Interleukin-10 (IL-10) 
 
IL-10 is an immunosuppressive and anti-inflammatory TH2 cytokine, which inhibits the activation of myeloid 
cells like monocytes, dendritic cells and macrophages leading to a decreased ”production of pro-inflammatory 
mediators” (Beebe et al., 2002) and a reduced T cell stimulation. IL-10 downregulates the function of APCs 
that leads to a repression of CD4+ T cells’ cytokine production and proliferation. Thereby IL-10 has positive 
effects on CD8+ T cells through its induction of their recruitment, proliferation and cytotoxic activity. 
”Activation of T cells in the presence of IL-10 can induce non-responsiveness/ anergy, which cannot be reversed 
by IL-2” (Moore et al., 2001), that can result in Treg production with a high IL-10 secretion and prevention of 
antigen specific responses (Beebe et al., 2002; Lynch et al., 2003; Moore et al., 2001). 
IL-10 is produced by many different cell types, like ”TH1 and TH2 cells, CD8+ T cells, mast cells, eosinophils, B 
cells, macrophages, monocytes, keratinocytes and various tumor cells” (Lynch et al., 2003). LPS-induced 
macrophages secret TH2 cytokines like IL-10 as well as IL-5 and IL-13 (Lynch et al., 2003). IL-10 influences 
TH1 cells, NK cells, granulocytes and endothelial cells negatively by inhibiting their pro-inflammatory 
functions through affecting their accessory cells’ functions (Beebe et al., 2002; Moore et al., 2001). The 
inhibition of macrophages’ and monocytes’ functions implies an inhibition of ”monokine synthesis, NO 
production as well as of the MHCII complex and co-stimulatory molecules like IL-12 and CD80/CD86” (Moore 
et al., 2001). IL-10 increases B cell activity and proliferation through anti-IgM or CD40 cross-linking and 
activation, and B cell survival through an enhanced expression of the anti-apoptotic protein Bcl-2. 
Additionally, it enhances the Ig-production of naive and differentiated B cells and can lead to B cell 
differentiation into plasma cells through distinct circumstances and long influence. IL-10 plays an important 
role in isotype switching. It causes switching to IgM, IgG1, IgG2, IgG3 and IgA and in combination with IL-4 
to IgG4 and IgE (Beebe et al., 2002; Moore et al., 2001).  
IL-10, coded on chromosome 1, is a non-covalent associated homodimeric cytokine with two 
interpenetrating polypeptid chains. Its expression is regulated differently in different cell types, whereas the 
transcription factors Sp1 and Sp3 that are constantly expressed in many different cell types and are controlled 
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via posttranscriptional degradation have a main regulatory function. Different IL-10 gene polymorphisms are 
associated with diverse IL-10 productions of T cells and monocytes (Beebe et al., 2002; Moore et al., 2001). 
The IL-10R belongs to the interferon receptor (IFNR) family, is heterodimeric and at least composed of two 
subunits (Beebe et al., 2002; Moore et al., 2001). The IL-10Rα/IL-10R1 subunit that is expressed on most 
hematopoietic cells but can also be expressed on non-hematopoietic cells is the ligand binding part that binds 
IL-10 with high affinity. T cell activation leads to low IL-10R1 expression, in contrast to it leads monocyte 
activation to high IL-10R1 expression, regarding that IL-10 inhibits both cell types. The IL-10R1 expression is 
induced in fibroblasts through LPS and in epidermal cells or keratinocytes through glucocorticoides. The IL-
10Rβ/IL-10R2 subunit is not responsible for IL-10 binding, its function is binding of tyrosine kinase 2 (Tyk2), 
a JAKKinase, in the signaling complex. IL-10R2 is constitutively expressed in most tissue cells and no distinct 
activation in e.g. immune cells is known. IL-10R1 regulates its expression. IL-10 signal transduction occurs 
via phosphorylation of the tyrosine kinases JAK1 that is constitutively associated with IL-10R1 and Tyk1 that 
is associated with IL-10R2, respectively resulting in activation of the transcription factors STAT3, STAT1 and 
STAT5 (except in macrophages). IL-10 is inhibited through IFN-γ-induced STAT1 activation and 
phosphorylation. There are also other signaling pathways known, like the activation of NF-κB in CD3+ T cells 
leading to inhibition of macrophage activation and monocyte production (shown in vitro). IL-10 activates 
NF-κB and AP-1 in CD8+ T cells resulting in increased growth, differenciation and cytotoxic activity of CD8+ 
T cells and NK cells. IL-10 can also induce Bcl-2 expression in CD34+ progenitor and germinal center B cells 
causing survival of those cells (Moore et al., 2001). 
 
 
               3.3.4.6 Interleukin-17 (IL-17) 
 
IL-17 belongs to the pro-inflammatory cytokines and induces the expression of those type of cytokines in 
many different cell types and tissues (Bettelli et al., 2008; Kastelein et al., 2007; Moseley et al., 2003; Weaver et 
al., 2007). It induces secretion of the pro-inflammatory cytokines IL-6, TNF-α, IL-1β, IL-8 and IFN-γ (Bettelli 
et al., 2008; Chen et al., 2007; O'Garra et al., 2008; Weaver et al., 2007). IL-17 is also known as cytotoxic T 
lymphocyte antigen 8 (CTLA8) or IL-17A, because it is a member of the IL-17 cytokine family. IL-17 is 
secreted by activated effector T cells belonging to the TH17 cells, CD8+ T cells, NK cells, γδ T cells, 
neutrophils, eosinophils and monocytes. TH17 cells that are part of the adaptive immune system try to destroy 
extracellular bacteria and microbes that cannot be eliminated by TH1 or TH2 cells, but TH17 cells can also 
cause tissue inflammation and autoimmunity through its IL-17 distribution (Bettelli et al., 2008; Moseley et 
al., 2003; Weaver et al., 2007). The TH17 cell linage is also seen to be associated with allograft rejection as well 
as GVHD development (Dander et al., 2009; Kappel et al. , 2009; Weaver et al., 2007) and ”may play an 
important role in the homeostasis of tissues and the progression of diseases” (Moseley et al., 2003). 
IL-17 causes acute inflammation through activation and infiltration of neutrophils to sites of infections 
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triggered via its activation of monocytes, epithelial and endothelial cells (Bettelli et al., 2008; Kastelein et al., 
2007; O'Garra et al., 2008; Weaver et al., 2007). For the development of TH17 cells from naive CD4+ T cells or 
dendritic cells the cytokines IL-1, IL-6 and transforming growth factor-β (TGF-β) are essential as well as the 
activation of the transcription factor retinoic acid-related orphan receptor γT (RORγT). IL-21 and IL-23 are 
involved too, whereas IL-21 is even produced by TH17 cells. IL-1, IL-6 and TGF-β cause TH17 cell 
differentiation, IL-21 their amplification and IL-23 their maintenance. IL-17 is not involved in the 
differentiation and proliferation of TH17 cells (Bettelli et al., 2008; O'Garra et al., 2008; Weaver et al., 2007). 
”TGF-β induces RORγT expression but, paradoxically, inhibits its transcriptional activity, thus preventing 
expression of IL-17” (O'Garra et al., 2008). Through the influence of inflammatory cytokines like IL-1, IL-6, 
IL-21 and IL-23 RORγT gets transcriptional active leading to IL-17 expression (O'Garra et al., 2008). Not only 
naive CD4+ T cells or dendritic cells but also Foxp3-expressing Tregs can differentiate into TH17 cells under the 
influence of IL-6, TGF-β and probably IL-1. TGF-β and IL-1 are both part of the innate immune system 
regulating the IL-17 expression as mentioned before and therefore is IL-17 seen to be an important 
component of the collaboration between the innate and the adaptive immune system (Weaver et al., 2007). 
”Naive T cells activated in the presence of CD4+CD25+ Tregs exhibite suppressed levels of IFN-γ and IL-2 but 
expresses high levels of IL-17” (Weaver et al., 2007). IFN-α, -β and -γ as well as IL-4 repress the development of 
the TH17 cell linage in vitro (Weaver et al., 2007). 
IL-17, a disulfid linked homodimer coded on chromosome 1, binds to the IL-17Rs, that are ”singel-pass 
transmembran proteins” (Moseley et al., 2003) leading to an activation of NF-κB or MAPkinase that causes 
induction of pro-inflammatory cytokines (Moseley et al., 2003). The receptor IL-17RA is expressed at high 
levels on haematopoietic cells, and at lower levels on osteoblasts, fibroblats, endothelial and epothelial cells 
(Bettelli et al., 2008). 
 
 
               3.3.4.7 Interleukin-23 (IL-23) 
 
IL-23 is mainly produced by activated dendritic cells and phagocytic cells, but also by T cells and endothelial 
cells. IL-23 plays an important role in the primary response to local inflammation by causing IFN-γ 
production of T cells and dendritic cells and triggers a T cell-dependent immunity by mainly enhancing the 
proliferation of memory T cells and stimulating their IL-17 production and causes neutorphils and 
macropahges infiltration to sides of infections (Kastelein et al., 2007; Watford et al., 2003; Weaver et al., 2007). 
Within a few hours after a microbial infection IL-23 is secreted causing a ”rapid IL-17 response from tissue-
resistant αβ, γδ T cells and NKT cells” (Kastelein et al., 2007) as well as TNF-α and IL-1β distribution from 
myeloid cells, only later CD4+ and CD8+ T cells are involved in the immune effector functions. In contrast it 
does neither stimulate naive CD4+ T cells, which are missing a receptor for IL-23, nor TH1 or TH2 cells. IL-23 
is therefore not required for the differantiation of CD4+ T cells into TH17 cells and their initial IL-17 secretion, 
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but is important for the maintenance and full effector function of this cell type, like IL-1 (Bettelli et al., 2008; 
Kastelein et al., 2007; Weaver et al., 2007). It also induces cells of the innate immune system to secret IL-1 and 
IL-6 causing inflammation and antibody producing B cells to proliferate (Bettelli et al., 2008). The TH1/ TH2 
pathways shut down the IL-23/IL-17 pathway which is important to avoid autoimmune diseases (Kastelein et 
al., 2007).  
IL-23 is a disulfid linked heterodimer and composed of the subunits p40 (like in IL-12) and p19 and its 
signaling is initiated through binding to its receptor that consists of two subunits, the IL-12Rβ1 chain binding 
to p40 and a particular IL-23R subunit binding to the p19 part (Bettelli et al., 2008; Kastelein et al., 2007; 
Watford et al., 2003). ”Many pathogens and TLR agonists enhance the expression of the p40, p35 and p19 
subunits, resulting in the release of bioactive IL-12 and IL-23” (Kastelein et al., 2007). Dendritc cells are seen to 
cannot co-express p35 and p19 at the same cell assuming that there are subpopulations specific for p35 and 
others for p19. Signaling is mediated by JAK2 association to the receptor and the following STAT1, 3, 4 or 5 
phosphorylation and activation leads to NF-κB signaling, whereas STAT4 is much weaker activated as 
through IL-12. The transcription factor RORγT is essential for IL-23R expression as well as for the expression 
of IL-1R1 (Kastelein et al., 2007; Watford et al., 2003). The expression of both IL-23R chains is mainly found 
on activated and memory T cells, TH17 cells, NK cells and NKT cells, but at lower levels also on monocytes, 
macrophages and dendritic cells (Bettelli et al., 2008; Kastelein et al., 2007). The IL-23R expression in 
activated and memory T cells is intensely induced by IL-6 amd IL-21, whereas IL-23 by itself can increase its 
receptor expression ”through an autocrine or paracrine feedback loop” (Bettelli et al., 2008). 
 
 
               3.3.4.8 Inducible Costimulator (ICOS) 
 
ICOS, which stands for inducible costimulator, because it is “incduced on T cells after stimulation” (Abbas and 
Lichtman, 2003, p.172), plays an important role in many immune responses, where its and its ligand ICOSL 
expression is upregulated. Signaling through the ICOS/ICOSL pathway leads to an enhanced lymphocyte 
level in the lymph nodes with increased stimulated T and B cell pools (Tesciuba et al., 2008; Watanabe et al., 
2008). Its pathway is also crucial for ” TH2 cell differentiation, cell effector functions and antibody response, 
especially for germinal center formation and class switch recombination” (Watanabe et al., 2008), as has been 
shown in murine studies. Because ICOS and ICOSL have an enhanced expression in immune reaction in 
mouse models, it is assumed that their pathway is important ”to prevent dysregulation of immune responses” 
(Watanabe et al., 2008). But their downregulation is also essential for the immune system homeostasis, 
because a long lasting signaling leads to a defect homeostasis (Watanabe et al., 2008). 
ICOS belongs to the CD28 family, which are Ig-like molecules such as CTLA-4 and programmed death-1 
(PD-1). ICOS and CD28 are both inducible factors for T to B cell interaction and therefore crucial for an ideal 
antibody response. ICOS is only expressed on CD4+ and CD8+ T cells after their activation and TCR 
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stimulation reaching its maximum induction through an accessory CD28 signal. Its ligand expression is 
enhanced on APCs through different mitogenic stimuli. ICOS is primarily expressed on activated TH2 cells 
that seems to be regulated by the transcription factor GATA3 rather than on TH1 cells. However, ICOS is 
important for the expansion of both TH1 and TH2 responses. It is additionally constitutively expressed on 
memory CD4+ T cells and on some subsets of CD25+CD4+ Tregs. ICOS gene transcription may is regulated by 
the transcription factors NFAT and AP-1 (Tesciuba et al., 2008; Warnatz  et al., 2006; Watanabe et al., 2008). 
Stimulation of CD40 leads to an induction of ICOSL, in contrast are LPS and IL4 downregulating factors for 
ICOSL (Tesciuba et al., 2008; Watanabe et al., 2008). IL-10 and IL-17 are released after ICOS ligation and their 
stimulation cannot be fully replaced through CD28, if ICOS is absent. ICOS deficiency leads to the 
development of an antibody deficiency syndrome looking like common variable immunodeficiency (CVID) 
with an enormous decrease of the B cell pool, particularly of switched memory and naive B cells. In case of its 
deficiency germinal center formation is negatively affected too that is due to lowered IL-10 production of T 
cells, whereas T cells are not further affected besides a decreased IL-17 production (Tesciuba et al., 2008; 
Warnatz et al., 2006). Due to decreased B cell level the total number of IgG and IgA is drastically low, the IgM 
level is also decreased and IgE is not even detectable (Warnatz et al., 2006). This indicates that ICOS is 
essential for ”the maintenance of a mature B cell compartment” (Tesciuba et al., 2008). It is interesting that a 
prolonged ICOS expression have been seen to be connected with the occurrence of chronic, but not acute 
GVHD, in the mouse model (Watanabe et al., 2008).  
 
               3.3.4.9 β7-Integrin (β7-int) 
 
There are two types of β7-integrins differing in their α-chain, the α4β7 subtype, also known as lymphocytea 
Peyer’s patch adhesion molecule-1 (LPAM-1) is involved in the lymphocyte homing to mucosal sites, whereas 
the αEβ7 integrin is important for the lymphocyote retention in the epithelium. It has been shown in mouse 
models that the α- and the smaller β-chain are building a non-covalently associated heterodimer (Shaw and 
Brenner, 1995).  
Naive lymphocytes have a homogenous moderate expression of the α4β7 subtype, in contrast 2 effector and 
memory celltypes concerning their α4β7 levels exist, those with low and those with high α4β7 integrin levels 
(Miles et al., 2008; Wright et al., 2002). The T and B cells’ α4β7 integrin expression is induced through their 
”activation by dendritic cells in gut-associated lymphoid tissues (GALT)” (Miles et al., 2008). Naive lymphocytes 
and lymphocytes with high α4β7 integrin expression home to secondary lymphoid tissues through their 
integrin binding to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on the cell surface of high 
endothelial venules (HEVs) on Peyer’s patches, lymph nodes and on the intestinal lamina propria. The two 
Ig-like domains of MAdCAM-1 are responsible for its interaction with the α4β7 integrin leading to rolling of 
the integrin at high MAdCAM-1 and to a stop and go movement at lower expressions, whereby the 
lymphocytes can enter the mucosal sites (Miles et al., 2008; Pachynski et al., 1998; Shaw and Brenner, 1995; 
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Wright et al., 2002). α4β7 integrin can also bind to vascular cell adhesion molecule-1 (VCAM-1) and to 
connecting segment-1 region of fibronectin (CS-1/FN) instead for its main binding to MAdCAM-1. The α4β7 
subtype that is expressed on most T cells in mucosal epithelial cells ”has been shown to mediate lymphocyte 
binding to epithelial cell E-cadherin” (Shaw and Brenner, 1995). The ligand E-cadherin is primarily found on 
epithelial cells but also on some leukocytes in the epidermis like Langerhans cells (Shaw and Brenner, 1995; 
Wright et al., 2002).  
 
               3.3.4.10 Fucosyltransferase VII (FuT7) 
 
The α-1,3-fucosyltransferase VII enzyme (FuT7) plays an important role in the onset of an inflammatory 
response leading to leukocytes’ homing to sites of infection. Its key role is assisting the synthesis of the sialyl 
Lewis x (sLex) epitope, which is an essential component of functional active ligands for E-, P- and L-selectin 
on leukocytes, by adding fucose residues and the synthesis of cutaneous lymphocyte antigen (CLA) 
carbohydrate determinates (Bengtson et al., 2002; Dudda et al., 2008; Knibbs et al., 1996; Liu et al., 2008; 
Martinez et al., 2005). Leukocytes, endothelial cells as well as tumor cells are the major FuT7 expressing 
celltypes, whereas T cells in lymph nodes and resting memory T cells express lower amounts that are 
enormously enhanced after their activation (Knibbs et al., 1996; Liu et al., 2008; Martinez et al., 2005). FuT7 
cell lines carry high avidity E-selectin ligands leading to their slow rolling and homing to centers of 
inflammation (Dudda et al., 2008). E- and P-selectins are adhesion molecules, whose expression on 
endothelial cells in the dermis is induced by inflammatory cytokines and highly enhanced during an infection 
via platelets or endothelial cells’ activation. L-selectin is expressed on nearly all leukocytes and bind to L-
selectin ligand on endothelial cells. P-selectin is important for leukocyte rolling early at inflammation, 
whereas L-selectin is essential for rolling of leukocytes that are already attached to vascular cell wall 
(Bengtson et al., 2002; Martinez et al., 2005). ”Functional E-selectin ligands are expressed on 5-20% of 
circulating αβ memory T cells, a large percentage of γδ T cells, NK cells and activated T cells after antibody-
induced proliferation” (Knibbs et al., 1996). Nearly all T cells found in the dermis express E-selectin ligand 
(Dudda et al., 2008). P-selectin glycoprotein ligand-1 (PSGL-1), expressed on most leukocytes, is the main 
ligand for P- and E-selectin, whereas E-selectin binds also to E-selectin ligand-1 (ESL-1), but also for L-
selectin. PSGL-1 binding to selectins is induced through sLex and CLA synthesis mediated by FuT7, whereas 
sLex induction through FuT4 is underpart. FuT7 and FuT4 are seen to can compensate each other in their 
function of providing selectin ligand. A missense mutation of FuT7 does exist that leads to an inactivation of 
FuT7 causing no sLex generation but although a normal leukocyte rolling on P- and E-selectin occurs due to 
an increased FuT4 activity (Bengtson et al., 2002; Martinez et al., 2005). ”sLex is required to support L-/P-
selectin cell rolling on PSGL-1+FuT7+ cells, but not on PSGL-1+FuT4+ cells” (Martinez et al., 2005).  
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    3.3.4.11 Forkhead box P3 (Foxp3) 
 
Foxp3 is a transcription factor that plays a crucial role in “maintaining peripheral immune tolerance” 
(Pallandre et al., 2007) (Fontenot et al., 2003; Hori et al., 2003). Foxp3 has been used as a marker to identify 
Tregs, although it is debated, if Foxp3 is exclusively expressed on Tregs (Corthay, 2009; Morgan et al., 2005; 
Wang et al., 2007). However, no alternative marker that is specific for Tregs is known yet. Different 
observations suggest that Foxp3+ T cells behave like Tregs (Corthay, 2009). 
CD4+Foxp3+ Tregs, which are involved in the regulation of the immune system, are important for establishing 
and maintaining self-tolerance and for preventing inflammatory and autoimmune diseases in the skin and 
lungs. Those Tregs are found in many non-lymphoid tissues, especially in the skin, representing 20-40% of all 
CD4+ T cells in this tissue. Many Tregs in the peripheral blood are carrying cutaneous homing receptors 
(Dudda et al., 2008; Fontenot et al., 2003; Sather et al., 2007). Skin CD4+Foxp3+ Tregs generate a normal 
immune homeostasis in the skin and are probably important in ”preventing cutaneous inflammatory disease” 
(Sather et al., 2007) through their cell-mediated immunosuppression leading to cutaneous self-tolerance in 
mouse models. In absence of Foxp3+ T cells spontaneous autoimmunity can occur (Dudda et al., 2008; Sather 
et al., 2007). 
”The relation of Tregs that constitutively express Foxp3, so-called naive Treg cells, to Tregs that arise in the periphery, 
induced Tregs, is unclear” (Lee et al., 2005). CD28 as well as ICOS are essential costimulators for the generation 
and maintenance of Tregs. In CD28-/- or ICOS-/- mice the Foxp3 expression level is markedly decreased (Lee et 
al., 2005). 
Tregs can migrate to lymphoid and also to non-lymphoid tissues that is essential for their induced prevention 
of aGVHD. Human CD4+CD25+ Tregs express Foxp3, chemokine (cystein-cystein motif) receptor 4 and 8 
(CCR4 and CCR8), whereas the chemokine receptor CCR4 is important to trigger Tregs into skin, lungs and to 
APCs in secondary lymphoid tissues (Fontenot et al., 2003; Lee et al., 2005; Sather et al., 2007). If a patient, 
getting a transplant is CCR4-/- the Foxp3 level is much lower after a few days after transplantation compared to 
a patient with normal CCR4 expression leading to a worse development of tolerance to the transplant (Lee et 
al., 2005). It has been seen that Tregs that are also CD25+ can lead to improvement of already developed 
GVHD (Sather et al., 2007).  
Foxp3 encodes the transcription factor scurfin (SFN), a winged helix/forkhead protein, which is primarily 
important in T cell homeostasis by controlling their activation and differentiation (Bennett et al., 2001; Lee et 
al., 2005; Schubert et al., 2001). When SFN is modified or absent, or when its DNA-binding site is mutated, 
the T cell homeostasis is destructed leading to an ”early-onset autoimmune disease” (Bennett et al., 2001). But 
SNF can also have the function of a T cell repressor. Different possibilities for this repressor function are 
discussed: SNF could act as a competitor for positive regulatory elements and disable their binding, SNF 
could ”actively repress target promoters” (Schubert et al., 2001), because other forkhead proteins with this 
function are known, or it could be a target for the binding of repressive elements (Schubert et al., 2001).  
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    3.4 Diseases 
 
In the following section the most common hematopoietic disorders appearing in our study are explained to 
overview when HSCT was applied. 
 
 
          3.4.1 Leukemia 
 
Leukemia is a collective name for different types of bone marrow and blood cancer (Piller, 2001). The Greek 
term leukemia stands for ”white blood”, which indicates that normal blood cell homeostasis have changed 
towards an augmentation of white blood cells (Abbott, 2006; Lane et al., 2009; McKenzie, 2005). Which cells 
are involved depends on the type of leukemia. We distinguish primarily between Acute Myeloid Leukemia 
(AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Chronic 
Lymphoblastic Leukemia (CLL) (Chiaretti and Foà, 2009; Mauro and Maziarz, 2006; Stone et al., 2004). The 
subtypes declare which blood cell types are affected and in which stadium the cells turn into cancer cells 
(Piller, 2001). But there are some several leukemia cases that cannot be classified into those common 
subtypes. Also mixed genotypes, like ALL in combination with AML can occur (Chiaretti and Foà, 2009). 
Leukemia represents about 2% of all cancer cases (Uzunel, 2003). Approved risk factors for the development 
of leukemia are high exposure to radiation and chemicals (like benzene). But other unknown factors like the 
genetic background and genetic disorders, tobacco smoking or a former treatment with cytostatica may also 
play an important role (Quintás-Cardama and Cortes, 2006; Zeeb and Blettner, 1998). 
This malignant disease develops from a disfunction of the bone marrow, where a single cell changes into a 
highly proliferating cancer cell. Those abnormal cells overgrow the healthy cells and can dispread in the body, 
if the disease is not treated (Kurzrock et al., 2001; Lane et al., 2009; Onciu, 2009). This usually leads to 
infections caused by the failure of normal leukocytes. Severe anemia, where the blood fails to carry enough 
oxygen throughout the body, is caused by the absence of red blood cells. Bruising and hemorrhaging can also 
occur, which is caused by the absence of platelets (Uzunel, 2003). 
Leukemia can be treated in different ways by using specific drugs, cytostatica or by accomplishing HSCT 
(Barkholt and Ringdén, 2004; Léger and Nevill, 2004). Its aim is a complete remission (CR) which comprises 
no indication of leukemia cells and a normal blood cell level also after years of treatment (Bettelli et al., 2008; 
Ikeda et al., 2002). So the patient can turn to its normal life again. 
 
In case of acute leukemia relatively immature blood cells are deformed to cancer cells, whereas more 
specialized white blood cells are affected in case of chronic leukemia, which has a more slow-going progress 
compared with the acute form (Pui et al., 2004; Sillaber et al., 2003). 
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               3.4.1.1 Acute Myeloid Leukemia (AML) 
 
The risk of getting AML that “represents a group of clonal hematopoiectic stem cell disorders” (Stone et al., 
2004) is increasingly higher in older patients (>60 years), although young adults and children can also be 
affected (McKenzie, 2005; Stone et al., 2004). AML occurs due to the change of one single hematopoietic bone 
marrow cell leading to a malignant neoplasm through altered proliferation of the myeloid precursor cell, 
mutations that affect myeloid cell cycle regulation or apoptosis and failure to differentiation. AML cells are 
more mature than HSC, but have limited self-renewal due to their oncogenic transformation (Lane et al., 
2009; McKenzie, 2005; Renneville et al., 2008). AML cells are often called myeloblast cells, representing a 
cluster of non-functional cells leading to “loss of normal bone marrow function” (McKenzie, 2005) through 
their accumulation (McKenzie, 2005; Stone et al., 2004). 
Genetic disorders, such as Down syndrome, and especially chromosome translocations lead to a higher risk of 
AML development (Renneville et al., 2008; Tenen, 2003). Eight different AML subtypes do exist (M0 to M7) 
according to the blood cell type affected by leukemia and the nature of leukemia cells (Uzunel, 2003). 
Chemotherapy has to be started as soon as AML is diagnosed. The therapy is arranged in two steps: the 
induction therapy, which stands for the initial treatment with chemotherapy, and the consolidation therapy, 
where drug treatment for eliminating the remaining cancer cells is accomplished. A CR after five years is only 
achieved in 40-60% of the cases with this treatment, thus HSCT is very usual in patients with AML (Stone et 
al., 2004). 
 
 
               3.4.1.2 Acute Lymphoblastic Leukemia (ALL) 
 
ALL is the most common type of leukemia in children (under the age of 15) and occurs more often in 
children than in adults, but the chance of getting ALL increases again with the age of 45 or older (Pui et al., 
2004; Teitell et al., 2009). This leukemia form occurs through abnormal changes in a B or T cell (very rarely in 
a NK cell) leading to lymphoid neoplasms due to inhibited cell differentiation, abnormal cell proliferation and 
survival (Onciu, 2009; Teitell et al., 2009). T-ALL, representing about 15% of pediatric and 25% of adult ALL, 
is less common than B-ALL, but T-ALL is more aggressive. The classification into T- and B-ALL can be 
subdivided regarding the distinct cell differentiation stage of the neoplastic clone. The precursor B cell stage, 
which forms precursor lymphoblastic leukemia, can mostly be diagnosed as the cancer cell source of B-ALL, 
whereas “pro-T-, pre-T-, cortical and mature T-ALL” (Chiaretti and Foà, 2009) can appear (Chiaretti and Foà, 
2009; Pui et al., 2004; Van Vlierberghe et al., 2008). 
Genetic disorders like chromosomal translocations, hyperdiploidy and gene-specific mutations can form the 
basis of ALL (Pui et al., 2004; Teitell et al., 2009). 2-4% of the children and about 20% of the adult ALL 
patients have leukemia cells that are carrying the Philadelphia (Ph) chromosome, whereas a chromosome 
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translocation between chromosome 9 and 22 occurs. The translocation involves the gene ABL1 at 
chromosome 9 and the gene BCR at chromosome 22, thus the aberrant BCR-ABL1 gene is built making the 
protooncogene c-ABL oncogenetic leading to alteration of the normal cell growth homeostasis which leads to 
leukemia (Chiaretti and Foà, 2009; Pui et al., 2004 Quintás-Cardama and Cortes, 2006). 
Chemotherapy should be started as soon as possible, whereas children correspond very well to it. 85-90% of 
pediatric and 40-50% of adult ALL cases have CR and are alive after five years, if they have been treated with 
chemotherapy (Onciu, 2009). However, relapse can be observed in many patients, depending on the ALL 
subtype, and those are candidates for HSCT (Pui et al., 2004). 
 
 
               3.4.1.3 Chronic Myeloid Leukemia (CML) 
 
This leukemia form is in contrast to ALL not common in children (<2% of all CML cases) and it is usually 
diagnosed in individuals older than 30 years, whereas its incidence increases with age. CML that is a “clonal 
myeloproliferative disorder of a pluripotent stem cell” (Abramson et al., 1977) is a rare leukemia form. It 
represents 14% of all leukemia cases and 20% of adult leukemia incidences (Abramson et al., 1977; Deininger 
et al., 2000; Quintás-Cardama and Cortes, 2006). 
About 95% of the CML patients have leukemia cells that are carrying the Philadelphia (Ph) chromosome and 
almost half of the remaining patients are carrying the translocated BCR-ABL1 gene as well (Gora-Tybor and 
Robak, 2008; Mauro and Maziarz, 2006; Quintás-Cardama and Cortes, 2006). The emitted BCR-ABL1 gene 
that “exhibits constitutive tyrosine kinase activity” (Sillaber et al., 2003) leads more frequently to CML than to 
ALL and very rarely to AML (Sillaber et al., 2003; Kurzrock et al., 1988).  
CML is divided into three phases: the chronic phase, where most patients are diagnosed, the accelerated phase 
and the blast crisis phase. The chronic phase mostly proceeds asymptomatically, because the white blood cells 
are still working and can combat infections, and diagnose occurs by chance. In the accelerated phase the 
white blood cell number is abnormal and anemia can be caused by CML, whereas the blast cell number is 
augmented in the blast crisis phase, thus the red blood cell and platelet number is decreased (Quintás-
Cardama and Cortes, 2006; Sillaber et al., 2003).  
Leukapheresis is often the first treatment of choice, where the white cells are extracted. This is important, 
because high levels of white blood cells can downgrate the blood flow to important organs like the brain and 
the lungs. Drug treatment, mainly with Imatinib mesylate that is a tyrosine kinase inhibitor is very successful 
in the chronic phase. Remission can be achieved, if the drug is taken continuously. Patients that do not 
respond to tyrosine kinase inhibitors are treated with IFN-α that has an anti-tumor activity in CML treatment 
or undergo HSCT (Gora-Tybor and Robak, 2008; Mauro and Maziarz, 2006; Quintás-Cardama and Cortes, 
2006). 
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               3.4.1.4 Chronic Lymphoblastic Leukemia (CLL) 
 
CLL is the most common adult leukemia form in the western world representing about 25% of new leukemia 
incidences and appears primarily in adults older than 50 (Abbott, 2004 and 2006; O'Brien et al., 1995). 
95% of CLL are deriving from a malignant B lymphocyte, whereas a T- or NK-CLL type is very uncommon. 
CLL that is the only form of leukemia that do not arise from the bone marrow can have a very slow 
progression so that the patients are feeling well and are asymptomatic for a long time, up to years, and no 
treatment is needed, whereas some patients with CLL have a rapid progression and develop symptoms 
(Abbott, 2004 and 2006). Different prognostic markers are associated with a more severe form of CLL, like the 
expression of ζ-chain-associated protein kinase 70 (ZAP70) in B cells, a fast lymphocyte doubling time, loss of 
Ig heavy chain rearrangements as well as distinct cytogenetic abnormalities (Abbott, 2004; Crespo et al., 2003; 
Wiester et al., 2003).  
A treatment, usually chemotherapy and/or monoclonal antibodies against CLL cells, may be started, when the 
CLL cells are very increased and the lymph nodes or spleen are enlarged. HSCT is applied very rarely, because 
chemotherapy leads to a high CR rate (Abbott, 2004 and 2006; O'Brien et al., 1995). 
 
 
          3.4.2 Myeolodysplastic Syndromes (MDS) 
 
MDS is a heterogeneous group of acquired malignant HSC disorders leading to ineffective hematopoiesis, 
cellular defects and blast cell increase in the bone marrow. MDS is primarily developed in older patients 
through long term defects of the bone marrow, whereas also activated oncogenes and chromosome 
aberrations can be involved. However, MDS rarely occurs in younger patients mostly due to applied 
cytostatica or radiation therapy. MDS affected patients have a higher risk for developing AML. 25% of MDS 
patients get this leukemia form, whereas younger patients are more prone to it (Anargyrou et al., 2010; Aul et 
al., 2002). 
High-risk MDS patients up to 60 years of age are mostly treated with HSCT, if they are in good conditions, 
whereas AML-type chemotherapy is also common in young patients (Aul et al., 2002). 
 
 
          3.4.3 Aplastic Anemia 
 
Aplastic anemia is mostly acquired and infrequently inherited, whereas “children, young adults, and those over 
60 years of age” (Keohane, 2004) are mainly affected (Brodsky and Jones, 2005; Keohane, 2004; Young, 2006). 
Aplastic anemia is a rare hematopoietic stem and progenitor cell disorder with destruction of hematopoietic 
cells in the bone marrow. The hypocellular bone marrow is caused by autoimmune T cell reactions. Some 
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patients develop a mild form of the autoimmune disease and may not need any therapy, whereas others 
develop a severe form and are often treated with HSCT. Patients with aplastic anemia are more prone to 
develop MDS or acute leukemia (Brodsky and Jones, 2005; Keohane, 2004; Young, 2006). 
 
 
          3.4.4 Lymphoma 
 
Malignant lymphomas are a heterogenic group of diseases with neoplastic proliferation of the lymph nodes or 
lymphatic tissues. Lymphomas are divided into Hodgkin lymphoma, where B cells are affected and non-
Hodgkin lymphomas with diverse subtypes that are mostly B cell- and rarely T or NK cell-derived (Hochberg 
et al., 2009). 
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4 Materials and methods 
 
     4.1 Patient Information 
 
76 patients, who got informed about the project and gave their consult, were included in our study and 
received HSCT between May 2006 and December 2007 at the Karolinska Institute, Huddinge University 
Hospital in Stockholm. The median age of the treated patients was 45 (range 10-67). Most of the patients had 
been diagnosed with leukemia (42 patients; 28 AML and 8 ALL, 5CLL and 1 CML cases), whereas MDS was 
the second common disease (16 patients). 54 patients had a HLA-matched unrelated donor and 22 patients a 
HLA-identical relative donor. PBSC were the most common stem cell source (56 patients), but also 
transplantations with bone marrow stem cells (BMSC) (13 patients) and CBSC (7 patients; 4 got double and 3 
got single CBSC) were done. CBSC were used, if no good HLA-matched donor was found. The hematopoietic 
progenitor cells that were transplanted were selected from the donor samples through their CD34 expression. 
The median range of CD34+ cells/kg that were transplanted varied between the different stem cell sources. 
PBSC transplants had a median of 7.8 × 106 CD34+ cells/kg (range 2.1 × 106 - 28.2 × 106), BMSC a median of 
2.3 × 106 (range 1.1 × 106 - 7.2 × 106) and CBSC a median of 0.11 × 106 cells/kg (range 0.07 × 106 - 0.72 × 106).  
About half the patients got RIC with fludarabine (30 mg/m2/day × 3), busulfan (4 mg/kg/day × 4) and ATG (2 
mg/kg/day × 5) administration and the other half got myeloablative conditioning (41 and 35 respectively), 
whereas busulfan (4 mg/kg/day × 4) and cyclophosphamid (60 mg/kg/day × 2) in combination with TBI (10 
Gy) was most commonly used in myeloablative conditioning. Some patients got fractioned TBI (3.6 Gy). 60 
out of 76 patients received ATG as prophylaxis for GVHD development. ATG was used in case of unrelated 
donors as well as part of RIC conditioning due to a higher GVHD risk under these circumstances. GVHD 
prophylaxis consisted mainly of an administration of cyclosporine A (2 mg/kg/day) and four doses of 
methotrexate (15 mg/kg/day × 1 + 10 mg/kg/day × 3). 
14 patients developed aGVHD grade I, 16 grade II and 5 developed grade III or IV. aGVHD was diagnosed 
through clinical symptoms, like skin rash, diarrhea or abnormal liver values as defined at the “Consensus 
conference on aGVHD grading” (Przepiorka et al., 1995). 52% (29 patients) who received PBSC and 45% (6 
patients) who received BMSC developed aGVHD, whereas no patient with cord blood as stem cell source 
developed aGVHD. Graft failure or rejection occurred in 7 patients and 12 patients got relapse. 20 of the 
patients died, whereof relapse (9 patients) was the main cause of death. The patient characteristics are listed 
up and described in more detail in table 1. Figure 2 graphically shows the frequency of aGVHD development 
in our study. 
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 Number of   Number of 
 patients   patients 
HSCT treated patients 76  Antithymocyte globulins 60 
Age, median (range) years 45 (10-67)  GVHD prophylaxis   
Diagnosis       MTX+CsA 58 
   Aplastic anemia 4     Pred+CsA 6 
   Acute leukemia 36     FK+Rapa 12 
   Chronic leukemia 6  Acute GVHD   
   Lymphoma 3     no 39 
   Multiple myeloma 1     grade I 14 
   Solid tumour 2     grade II 16 
   MDS/MPS 16     grade III/IV 5 
   Metabolic diseases 6  CMV reactivation 36 
   Myelofibrosis 1  Bacteremia 15 
   Immunocytomegali 1  Graft failure/rejection 7 
Donor    Relapse 12 
   HLA-identical (sibling, parent) 22  Dead 20 
   HLA-matched unrelated donor 54     Relapse 9 
Stem cell source       Fungal infection 3 
   Peripheral blood stem cells 56     Pneumonia 3 
   Bone Marrow 13     EBV-lymphoma 2 
   Cord Blood 7     GVHD 1 
Conditioning       Liver disease 1 
   RIC 41     Other 1 
   Myeloablative 35    
 
 
 
 
    
 
Table 1: Patient information 
MDS indicates myelodysplastic syndromes; MPS, mucopolysaccharidoses; RIC, reduced intensity conditioning; 
HLA, human leukocyte antigen; MTX, methotrexate; CsA, cyclosporine A; Pred, prednisolone; FK, tacrolimus; Rapa, 
rapamycin; CMV, Cytomegalovirus; EBV, Ebstein Barr Virus. 
Figure 2: aGVHD cases 
Grey: no aGVHD; diagonally striped: aGVHD grade I; checkered: aGVHD grade II; 
horizontally striped: aGVHD grade III; dotted: aGVHD grade IV 
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     4.2 Preface 
 
In our study RQ-PCR and ELISA were the methods of choice. RQ-PCR made it possible to measure the 
cytokines’ mRNA levels in CD4+ and CD8+ T cells. We were analyzing the mRNAs of IFN-γ, IL-10, IL-18, 
ICOS, Foxp3, FuT7 and B7-int, whereas we measured the cytokine protein plasma levels of IFN-γ, IL-10, IL-
18, IL-12, IL-17 and IL-23 with ELISA. IFN-γ, IL-10 and IL-18 were analyzed both with RQ-PCR and with 
ELISA. 
ICOS, Foxp3, FuT7 and B7-int are membrane bound and therefore could not be measured in the plasma. 
Whereas IL-12 is mainly distributed by phagocytic cells, B cells and dendritic cells, it could not be detectable 
in T cells’ mRNA. IL-23 is only secreted at low amounts of T cells and was therefore not measured via RQ-
PCR. IL-17 is however mainly distributed by TH17 cells and because we analyzed the gene expression levels in 
CD4+ and CD8+ T cells, only the plasma protein level of IL-17 was studied.  
The following steps that are schematiclally listed upp in figure 3 were done to analyze all patients’ blood 
samples. 
 
 
Figure 3: Surfey of the steps 
Cond., conditioning; d, days after HSCT; ELISA, enzyme-linked immunosorbent assay; HSCT, hematopoietic stem cell 
transplantation; rpm, rounds per minute; RQ-PCR, real time-quantitative polymerase chain reaction 
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     4.3 Samples 
 
The patient samples consisted of 5-10 ml of peripheral blood and were collected at 7 different timepoint 
occasions: before conditioning, at the day of HSCT, 14, 21, 28 days, 3 and 6 months after HSCT. A total of 936 
patient samples (CD4+ and CD8+ T cells) were analyzed. The donor samples consisted also of 5-10 ml of 
peripheral blood or 1-5 ml of bone marrow. Cord blood samples were not analyzed, because the cell amount 
was low and the whole isolated blood was needed for the transplantation. A total of 168 donor samples were 
analyzed, whereas in some cases only donor and no patient samples were available.  
 
 
     4.4 Plasma and T cell Isolation 
 
The plasma samples were obtained from peripheral blood samples collected from the patients, as well as from 
peripheral blood or bone marrow donor samples. The samples were centrifuged (1400 rpm, 10 min, 4˚C) to 
get different phases. The plasma (upper phase) was stored at -20 °C and then used for the ELISA assay.  
The cells in the buffy coat (including most of the white blood cells, therefore also the interesting T cells) were 
collected and beaded with immunomagnetic beads specific against CD4+ T cells. The CD4+ T cells (bound to 
the beads) were separated with a magnet and the remaining coat sample was beaded again with beads specific 
against CD8+ T cells and separated. The two different T cell populations were purified by washing with 
phosphate buffered saline (PBS) to get rid of the unbound cells. 
 
 
     4.5 RNA Extraction 
 
The RNA extraction was operated with the Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany). 
The RLT lysis buffer for disruption and homogenization and β-mercaptoethanol (14,3 M) was added to the 
CD4+ and CD8+ T cells, respectively to break up the cell walls and plasma membranes (disruption) to release 
the cell contents, whereas the RNA was of interest. The RLT buffer contained guanidine thiocyanate to 
inactivate RNases. β -mercaptoethanol denatured proteins through its capacity to cleave disulfide bonds. 
Homogenization was important to lower the viscosity of the cell lysate so that the RNA could bind more 
efficiently to the RNeasy spin column (in the next step). The RNA got stabilized and the cell lysates were 
stored at -75 °C. 
The thawed CD4+ and CD8+ T cell lysats had to get rid of the magnetic beads by using a magnet so that the 
beads could not influence the RNA extraction process. 70% ethanol was added leading to precipitation of 
DNA and RNA. The RNA could bind to the specific ion exchange column and the bulk of the DNA was 
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washed through a filter. Some DNA contaminations always occurred. RW1 and RPE buffers containing 
ethanol were used as washing buffers for a more efficient RNA binding to the filter membrane. RNase-free 
water was added for washing the purified RNA, which is water soluble, from the membrane.  
The RNA concentration was measured with a spectrophotometer at a 1:10 dilution. The 260nm/280nm yield 
delivered a possible protein contamination of the sample. There was no contamination, if the yield lay 
between 1,7 – 2,0 and not above. RNA absorbed the light at 260nm. The samples were nearly always not 
contaminated. The RNA samples were diluted to an end concentration of not more than 50 ng/ml with an end 
volume of 30 µl, because the RQ-PCR signal would not correlate with the RNA yield (respectively cDNA) at 
to high RNA amounts so that primers and probes would not be able to bind all specific cDNA. The primer 
and probe concentration could not be increased neither, because it would result in a more unspecific binding 
to the RNA, adulterating the measuring. 
 
 
     4.6 cDNA Synthesis 
 
cDNA was built form the RNA for the RQ-PCR. It included 1× first strand buffer (50 mM Tris-HCl pH 8.3, 
75 mM KCl, 3 mM MgCl2),  105 µg/ml pdN6 (random hexamer primer; Pharmacia Biosciences, Uppsala, 
Sweden), 1 mM DTT (dithiothreidol; Promega, Madison, WI, USA) and 1 mM of each dNTP 
(deoxyribonucleotide; Pharmacia Biosciences). 4.8 units/µl M-MLV RT (reverse transcriptase; Invitrogen, 
Paisley, Scotland) and 0.48 units/µl RNasin (Promega) were added immediately before the cDNA synthesis 
was started.  
DTT was used for reducing disulfide bonds and as a stabilizer for the Taq polymerase (reverse transcriptase).  
The RNA samples had to be heated at 68 °C for 10 min. before the cDNA mix (21 µl for each sample) was 
added to open secondary and tertiary structures of the RNA so that the primers could bind. The samples were 
incubated at 37 °C for 1½ hours. RT and the RNasin are most active at this temperature. When RNA was 
bound to cDNA, it was broken down by RT, whereas RNasin stabilized the RNA in its unbound form. After 
incubation time the samples were heated at 68 °C for 2 min. to inactivate the enzymes. The samples were 
diluted with 80 µl RNase-free water and stored at -20 °C. 
 
 
     4.7 Real time Quantitative Polymerase Chain Reaction (RQ-PCR) 
 
RQ-PCR has a big advantage over standard PCR, which just delivers cDNA information on qualitative 
analysis. Furthermore a post-PCR analysis (gel-electrophoresis) is required in the standard PCR to make this 
statement. The RQ-PCR is a quantitative method, where the PCR products are accumulated in real time, the 
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PCR products are doubled in every cycle. The detection of the product is done through measuring the 
fluorescence signals generated during the PCR process. The fluorescence signal can be produced in different 
ways through different methods (Uzunel, 2003). 
We used the TaqMan-probes, where two fluorochromes, a reporter fluorochrome at the 5' end and a quencher 
fluorochrome at the 3' end were bound. If the probe bound to the DNA, the reporter and quencher were in 
close distance to each other and therefore the quencher could silence the fluorescence signal, which was 
emitted from the reporter dye. This occurred because the quencher dye had lower fluorescence energy than 
the reporter dye and it took up the free, from the reporter dye emitted electrons leading to no fluorescence 
signal in the reporter dye wavelength. Only a quencher specific fluorescence signal appeared. 
During polymerization the probe was displaced by the Taq-polymerase and hydrolyzed by the 5' to 3' 
exonuclease activity of this enzyme. The reporter and quencher were more distant to each other and therefore 
lost the quencher its function. Thus a reporter fluorescence signal could be measured. The intensity of the 
signal was doubled in every cycle in the logarithmic phase. The signal formation and polymerization during 
the RQ-PCR run is shown in figure 4. 
 
 
Figure 4: RQ-PCR with Taqman-probe 
The fluorescence signal of the reporter dye can be measured, if the quencher 
is more distant to the reporter, thus is no longer able to absorb the reporter’s 
fluorescence signal.  
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The total cDNA (corresponding to the RNA) amount could be measured by using a standard curve with 
known cDNA concentrations. The concentration correlated with the fluorescence intensity and therefore with 
the threshold cycle (Ct) value (see below). We were instead only interested in a relative quantification, where 
the RNA amount of one gene was seen as its correlation to another. Therefore no standards were used. We 
used the G6PD (Glucose-6-phosphate dehydrogenase) gene as internal reference gene that is part of the 
pentose phosphate pathway and is relative constantly expressed in T cells providing to see if a higher signal in 
different genes was due to more cells (resulting also in a higher G6PD signal) or to a higher RNA amount 
(G6PD signal was not altered).  
The Ct was defined as the cycle where the fluorescence signal could be measured over a distinct threshold and 
could therefore be distinguished from the background. If the Ct was low, the mRNA (cDNA) concentration 
was high. 
FAM (6-carboxy fluorescein; Applied Biosystems, Foster City, CA, USA) was used as reporter and TAMRA 
(6-carboxy-tetramethyl rhodamine; Applied Biosystems) was used as quencher dye. FAM had its emission 
maximum at 520 nm and TAMRA its excitation maximum at 555 nm and its emission maximum at 576 nm. 
TAMRA was able to absorb the emission light of FAM, because it did not only absorb light at the wavelength 
of 555 nm and FAM emitted light up to 570 nm. 
The ABI 7000 Sequence Detection System (Applied Biosystems) was used for RQ-PCR running.  
The PCR mix included 1×TaqMan Universal PCR Master Mix (Applied Biosystems, containing dNTPs with 
deoxyuridine-triphosphate (dUTP), MgCl2, AmpliTaq Gold® DNA polymerase, AmpErase® uracil-DNA-
glycosylase (UNG) and 300 nM of gene specific primers (Applied Biosystems) and 200 nM of probes. UNG 
was used for preventing false positives through its capacity to remove uracil from PCR contaminating 
products, such as from probe-bound RNA. 
22.5 µl mix and 2.5 µl samples were added in each well and centrifuged (1400 rpm; 45 sec) to get rid of 
bubbles at the bottom that could influence the RQ-PCR.  
The following primer and probe sequences for Foxp3, IFN-γ, IL-10, IL-18, ICOS, FuT7, B7-int and G6PD 
were used: 
Foxp3 forward primer: 5'-AACAGCACATTCCCAGAGTTCCT-3' 
Foxp3 reverse primer: 5'-CATTGAGTGTCCGCTGCTTCT-3' 
Foxp3 probe: 5'-FAM-CCTTTCACCTACGCCACGCTCATCC-TAMRA-3' 
IFN-γ forward primer: 5'-GAAAAGCTGACTAATTATTCGGTAACTG-3' 
IFN-γ reverse primer: 5'-GTTCAGCCATCACTTGGATGAG-3' 
IFN-γ probe: 5'-FAM-TTGAATGTCCAACGCAAAGCAATACATGA-TAMRA-3' 
IL-10 forward primer: 5'-GAGGCTACGGCGCTGTCAT-3' 
IL-10 reverse primer: 5'-AGATGCCTTTCTCTTGGAGCTTATT-3' 
IL-10 probe: 5'-FAM-CAAGAGCAAGGCCGTGGAGCAGG-TAMRA-3' 
IL-18 forward primer: 5'-GACCAAGGAAATCGGCCTCTA-3' 
IL-18 reverse primer: 5'-ACCTCTAGGCTGGCTATCTTTATACATAC-3' 
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IL-18 probe: 5'-FAM-ACTGATTCTGACTGTAGAGATAATGCACC-TAMRA-3' 
ICOS forward primer: 5'-CCATAGGATGTGCAGCCTTTG-3' 
ICOS reverse primer: 5'-GGTCGTGCACACTGGATGAA-3' 
ICOS probe: 5'-FAM-CATTTTGGGATGCATACTTATTTGTTGGCTTACA-TAMRA-3' 
FuT7 forward primer: 5'-CGGCTGCCGTGATTTGAG-3' 
FuT7 reverse primer: 5'-GGCCGTGCCCAGCAT-3' 
FuT7 probe: 5'-FAM-TTGGCTGACTGATCCTGGGAGACTGTG-TAMRA-3' 
B7-int forward primer: 5'-CAGCACAGAGTTTGACTACCCTTCT-3' 
B7-int reverse primer: 5'-GGCACTGGTGACAGCAAAGA-3' 
B7-int probe: 5'-FAM-CCTCTCTGCAGCAAATATCCAGCC-TAMRA-3' 
G6PD forward primer: 5'-TGCCCCCGACCGTCTAC-3' 
G6PD reverse primer: 5'-ATGCGGTTCCAGCCTATCTG-3' 
G6PD probe: 5'-FAM-ACTCGTGAATGTTCTTGGTGACGGCC-TAMRA-3' 
 
The RQ-PCR was run according to the scheme (Table 3). All samples were run in duplicates using 96-well 
plates. The threshold (between 0.15 and 0.20) was adjusted manually, which allowed a precise tuning after a 
RQ-PCR run. The baseline was set manually between the first 3 cycles and about 3 cycles before the first 
exponential increase crossing the threshold line. 
 
 
PCR cycle       
Stage 1 Stage 2 Stage 3 step1 Stage 3 step2 
1x 1x 40x 40x 
50°C 95°C 95°C 60°C 
2 min 10 min 15 sec 1 min 
UNG Polymerase Denaturation Annealing  
Deactivation Activation   Elongation 
 
 Table 3: PCR cycle 
 Stage 1 and 2 were only perfomed at the beginning of the RQ-PCR run. Step 1 
 and 2 of stage 3 were run alternating for 40 times.  
 
 
     4.8 Enzyme-linked immunosorbent assay (ELISA) 
 
Sandwich ELISA was the method of choice to measure the protein expression level. The proteins, in which we 
were interested, were the cytokines that were probably relevant in GVHD: IL-10, IL-12, IL-17, IL-18, IL-23 
and IFN-γ. Figure 5 shows a schematic overview of the different ELISA steps. 
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Figure 5: Sandwich ELISA 
The wells turn blue after addition of the substrate, if enough biotin-labeled detection antibodies can bind (positive samples). If the 
reaction gets stopped with H2SO4, the wells turn into yellow. For description see text. 
Ab, antibody; h, hours; HRP, horseradish peroxidase; inc, incubation; RT, room temprature 
 
The ELISAs were put up with the help of the “ELISA development guide” provided by R&D Systems 
(Minneapolis, MN, USA), using flat-bottom polystyrene 96 well half-area enzyme immunoassay plates 
(Costar, Cambridge, MA, USA), thereby allowing an addition of 50 μl per well in each step instead of 100 μl 
as in the manual. Coating was performed with a cytokine specific antibody overnight at room temperature 
(R&D Systems coating antibodies for IL-10, IL-12 and IL-17; MBL, Woburn, MA, USA coating antibody for 
IL-18; eBioscience, San Diego, CA, USA coating antibody for IL-23) and during four nights at +7 °C (IFN-γ, 
R&D Systems), with the antibodies diluted in 0.05 M carbonate-bicarbonate buffer (pH 9.6). The plates were 
washed four times in a 0.15 M sodium chloride (NaCl) 0.05% Tween-20 buffer (after each step) to get rid of 
the unbound antibodies. Blocking was performed during two hours in PBS buffer containing 1% bovine 
serum albumin (BSA) to avoid unspecific bindings. Samples, recombinant human cytokines (R&D Systems 
for IL-10, IL-12, IL-17, IL-23, IFN-γ; MBL for IL-18) for standard curves, detection antibodies and 
streptavidine-conjugated poly horseradish peroxidase (HRP; Sanquin Reagents, Amsterdam, The 
Netherlands) were diluted in 1% BSA and 0.05% tween in PBS (IL-10, IL-17, IL-18), and high performance 
ELISA (HPE) dilution buffer (Sanquin Reagents) diluted 1:8 in sterile water (IL-12, IL-23, IFN-γ). The 
detection antibodies were diluted in 1% BSA and 0.05% tween in PBS or HPE dilution buffer, respectively 
containing 2% goat serum. After blocking and thoroughly washing the samples, different standard 
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concentrations and a blank (50 μl/well) were added in duplicates. The incubation time was 2 hours so that the 
samples and standards could bind to the immobilized antibodies. After another washing step for getting rid of 
the unbound analytes a biotin conjugated detection antibody (R&D Systems detection antibodies for IL-10, 
IL-12, IL-17 and IFN-γ; MBL detection antibody for IL-18; eBioscience detection antibody for IL-23) that 
could bind to another analyte-epitope was added and incubated for 1 hour. The streptavidine-conjugated 
poly-HRP (diluted 1:10.000) detection agent was added after washing to bind to the biotin-labeled detection 
antibody (20 minutes incubation). In the final step a substrate solution containing tetramethylbenzidine 
dihydrochloride - 1 tablet/10 ml (SIGMA, Saint Louis, MO, USA) and hydrogen peroxide (1:10.000) in 0.05 
M phosphate-citrate buffer (pH 5.0) was added and the reaction was stopped by the addition of 50 μl 1M 
sulfuric acid (H2SO4), when the product got colored bluish. The reaction was stopped after not more than 20 
minutes even though the substrate did not turn blue to avoid false positives. 
The concentrations of the coating, detection antibodies, sample dilutions and standard curves were listed up 
in table 4. 
 
 
 
Coating-ab 
(μg/ml) 
Standard 
curve (pg/ml) 
Detection-ab 
(ng/ml) 2% 
goat serum 
Sample 
dilution 
IL-10 1 2,1 - 1500 50 01:02 
IL-12p70 (IL-12) 4 8,2 - 6000 50 01:02 
IL-12p40 (IL-23) 4 8,2 - 6000 500 01:02 
IL-17 4 4,1 - 3000 50 01:02 
IL-18 2 1,4 - 1000 125 1:30 1:90 
IL-23 2 8,2 - 6000 500 01:02 
IFN-γ 1 8,2 - 6000 50 01:02 
 
 
 
 
Table 4: ELISA detai ls 
Antibody concentrations, standard curves and sample dilutions; ab, antibody 
 
The recombinant human antibodies were used for standard curves. They were diluted threefold in order to 
see the lower and the linear part of the sigmoidal curve. All plates were read with the VMax Kinetic 
Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) at 450 nm, using 550 nm as reference 
wavelength, and the results were analyzed with help of Softmax Pro 3.0 (Molecular Devices). The detection 
level of the distinct cytokines was set at the initiation of the linear phase of the sigmoidal curve of each 
standard curve. The sensitivity in detection was in the range of 10-1000 pg/ml for IL-10, 20-1000 pg/ml for 
IL-12, 50-1000 pg/ml for IL-17, 5-1000 pg/ml for IL-18, 200-2000 pg/ml for IL-23 and 70-5000 pg/ml for 
IFN-γ. The samples, which concentrations did not exceed the lowest detection level were set as half of that 
concentration (5 pg/ml for IL-10, 10 pg/ml for IL-12 and so one).  
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     4.9 Statistical Analysis 
 
Survival and incidence curves were generated using the Kaplan-Meier method. For univariate and 
multivariate analysis, the Cox proportional hazards regression model was used. Mann-Whitney U test and 
Fisher’s exact tests were used to evaluate differences between groups. Analyses were performed using 
Statistica software (StatSoft, Tulsa, OK, USA). 
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5 Results 
 
     5.1 RQ-PCR Results 
 
          5.1.1 Overall Gene Expression Levels at Different Timepoint Occasions 
 
The different gene expression levels in CD4+ and CD8+ T cells of donors and all patients were compared, not 
distinguishing patients with and without GVHD, to see an overall trend of the gene expression levels’ 
expansions from the time period of conditioning to 6 months after transplantation, as shown in figure 6a-g. 
This may elucidate which cytokine productions got more influenced by conditioning as well as HSCT and 
how fast, if at all, they reached their pre-conditioning states again. 
 
 
Figure 6a:  Foxp3 gene expression in CD4+ and CD8+ T cel ls  
black striped - CD4+ T cells; white - CD8+ T cells; DON, donor; Condt, pre-conditioning; D+0, day of HSCT; 
D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 months after HSCT 
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Figure 6b:  IFN-γ  gene expression in CD4+ and CD8+ T cel ls 
black striped - CD4+ T cells; white - CD8+ T cells; DON, donor; Condt, pre-conditioning; D+0, day of HSCT; 
D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 months after HSCT 
 
 
Figure 6c:  IL-10 gene expression in CD4+ and CD8+ T cel ls 
black striped - CD4+ T cells; white - CD8+ T cells; DON, donor; Condt, pre-conditioning; D+0, day of HSCT; 
D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 months after HSCT 
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Figure 6d:  IL-18 gene expression in CD4+ and CD8+ T cel ls 
black striped - CD4+ T cells; white - CD8+ T cells; DON, donor; Condt, pre-conditioning; D+0, day of HSCT; 
D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 months after HSCT 
 
 
Figure 6e:  ICOS gene expression in CD4+ and CD8+ T cel ls 
black striped - CD4+ T cells; white - CD8+ T cells; DON, donor; Condt, pre-conditioning; D+0, day of HSCT; 
D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 months after HSCT 
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Figure 6f:   FuT7 gene expression in CD4+ and CD8+ T cel ls 
black striped - CD4+ T cells; white - CD8+ T cells; DON, donor; Condt, pre-conditioning; D+0, day of HSCT; 
D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 months after HSCT 
 
 
Figure 6g:  B7-int gene expression in CD4+ and CD8+ T cel ls 
black striped - CD4+ T cells; white - CD8+ T cells; DON, donor; Condt, pre-conditioning; D+0, day of HSCT; 
D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 months after HSCT 
 
 
 
Comparing the donors’ gene expression levels with the patients’ pre-conditioning gene expressions in 
CD4+ and CD8+ T cells, respectively, no signi!cant diﬀerences of Foxp3, IFN-γ, IL-10, IL-18, ICOS and 
FuT7 expression levels were seen (!gure 6a-f). But the mRNA level of B7-int in CD4+ T cells was lower in 
pre-conditioning patients’ than in donors’ samples, although not signi!cantly (!gure 6g).
Looking at the donors’ or patients’ pre-conditioning mRNA levels of Foxp3, IL-10, IL-18 and FuT7, genes 
were stronger expressed in CD4+ T cells than in CD8+ T cells, whereas IFN-γ was more expressed in CD8+ 
T cell and ICOS had comparable mRNA levels in both T cell types. We measured equal B7-int gene 
expression levels in donors’ CD4+ T cells and CD8+ T cells, but a lower B7-int expression in patients’ CD4+ 
T cells than in CD8+ T cells at pre-conditioning state that was comparable with the donors’ B7-int level in 
CD8+ T cells. 
Foxp3 and IFN-γ showed both a downregulation of their mRNA levels aer conditioning, but the levels 
increased again 14 days aer transplantation. Foxp3 reached a normal, pre-conditioning level aer 6 
months and IFN-γ aer 3 months. e conditioning regime did not shi the expression of Foxp3 or IFN-γ 
from more expressing CD4+ T cells to more expressing CD8+ T cells or vice versa. Foxp3 had always higher 
mRNA levels in CD4+ T cells and IFN-γ in CD8+ T cells.
e ICOS gene expression level strongly decreased in CD4+ T cells, but only slightly in CD8+ T cells aer 
conditioning, so that not both T cell types were expressing likely the same amount of ICOS any more. e 
gene expression level of ICOS increased 14 days aer transplantation and reached a normal, pre-
conditioning level aer 3 to 6 months, whereas both T cell types were expressing the same ICOS mRNA 
amount again.
e overall gene expression level of FuT7 was in principle the same, whereby CD8+ T cells were producing 
more FuT7 than CD4+ T cells aer conditioning, thus the T cell types changed their expression levels. 3 
months aer transplantation CD4+ T cells were producing more FuT7 than CD8+ T cells again, as under 
pre-conditioning circumstances.
e gene expressions of B7-int was very decreased aer conditioning, whereas CD8+ T cells were 
expressing more B7-int than CD4+ T cells, like in the patients’ pre-conditioning state.  e B7-int mRNA 
level slightly increased aer 3 months and was comparable with the pre-conditioning state aer 6 months.
IL-10 and IL-18 were the only genes measured in this study that increased aer conditioning, whereas 
their gene expression was always stronger in CD4+ than in CD8+ T cells. IL-10 had a strong and IL-18 only 
a weak increase. Both IL-10 and IL-18 reached a pre-conditioning gene expression state 3 months aer 
transplantation. 
          5.1.2 Gene Expression Levels in T Cells - with and without ATG
ATG was used for depleting T cells aer HSCT, thus reducing the risk of aGVHD (see page 15). We were 
therefore interested if there were any diﬀerences of the cytokine gene expression levels between patients, 
who received ATG and patients, who did not, thus may explaining the diverse outcome of aGVHD 
development.
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Figure 7a: Foxp3 gene expression in CD4+ and CD8+ T cells - comparing with (black striped) and without (white) 
ATG 
***: p < 0.001; **: p < 0.01; *: p < 0.05
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Figure 7b: IFN-γ gene expression in CD4+ and CD8+ T cells - comparing with (black striped) and without (white) 
ATG 
***: p < 0.001; **: p < 0.01; *: p < 0.05
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Figure 7c: IL-10 gene expression in CD4+ and CD8+ T cells - comparing with (black striped) and without (white) 
ATG 
***: p < 0.001; **: p < 0.01; *: p < 0.05
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Figure 7d: IL-18 gene expression in CD4+ and CD8+ T cells - comparing with (black striped) and without (white) 
ATG 
***: p < 0.001; **: p < 0.01; *: p < 0.05
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Figure 7e: ICOS gene expression in CD4+ and CD8+ T cells - comparing with (black striped) and without (white) 
ATG 
***: p < 0.001; **: p < 0.01; *: p < 0.05
55
Figure 7f: FuT7 gene expression in CD4+ and CD8+ T cells - comparing with (black striped) and without (white) 
ATG 
***: p < 0.001; **: p < 0.01; *: p < 0.05
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Figure 7g: B7-int gene expression in CD4+ and CD8+ T cells - comparing with (black striped) and without (white) 
ATG 
***: p < 0.001; **: p < 0.01; *: p < 0.05
e most signi"cant diﬀerences occurred in gene expression levels of Foxp3, IFN-γ, ICOS and B7-int, in 
both CD4+ and CD8+ T cells ("gure 7a-g).
Foxp3 and ICOS had a similar gene expression development from the day of transplantation to 6 months 
aer HSCT. Without ATG the levels of Foxp3 and ICOS were quite constant in both T cell types, 
comparing to the donors’ samples and pre-conditioning states, whereas both Foxp3 and ICOS were 
signi"cantly decreased in patients with ATG treatment. In CD4+ T cells the gene expression levels of Foxp3 
and ICOS were lowered up to 100-times with ATG (p < 0.001), but the expressions started to increase 21 
days aer transplantation again and reached the same gene expression levels as without ATG 6 months 
aer HSCT. In CD8+ T cells the mRNA levels of Foxp3 and ICOS were decreased 10-times with ATG (p < 
0.001) and also started to increase, like in CD4+ T cells at day 21. A comparable Foxp3 gene expression 
level of patients with and without ATG was reached aer 6 months and a comparable ICOS gene 
expression level aer 3 months in CD8+ T cells. 
e gene expression levels of IFN-γ were constant over time without ATG treatment in CD4+ T cells, but 
slightly decreased in CD8+ T cells. A strong IFN-γ decrease occurred with T cell-depleted transplants, up 
to 100-times in CD4+ T cells (p < 0.001) and up to 10-times in CD8+ T cells (p < 0.01 – 0.001). e mRNA 
level of IFN-γ was increased at day 21 aer transplantation in both T cell types and reached a normal level, 
corresponding to donors’ value and patients’ pre-conditioning state, aer 3 months.
In CD4+ T cells the gene expression of B7-int was slightly decreased without ATG 21 days aer 
transplantation. 6 months aer HSCT the B7-int mRNA levels of patients with non-T cell-depleted 
transplants was still lowered, comparing to pre-conditioning state. In CD8+ T cells of patients without 
ATG administration the mRNA levels of B7-int was almost constant. In both CD4+ and CD8+ T cells the 
gene expressions of B7-int was signi"cantly decreased in ATG treated patients (p < 0.01 – 0.001). e 
levels started to increase in CD8+ T cells 14 days aer transplantation again.
e gene expression levels of FuT7 hardly diﬀered in both T cell types comparing patients with and 
without ATG. However, the mRNA level of FuT7 was decreased with ATG from day 14 to day 28 aer 
transplantation in CD4+ T cells (p < 0.05 – 0.01). Furthermore the overall expression was rather constant. 
e mRNA level of IL-10 was quite constant in CD8+ T cells without ATG, but was slightly increased at the 
day of transplantation and 14 days aer with ATG (p < 0.05 – 0.01). In CD4+ T cells IL-10 was mildly 
increased at the day of transplantation, not mattering if the transplant was T cell-depleted or not. 
e gene expression level of IL-18 was slightly increased in CD8+ T cells during the time period aer 
conditioning to day 28 aer transplantation without ATG, whereas IL-18 was signi"cantly more increased 
at the day of transplantation and 14 days aer with ATG (p < 0.01). In CD4+ T cells the IL-18 gene 
expression was decreased at the day of transplantation without ATG, but signi"cantly increased with ATG 
administration (p < 0.001). In CD4+ T cells IL-18 was expressed similarly in patients with and without 
ATG from 14 days to 6 months aer HSCT.
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          5.1.3 Gene Expression Levels in Donor T Cells - BMSC versus PBSC
Maybe the stem cell source was important for a diverse expression of the genes and thus for diﬀerences in 
aGVHD development. We compared therefore the donors’ gene expression levels of BMSC with PBSC 
gras, as shown in " gure 8a-b. CBSC only delivered a few amount of cells, which all were used for 
transplantation and not for further studies. Comparing the gene expression levels of BMSC donor gras 
with PBSC donor gras delivered some signi"cant diﬀerences.
Figure 8a: Gene expression levels in donor graft CD4+ T cells – comparing BMSC (white) with PBSC (black 
striped)
BM – bone marrow; PBSC – peripheral blood stem cells
***: p < 0.001; **: p < 0.01
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Figure 8a: Gene expression levels in donor graft CD4+ T cells – comparing BMSC (white) with PBSC (black striped)
BM – bone marrow; PBSC – peripheral blood stem cells
***: p < 0.001
Figure 8b: Gene expression levels in donor graft CD8+ T cells – comparing BMSC (white) with PBSC (black striped)
BM – bone marrow; PBSC – peripheral blood stem cells
***: p < 0.001; **: p < 0.01
In CD4+ T cells Foxp3, IFN-γ, ICOS, FuT7 and B7-int were signi"cantly higher expressed in donor 
samples of PBSC gras than in samples of BMSC gras (p < 0.001), whereas IL-10 and IL-18 were 
signi"cantly lower expressed (p < 0.001). Foxp3, FuT7 and B7-int also had a signi"cantly higher and IL-10 
a signi"cantly lower expression (p < 0.001) in CD8+ T cells deriving from PBSC donor gras than those 
from BMSC gras, like in CD4+ T cells. IFN-γ and IL-18 were in contrast equally expressed in CD8+ T 
cells of both diﬀerent stem cell sources. In CD8+ T cells ICOS was higher expressed in blood samples of 
BMSC donor gras than in samples of PBSC gras, inversely to CD4+ T cells, resulting that the overall 
ICOS expression was equal in both diﬀerent donor gra types. 
ese gene expression diﬀerences of the two diverse stem cell sources were only seen in the donors’ but 
not patients’ samples (data not shown). Additionally, the used stem cell source had no in&uence on the 
development of aGVHD. 45% of the patients, who got BMSC transplants and 52% receiving PBSC 
transplants developed aGVHD.
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           5.1.4 Gene Expression Levels in T Cells - with and without GVHD
We compared the gene expression levels of Foxp3, IFN-γ, IL-10, IL-18, ICOS, FuT7 and B7-int with help 
of RQ-PCR in patients, who did not develop aGVHD with patients, who got aGVHD, to see if there were 
any signi"cant diﬀerences between those 2 groups. us, cytokines that act as diagnostic markers or as 
therapeutic approaches could maybe identi"ed. Only patients’ sampels with ATG treatment were analyzed, 
because ATG, as seen before, had a huge in&uence on the gene expressions, so that altered expression 
levels were due to aGVHD and not to ATG.
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Figure 9a: Foxp3 gene expression levels in CD4+ and CD8+ T cells – comparing patients with (red) and 
without (blue) aGVHD
DON, donor; Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 
3/6 months after HSCT
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Figure 9b: IFN-γ gene expression levels  in CD4+ and CD8+ T cells – comparing patients with (red) and without 
(blue) aGVHD 
DON, donor; Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 
months after HSCT
Figure 9c: IL-10 gene expression levels in CD4+ and CD8+ T cells – comparing patients with (red) and without 
(blue) aGVHD 
DON, donor; Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 
months after HSCT
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Figure 9d: IL-18 gene expression levels in CD4+ and CD8+ T cells – comparing patients with (red) and without 
(blue) aGVHD 
DON, donor; Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 
3/6 months after HSCT
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Figure 9e: ICOS gene expression levels in CD4+ and CD8+ T cells – comparing patients with (red) and without 
(blue) aGVHD 
DON, donor; Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 
3/6 months after HSCT
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Figure 9f: FuT7 gene expression levels in CD4+ and CD8+ T cells – comparing patients with (red) and without 
(blue) aGVHD 
DON, donor; Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 
3/6 months after HSCT
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Figure 9g: B7-int gene expression levels in CD4+ and CD8+ T cells – comparing patients with (red) and 
without (blue) aGVHD 
DON, donor; Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 
3/6 months after HSCT
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e gene expression levels in the 2 diﬀerent patient groups did not show any signi"cant diﬀerences 
regarding IL-10 or B7-int in CD4+ and CD8+ T cells ("gure 9c+g), respectively. However, we measured 
some signi"cant expression diﬀerences in the other analyzed genes. Foxp3 ("gure 9a) was signi"cantly 
more expressed in CD8+ T cells of patients with aGVHD comparing to patients without aGVHD at the day 
of transplantation (p = 0.005) and 28 days aer HSCT (p = 0.020). Furthermore was a trend seen towards 
more Foxp3 expression in CD8+ T cells of patients with aGVHD 6 months aer transplantation (p = 
0.053). In CD4+ T cells Foxp3 was signi"cantly more expressed in patients with aGVHD 21 days aer 
transplantation (p = 0.016), although no trend was detected at any other timepoint. IFN-γ ("gure 9b) had 
signi"cantly higher gene expression levels in CD4+ T cells of patients without aGVHD 21 days aer HSCT 
(p = 0.033). However no such signi"cance was detected in CD8+ T cells, nor was a trend seen at any other 
timepoint occasion. Patients, who developed aGVHD had increased IL-18 gene expression ("gure 9d) in 
CD4+ T cells 21 days aer HSCT compared to patients without aGVHD (p = 0.008), although no trend 
could be measured at any other timepoint. ere were no signi"cantly diﬀerent IL-18 gene expressions in 
CD8+ T cells between the 2 patient groups. ICOS ("gure 9e) was elevated in both CD4+ and CD8+ T cells of 
patients with aGVHD development 21 days aer transplantation (p = 0.029 in CD4+; and p = 0.039 in 
CD8+ T cells). In CD8+ T cells of patients with aGVHD the gene expression of FuT7 ("gure 9f) was 
signi"cantly higher than in patients without aGVHD 21 and 28 days aer transplantation (p = 0.001 at day 
21; and p = 0.023 at day 28), whereas the expression did not alter between the 2 patient groups in CD4+ T 
cells.
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5.2 ELISA
          5.2.1 Cytokine Plasma Levels - with and without GVHD
e T cells that were analyzed via RQ-PCR were not the only source for cytokine productions.  us, 
diverse cytokine levels in the plasma were analyzed further with ELISA comparing ATG-treated patients 
with and without aGVHD to "nd markers for aGVHD onset as well as possible therapeutic interventions. 
Figure 10a: IFN-γ protein plasma levels – comparing patients with (red) and without (blue) aGVHD
Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 
months after HSCT
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Figure 10b: IL-12 protein plasma levels – comparing patients with (red) and without (blue) aGVHD
Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 
months after HSCT
Figure 10c: IL-10 protein plasma levels – comparing patients with (red) and without (blue) aGVHD
Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 
months after HSCT
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Figure 10d: IL-18 protein plasma levels – comparing patients with (red) and without (blue) aGVHD
Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 
months after HSCT
Figure 10e: IL-17 protein plasma levels – comparing patients with (red) and without (blue) aGVHD
Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 
months after HSCT
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Figure 10f: IL-23 protein plasma levels – comparing patients with (red) and without (blue) aGVHD
Condt, pre-conditioning; D+0, day of HSCT; D+14/21/28, 14/21/28 days after HSCT; M+3/6, 3/6 months 
after HSCT
IL-10, IL-12, IL-17 and IL-23 did not deliver any signi"cant diﬀerences in the plasma between the 2 
patient groups ("gure 10b,c,e,f). However, the IFN-γ plasma level ("gure 10a) was signi"cantly higher in 
patients without aGVHD than in patients, who developed the disease at the day of transplantation as well 
as 3 months aer SCT (p=0.009 at day 0; p=0.037 at 3 months). ere was a trend towards higher IFN-γ 
plasma levels in patients without aGVHD at pre-conditioning state, 14 days and 28 days aer 
transplantation (p=0.08). Patients with aGVHD (grade I-IV) had lower IFN-γ levels at the day of 
transplantation (median: 35pg/ml) compared to those without aGVHD (median: 235pg/ml), shown in 
"gure 11.
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Figure 11: IFN-γ protein plasma levels at day 0, comparing patients without aGVHD (on the left) and 
patients with aGVHD at grad I, II, III or IV (on the right)
e IFN-γ plasma level diﬀered also signi"cantly between the group including patients without aGVHD + 
aGVHD grade I (median: 144pg/ml) and the group including patients with more severe aGVHD (grade 
II-IV) (median: 35pg/ml), shown in "gure 12.
Figure 12: IFN-γ protein plasma levels at day 0, comparing patients without aGVHD or a aGVHD grad I (on 
the left) and patients with aGVHD grad II, III or IV (on the right)
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Figure 13 shows that the incidence of getting aGVHD was much higher, if the IFN-γ plasma level was lower 
than 200pg/ml at the day of transplantation. 64% of the patients with an IFN-γ level lower than this threshold 
developed aGVHD, whereas only 17% of the patients with IFN-γ levels above this value developed the 
disease.  
 
 
Figure 13: Incidence of aGVHD grad I - IV 
comparing IFN-γ protein levels at day 0 higher and lower than 200pg/ml. 64% of the patients with 
low IFN-γ levels got aGVHD, whereas 17% of the patients with IFN-γ levels over 200pg/ml got 
aGVHD. 
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In figure 14 the incidence of getting aGVHD (grade II-IV) is shown. 42% of the patients with IFN-γ plasma 
levels lower than 200pg/ml on the day of transplantation developed aGVHD (grade II-IV), compared to 4% 
that had higher IFN-γ levels (>200pg/ml) in the circulation. 
 
 
Figure 14: Incidence of aGVHD grad I I - IV 
comparing IFN-γ protein levels at day 0 higher and lower as 200pg/ml. 42% of the patients with low IFN-γ 
levels got aGVHD, whereas 4% of the patients with IFN-γ levels over 200pg/ml got aGVHD.  
 
 
Comparing plasma IL-18 levels between patients with and without aGVHD at the different timepoint 
occasions did not deliver any significant differences. But an interesting correlation between the IL-18 plasma 
level and the onset day of aGVHD could be found. The IL-18 plasma levels were significantly increased in 
patients with aGVHD on the onset day of the disease (p < 0.001). 
 
In figure 15 the IL-18 levels of all patients (with and without aGVHD) are shown. Day “0” was defined as the 
day of aGVHD onset. For patients, who did not develop the disease, day “0” was set as day 30 after 
transplantation as this was the median time for aGVHD development. The measured data of the different 
timepoints were related to this day “0”. IL-18 was significantly elevated at the onset day of aGVHD, 
comparing to IL-18 levels before aGVHD development in aGVHD patients, after aGVHD onset and to 
patients without aGVHD. 
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Figure 15: IL-18 protein levels in relation to the development of aGVHD 
The level of IL-18 is elevated at the day of aGVHD onset, marked as day ”0” 
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6 Discussion 
 
     6.1 Preface 
 
To can better understand the development of GVHD and thus be able to prevent it as well as to design 
potential therapy forms and betimes recognition mechanisms, it is most important to know which role 
different cytokines play in GVHD. It is not clear yet if TH1 cytokines enhance the development of GVHD or if 
they have positive effects by inhibiting the disease, or if TH2 cytokines are the key regulators to prevent or in 
contrast impair GVHD, because studies with conflicting outcomes have been reported (Blazar et al., 1995; 
Krenger et al., 1995; Murphy et al., 1998; Yang et al. 2005).  
 
 
     6.2 Overall Gene Expression Levels in CD4+ and CD8+ T cells 
 
In our study the equal gene expression levels of donors’ and patients’ pre-conditioning samples, CD4+ and 
CD8+ T cells, respectively, indicated that an altered gene expression in patients’ samples after conditioning 
was not due to different graft cells, but to the conditioning regime. It may also suggested that the patients’ 
diseases did not alter the expression of the analyzed genes, although this has to be confirmed in further 
studies, because all patients with different diseases were analyzed together that may led to a reciprocal 
influence on the gene expressions. Both CD4+ and CD8+ T cells reached the same gene expression levels of all 
analyzed genes 6 months after HSCT as at pre-conditioning state, suggesting that the stem cells engrafted and 
were capable of expressing genes at the same amount as healthy donor controls. 
The conditioning regime led to decreased gene expression of Foxp3, IFN-γ, B7-int and ICOS, whereas it led 
to increased expression of IL-10 and slightly increased expression of IL-18. 
The decreased expression levels were due to the conditioning regime that caused the immune system’s 
downregulation, described above, leading therefore to less immunostimulatory gene expressions. IL-10 is an 
immunosuppressive cytokine and thus was probably not negatively affected through the conditioning regime. 
Its expression was contrary slightly upregulated after the conditioning. IL-18 is in contrast to IL-10 an 
inflammatory cytokine, but its expression was also a tad increased after conditioning, although it was 
generally quite constant. A possible reason for this decreased expression level could be that the conditioning 
regime could not downregulate the IL-18 expression and because many other immunostimulatory cytokines 
had a decreased expression, IL-18 may was slightly heightened as a compensative effect. 
This may indicated that the conditioning enhanced the expression of anti-inflammatory cytokines, whereas it 
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downregulated the expression of the pro-inflammatory cytokines IFN-γ and ICOS. A decreased gene 
expression of B7-int could be due to an earlier migration of the T cells to the epithelium or mucosal sites or 
due to the conditioning that suppressed the homing through reduced B7-int gene expression. As discussed 
below, Foxp3 is may not a restrictive regulatory T cell marker, as believed (Allan et al., 2007; Corthay, 2009; 
Morgan et al., Wang et al., 2007). Foxp3+ T cells could also represent recently activated T cells that got reduced 
through conditioning.  
 
 
     6.3 Gene Expression Levels in T Cells - with and without ATG 
 
60 out of all 76 patients got ATG treatment, thus the reduced gene expressions of Foxp3, IFN-γ, ICOS and B7-
int that had been seen in the overall gene expression levels in CD4+ and CD8+ T cells of ATG patients, 
respectively, were probably also caused by ATG and not only by the conditioning regime, as believed. Very 
reduced gene expression levels of Foxp3, IFN-γ, ICOS and B7-int were connected with the administration of 
ATG, as our results have shown, indicating that T cell-depleted transplants influenced the overall gene 
expressions. However, even without ATG treatment the expression of IFN-γ was reduced in CD8+ T cells as 
well as the expression of B7-int in CD4+ T cells after conditioning, indicating that also the conditioning 
regime influenced the gene expression levels. The levels of IL-10 and IL-18 were enhanced in both CD4+ and 
CD8+ T cells after conditioning in case of ATG administration. IL-18 hardly increased without ATG. With this 
results it could be concluded that ATG influenced the gene expression of the analyzed genes more that the 
conditioning, although not all genes were influenced equally strong. The expression of ICOS, Foxp3 and IL-
18 were probably mainly altered through ATG, whereas the levels of IFN-γ, B7-int and IL-10 were also 
influenced through conditioning. 
 
 
     6.4 Gene Expressions in Donor Grafts - BMSC versus PBSC 
 
The donors’ samples delivered different gene expression levels comparing bone marrow with peripheral blood 
as stem cell sources. Foxp3, FuT7 and B7-int were more expressed and IL-10 was less expressed in PBSC that 
in BMSC donor grafts in both CD4+ and CD8+ T cells. IFN-γ and IL-18 had similar expression levels in CD8+ 
T cells of both stem cell sources, whereas IFN-γ was more and IL-18 less expressed in CD4+ T cells deriving 
from PBSC grafts. The overall expression of ICOS was equal in both stem cell sources.  
But those gene expression differences were not seen in the patients’ samples. The expressions of the analyzed 
genes were equal not mattering if the stem cells derived from the bone marrow or peripheral blood. 
Furthermore, the development of aGVHD was about the same in patients with BMSC and PBSC grafts, 45% 
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and 52% respectively, as has been seen in other studies (Bensinger et al., 2001; Meisel et al., 2007). It could be 
speculated that on the one hand the treatment with ATG had influenced the gene expression levels in both 
stem cell sources, thus maintaining the same gene levels in the different patient groups, transplanted with 
BMSC or PBSC, and that on the other hand the donor T cells maybe had changed their gene expression 
features during time as response to their new environment, independent from their origin. 
Contrary to our results has the group of Gallardo seen that patients with PBSC as graft develop more 
frequently GVHD than patients with BMSC, although their overall survival is the same (Gallardo et al., 2009). 
 
 
     6.5 IFN-γ Plasma Level and its Correlation to aGVHD Development 
 
In our study we could see a significant higher IFN-γ protein level by analyzing the plasma in patients without 
aGVHD at the day of transplantation (p = 0.009) and 3 months after transplantation (p = 0.037). The IFN-γ 
levels trended to an elevated level in the case of no aGVHD development at the timepoints of pre-
conditioning (p = 0.083), 14 days (p = 0.082) and 28 days after transplantation (p = 0.087). Through analyzing 
the gene expression levels in CD4+ and CD8+ T cells we could not detect any significant differences or at least 
a trend between patients with and without aGVHD, thus suggesting that other cells, mainly NK cells were 
responsible for a diverse IFN-γ production. 
 
The pro-inflammatory cytokine IFN-γ has been seen to inhibit aGVHD in many mouse models (Brok et al., 
1993; Murphy et al., 1998; Sykes et al., 1990; Yang et al., 1998, 2002 and 2005) but also in patients’ studies 
(Bogunia-Kubik et al., 2006; Mlynarczewska et al., 2004; Teshima and Ferrara, 2002), which was confirmed in 
our study. We could see that patients with elevated IFN-γ protein levels at the day of transplantation did not 
develop aGVHD, whereas patients with low IFN-γ levels got aGVHD, indicating that low IFN-γ levels at the 
day of transplantation were associated with a higher probability of aGVHD development.  
In murine models different approaches have been performed to identify the role of IFN-γ in the development 
of aGVHD. It has to be pointed out, that the mice have been lethally irradiated before HSCT in most of the 
studies. IFN-γ knock out mice have commonly been used as donors or as recipients to see if the disease could 
occur in absence of this cytokine. It has been approved in diverse studies that aGVHD occurs significantly 
more often in recipients that get stem cells transplanted from IFN-γ deficient donors, independent of the fact 
if the recipients are IFN-γ deficient or not (Murphy et al., 1998; Yang et al., 2002 and 2005). This indicates 
that donor derived and not recipient derived IFN-γ is crucial for the cytokine’s protective effect against 
aGVHD development (Murphy et al., 1998; Welniak et al., 2000; Yang et al., 2005). However recipient derived 
IFN-γ is seen to be important for a positive transplantation outcome in another way namely by enhancing 
graft survival (Murphy et al., 1998). Murine studies have also shown that donor derived IFN-γ is important 
for the positive GVL effect (Sykes et al., 1988; Yang et al., 2002). A further approach for studying the features 
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of IFN-γ has been the injection of neutralizing anti-IFN-γ mononuclear antibodies or different cytokines into 
mice. IL-12 administration has been seen to have a protective effect against the development of aGVHD, but 
if IFN-γ is neutralized, IL-12 looses its ability indicating that aGVHD inhibition through IL-12 is IFN-γ 
dependent (Murphy et al., 1998; Yang et al., 1998 and 2005). If IL-10 that inhibites a TH1 response and IFN-γ 
production is administered to mice recipients after allogeneic HSCT, no amelioration of aGVHD can be 
observed (Krenger et al., 1994). These findings suggest that TH1 cytokines, mainly IFN-γ, are preventing the 
development of aGVHD. 
 
There are different explanations through which mechanisms IFN-γ can lower the appearance of aGVHD after 
HSCT in humans, some have already been verified in the mouse model. 
High IFN-γ levels may deactivate donor T cells or induce activation-induced cell death (AICD) in those 
lymphocytes after HSCT as it has been described in murin models (Dey et al., 1998; Teshima and Ferrara, 
2002). There is evidence that IL-12 induces a strong and rapid “IFN-γ-dependent AICD of donor T cells” 
(Teshima and Ferrara, 2002), and thus inhibiting the development of aGVHD in mice (Dey et al., 1998; Reddy 
et al., 2001; Teshima and Ferrara, 2002). AICD may occur due to the IFN-γ-induced Fas expression on donor 
T cells leading to their caspase8-dependent apoptosis (Dey et al., 1998; Teshima and Ferrara, 2002; Yang et al., 
2002 and 2005). The pro-inflammatory cytokine also accelerates Fas and HLA I expression on tumor cells 
leading to an enhanced GVL effect, thus lowering the risk for relapse (Böhm et al., 1998; Sayers et al., 1998). 
The Fas-dependent apoptosis of alloreactive donor T cells is one way how IFN-γ is believed to suppress the 
development of aGVHD, whereas the maintenance of the P27Kip1 capacity by IFN-γ is another explanation for 
the suppression of aGVHD by this TH1 cytokine. P27Kip1 restrains T cell growth and thus inhibits donor T cell 
proliferation and it is additionally a potential tumor suppressor protein, seen in mice, thus may positively 
affeccting the GVL effect in HSCT patients. P27Kip1 can be downregulated by distinct growth factors, which is 
prevented by IFN-γ (Takami et al., 2002). Furthermore IFN-γ can inhibit an overproliferation of alloreactive 
donor T cells and thus prevent aGVHD by upregulating the expression of programmed death ligand 1 (PD-
L1) on those lymphocytes (Murphy et al., 1998; Welniak et al., 2007; Yang et al., 2005). 
There is evidence that IFN-γ is crucial for homing of alloreactive T cells leading to their migration into 
lymphoid tissue, where the donor T cells can start an immune reaction against lymphohematopoietic tissue, 
thus augmenting the GVL effect, whereas IFN-γ is suppressing the donor T lymphocyte migration to 
“parenchymal GVHD target tissues” (Yang et al., 2002), thus inhibiting aGVHD (Klimpel et al., 1990; Parfrey 
et al., 1999). Another explanation for the aGVHD preventing feature of IFN-γ is that the cytokine has been 
seen to be crucial for the development of Tregs in mouse models, whereas it “inhibites self-antigen-induced 
generation and activation of CD4+CD25+ Tregs” (Yang et al., 2005) (Murphy et al., 1998; Nishikawa et al., 2005; 
Sawitzki et al., 2005). Those Tregs could prevent the expansion and alloreaction of donor T cells. 
The enzyme indoleamine 2,3-dioxygenase (IDO) may also play a crucial role in IFN-γ induced donor T cell 
deactivation. IFN-γ activates IDO, which consumes tryptophan and suppresses adaptive T cell-mediated 
immunity, shown in humans, and probably induces therefore tolerance in alloimmunity and transplantation 
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(Brandacher et al., 2008; Chen et al., 2008). This confirms that high IFN-γ levels decrease the risk of aGVHD 
development. 
Different IFN-γ polymorphisms are associated with inter-individual diverse cytokine production levels, thus 
are correlated with differing aGVHD outcomes in humans. There are 5 different IFN-γIntron1 alleles, 
whereas the alleles 2 and 3 are most common and the alleles 4 or 5 are quite rare. Patients, who are 
homozygous for the IFN-γIntron1 allele 3, which is responsible for lower IFN-γ levels, are more prone to 
develop aGVHD (Bogunia-Kubik et al., 2006; Cavet et al., 2001). The allele 2 is in contrast associated with 
higher IFN-γ production and patients being homozygous for this allele develop less common aGVHD or 
cGVHD (Bogunia-Kubik et al., 2006; Cavet et al., 2001; Pravica et al., 1999). cGVHD has similarities to 
autoimmune diseases, and IFN-γ has also been postulated to attenuate the outcome of autoimmunity in mice 
(Caspi et al., 1994; Ferber et al., 1996; Rosloniec et al., 2002; Segal et al., 1998). The appearance of the 
homozygous IFN-γIntron1 allele 3 has the same aGVHD outcomes as if the homozygous allele 2 is absent, 
suggesting that the other allele combinations cannot lead to equally high IFN-γ productions as allele 2 
(Bogunia-Kubik et al., 2006). The differing nucleotide sequences in those alleles “may affect the binding of NF-
κB transcriptional factor and thus the cytokine production” (Bogunia-Kubik et al., 2006). The correlation of 
high IFN-γ levels and low aGVHD risk could be confirmed in our studies.  
 
But also contrary results have been documented in different murin (Allen et al., 1993; Mowat, 1989; Welniak 
et al., 2000) and patient studies (Krenger et al., 1997; Holler, 2002; Niederwieser et al., 1990), where a high 
IFN-γ level has been associated with an augmented GVHD outcome, that is converse to our results. In some 
mouse models reduced aGVHD appearance is due to the blockade of IFN-γ (Allen et al., 1993; Krenger et al., 
1997), and TH1 cytokines (like IFN-γ and IL-2) are seen to be crucial for the induction of aGVHD (Ferrara et 
al., 1999; Krenger and Ferrara, 1996; Williamson et al., 1997). Also in preclinical and clinical studies elevated 
levels of the pro-inflammatory cytokines IL-2 and IL-12, an IFN-γ inducer, have been linked to more aGVHD 
and especially cGVHD development (Bunjes et al. 1995; Murphy et al., 1998). 
 
The main explanations for a direct correlation of IFN-γ levels and GVHD development are that IFN-γ can 
activate macrophages to produce pro-inflammatory cytokines (like TNF-α and IL-1), and induce the 
production of NO (Allen et al., 1993; Niederwieser et al., 1990; Teshima and Ferrara, 2002). Furthermore, TH1 
cytokines are associated with cell-mediated immune reaction, thus augmenting an alloreactive donor T cell 
response against the recipient as well as the infiltration of these cells into the tissue leading to more GVHD 
(Allen et al., 1993; Krenger and Ferrara, 1996; Mowat, 1989; Williamson et al., 1997). As described in the 
positive effects of IFN-γ the cytokine can induce Fas expression on donor T cells, but some murine studies 
have indicated that it can also upregulate Fas on recipient cells leading to apoptosis of the body’s own cells 
and thus to more severe GVHD (Welniak et al., 2007). 
 
Maybe the different observations of IFN-γ levels and GVHD development do not have to be contradictory to 
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each other regarding to the point of time when the cytokine is expressed. We could see that only high IFN-γ 
plasma levels at the day of transplantation were connected to decrease the risk for aGVHD, whereas no high 
significant correlations between the IFN-γ levels in the plasma and aGVHD outcome could be observed at 
any other timepoint of sampling, except 3 month after HSCT, although this significance could have occurred 
coincidentally. 
In the murine model an “early TH1 polarization of donor T cells by administration of cytokines such as IFN-γ, 
IL-2, IL-12 and IL-18” (Reddy and Ferrara, 2003) can decrease aGVHD, suggesting that high IFN-γ levels are 
important directly after HSCT to attenuate aGVHD (Brok et al., 1993; Reddy and Ferrara, 2003). Maybe later 
IFN-γ distributions or administrations would be connected with more severe aGVHD or cGVHD. However, 
this has to be determined in further studies. 
The conditioning regime of the patients may be very important concerning the IFN-γ feature to ameliorate 
GVHD (Murphy et al., 1998; Yang et al., 1998). It is still not fully understood if “the conditioning can alter the 
role of IFN-γ” (Murphy et al., 1998). Patients treated with fludarabine, an immunosuppressive chemotherapy 
drug, are producing less IFN-γ thus may have higher risk for getting GVHD (Bogunia-Kubik et al., 2006). 
Additionally the grade of irradiation has altered the effect of IFN-γ in murine studies. If the recipient gets 
lethally-irradiated, high IFN-γ levels are more likely seen to protect from aGVHD development, whereas the 
cytokine can have a deleterious effect in sublethally-irradiated or non-irradiated mice (Murphy et al., 1998; 
Welniak et al., 2000; Yang et al., 1998). IFN-γ is suggested to attenuate aGVHD in mice after non-
myeloablative or myeloablative conditioning (Welniak et al., 2007; Yang et al., 2002 and 2005). 
 
Low donor IFN-γ levels but maybe also patient IFN-γ levels on the verge of transplantation can be postulated 
as an additional risk factor for the development of GVHD. Different theoretical possibilities are considered 
for decreasing this risk factor. First of all a donor that is not homozygous for the IFN-γIntron1 allele 3 should 
be chosen, if possible. IFN-γ and IL-12, that induces the IFN-γ production, could be applied to the patient 
some days before transplantation to augment the IFN-γ level. Another approach could be to stimulate the 
donor T cells and/or NK cells in vitro to produce more IFN-γ before the transplantation. This could have the 
advantage over the strategy of IFN-γ or IL-12 administration that IFN-γ is produced whereto the donor T 
and NK cells migrate, whereas it is not clear whereto IFN-γ would home after administration, and thus maybe 
not having the same advantage effect. But these strategies have to be proven in preclinical and clinical trails 
first. With the knowledge that low IFN-γ plasma levels at the day of transplantation were connected with 
more aGVHD development the treatment against aGVHD could be started much earlier, which gains time. 
 
 
     6.6 IL-18 Plasma Level at aGVHD Onset 
 
On the day of aGVHD onset IL-18 was significantly increased (p < 0.001) in patients, who developed the 
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disease, comparing to IL-18 plasma levels before aGVHD development, after the onset and to patients 
without aGVHD in our study. Analyzing the gene expression levels in CD4+ T cells gave a significant higher 
IL-18 level in patients with aGVHD 21 days after transplantation (p = 0.008). The median for aGVHD onset 
lay 30 days after transplantation leading to a correlation between IL-18 increase and aGVHD onset also in the 
gene expression level in CD4+ T cells, thus confirmed the correlation of elevated protein plasma level and 
aGVHD onset. The protein level of IL-12 was not increased at the day of GVHD development, thus probably 
leading to a TH2 cell response that is provided by IL-18 without the combination of IL-12 (Kashiwamura et al., 
2002; Nakanishi et al., 2001). 
 
Previous studies in mice and humans have detected increased IL-18 levels, if aGVHD developed, but it is 
debated, if IL-18 causes aGVHD or if its augmentation is a consequence of the disease (Arnold et al., 2002; 
Fujimori et al., 2000; Min et al., 2004; Nakamura et al., 2000; Reddy et al., 2001; Zecchina et al., 2001). In a 
patient study IL-18 is not altered due to conditioning or bacterial infections, but augmented IL-18 plasma 
levels have been observed in the recovery phase, at the time of engraftment, in case of aGVHD development, 
as supported in our study (Fujimori et al., 2000). To prove if IL-18 causes aGVHD, neutralization antibodies 
against this cytokine have been used in mouse model leading to the result that blocking of IL-18 does not 
prevent aGVHD development, whereas the donor T cell expansion and alloreactive CTL activity have not 
been inhibited. This indicates that IL-18 is not inducing aGVHD, but instead caused by it – at least in mice 
(Arnold et al., 2002; Reddy et al., 2001). Further clinical studies have to prove this in humans. IL-18 can be 
involved in tissue repair and regeneration, thus its augmented level is maybe the response to systemic 
alloreaction appearing in GVHD (Arnold et al., 2002; Kashiwamura et al., 2002; Reddy et al., 2001). 
 
The levels of Akt, a protein, that causes cell survival and inhibits apoptosis and growth arrest and DNA 
damage-45 (GADD45) that is involved in DNA repair, suppression of cell growth and also cell survival can be 
elevated by IL-18, seen in mice and humans (Min et al., 2004; Yang et al. 2001). Akt and GADD45 may are 
activated after aGVHD by IL-18 leading to tissue repair and thus having a positive effect on the host but they 
can also inhibit apoptosis, which would support the donor T cells to expand and thus also having a negative 
effect in combating aGVHD. 
Although IL-18 is also attributed to a protective effect against aGVHD in mice, this is skeptical, because this 
positive effect failes to appear in absence of IFN-γ, indicating that IFN-γ and not IL-18 is mainly responsible 
for decreasing aGVHD development. If IL-18 has been administered early after HSCT in mouse studies, a 
decline of aGVHD is detected due to reduced donor T cell expansion caused by elevated Fas expression levels 
and thus more apoptosis of alloreactive donor T cells (Min et al., 2004; Reddy et al., 2001 and 2003). This Fas-
dependant apoptosis is also IFN-γ regulated and connected with a TH1 response, thus this is no evidence for a 
protective effect of IL-18 against aGVHD (Arnold et al., 2002; Reddy et al., 2001 and 2003).  
It has been seen in mice that the expression of CD25 and CD69 are upregulated on donor T cells through IL-
18, thus leading to more activated donor T cells and worsening aGVHD (Reddy et al., 2001). But cGVHD can 
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in contrast be ameliorated through the cytokine “by promoting the development of regulatory alloreactive 
CTLs” (Arnold et al., 2002), as seen in mice and humans (Min et al., 2004; Okamoto et al., 2000).  
IL-18 has been seen to influence TH polarization and other cytokine responses differently “depending on 
weather the donor T cells are resting or already activated” (Reddy et al., 2003), thus leading to different effects 
on GVHD. The GVL effect can also be preserved in presence of IL-18, as proven in different studies (Min et 
al., 2004; Reddy et al., 2003). 
The grade of aGVHD has been shown to positively correlate with the IL-18 plasma level and after a successful 
aGVHD treatment the IL-18 level decreases again (Arnold et al., 2002; Fujimori et al., 2000). This indicates 
that IL-18 may be a good marker for diagnosing aGVHD, which would help to start an early treatment of the 
disease. To be able to determine the onset day of aGVHD that was correlated with augmented IL-18 plasma 
levels in our study, would be a big step forward in diagnosing aGVHD (especially at grade I and II) right, and 
thus gaining time in its treatment. Regarding the current results the advantage of IL-18 is that the cytokine 
can be used as a marker for aGVHD, but not as a regulative cytokine that could be applied in therapy for 
ameliorating aGVHD.  
 
 
     6.7 Foxp3 Gene Expression in CD8+ T Cells in Case of aGVHD 
 
We could observe significantly elevated Foxp3 gene expression levels in CD8+ T cells at the day of 
transplantation (p = 0.005) and 28 days after HSCT (p = 0.020) in patients with aGVHD. 21 days (p = 0.083) 
and 6 months (p = 0.053) after transplantation a trend could be reported towards increased Foxp3 gene 
expression levels in CD8+ T cells of aGVHD patients. Although a significant Foxp3 gene expression increase 
was detected in CD4+ T cells 21 days after HSCT (p = 0.016) in patients with aGVHD, this statistical 
significance might occurred by chance, because no trend of augmented Foxp3 levels had been seen at any 
other timepoints as in CD8+ T cells. These results were unexpected, because the transcription factor Foxp3 is 
seen to be a specific marker for Tregs, which can induce tolerance and prevent inflammatory and autoimmune 
diseases, thus were believed to ameliorate aGVHD, as detected in other studies (Chen et al., 2007; Mielke et 
al., 2007; Miura et al., 2004; Pallandre et al., 2007; Rezvani et al., 2006).  
We only measured the gene expression hence the mRNA level and not the protein level of Foxp3 in T cells. 
Because Foxp3 is intracellular, its protein level could be analyzed with FACS after fixation and 
permeabilization of the cells to see if the Foxp3 mRNA level would correlate with the protein level. This was 
done in another human study confirming a correlation between its mRNA and its protein level, so that it 
could be suggested in our study that the Foxp3 mRNA reflected its protein level thus the Foxp3+ CD8+ T cells 
could be seen as certain Foxp3+ (Rezvani et al., 2006). 
 
In diverse mouse and patient studies elevated Foxp3 gene expression levels have been connected with a lower 
 84 
aGVHD outcome, in contrast to our results. Although most of the studies have determined Tregs by analyzing 
Foxp3 expression in CD4+ T cells and not in CD8+ T cells, considering that only little is known about CD8+ 
Tregs. These studies suggeste that the CD4+ Foxp3+ Tregs lead to immunosuppression and thus prevent aGVHD 
(Mielke et al., 2007; Miura et al., 2004; Pallandre et al., 2007; Rezvani et al., 2006; Rieger et al., 2006). It has 
been seen that high donor and not recipient T cell rates, which are CD4+ and Foxp3+ are essential for the 
ameliorating effect on aGVHD in humans, even if the transplant is T cell-depleted (Rezvani et al., 2006). The 
gene expression level of Foxp3 in CD4+ T cells is reduced in patients with aGVHD comparing to a healthy 
population, whereas it is increased in patients without aGVHD (Mielke et al., 2007; Miura et al., 2004; 
Rezvani et al., 2006; Rieger et al., 2006). Besides, the number of appearing Foxp3+ Tregs can be linked to the 
occurring grade of GVHD in humans (Miura et al., 2004).  
In order that Tregs can act in a suppressive way a cell-cell contact between the Treg and the suppressed T cell is 
necessary (Cosmi et al., 2003; Lee et al., 2005; Takahashi et al., 1998). Thus Foxp3+ Tregs may have to be 
present in target tissues of aGVHD to can prevent the development of the disease by suppressing alloreactive 
T cells there. It has been detected in mouse model that CD4+ Foxp3+ T cells are decreased in aGVHD target 
tissues during the disease, whereas those T cell levels are elevated, if no aGVHD occurs (Chen et al., 2007). 
The Tregs level in the peripheral blood does not have to reflect their level in GVHD target tissues (Rieger et al., 
2006). This could indicate that, as we could see in our study, elevated Foxp3+ T cell levels in the peripheral 
blood may were connected with reduced Foxp3+ T cell levels in aGVHD target tissues, like the skin, mucosa 
or lung, thus leading to more aGVHD. If no aGVHD occurred in the patients, the regulatory Foxp3+ T cells 
may had already migrated to the target tissues, where they could suppress the function of alloreactive T cells 
correlating with reduced Foxp3+ CD8+ T cells in the peripheral blood, like measured in our study. 
It has been seen in human studies that the chemokine receptor CCR4 is important to trigger Tregs into skin 
and lungs, thus Foxp3+ T cells that maintain in the blood are maybe CCR4- that would explain why some 
Foxp3+ T cells migrate to aGVHD target tissues (CCR4+) and others (CCR-) do not (Fontenot et al., 2003; Lee 
et al., 2005; Sather et al., 2007). 
It is still not fully understood, if a distinct Treg lineage does exist, or if the Tregs that are known to have 
suppressive characteristics also have activating features, as well as effector T cells can have suppressive effects 
too (Corthay, 2009). Furthermore, Foxp3 as specific marker for Tregs is challenged, because it has been 
detected that “human CD4+ and CD8+ T cells transiently express Foxp3 upon activation” (Corthay, 2009) 
(Morgan et al., 2005; Wang et al., 2007). Other markers that have been used in different studies to identify 
Tregs, like CD25, CTLA-4 or glucocorticoid-induced tumor necrosis factor receptor (GITR) were not 
exclusively expressed on Tregs either. Thus no specific marker for Tregs is known yet. This suggests that the 
CD8+ Foxp3+ T cells, which we measured, are not Tregs without any doubt. There is the assumption that 
Foxp3+ T cells are not totally differentiated TH cells (Corthay, 2009). A human study indicates that “de novo T 
cell development” (Miura et al., 2004) is correlated with Foxp3 gene expression (Miura et al., 2004). It is 
assumed that “Foxp3 regulatory T cells may differentiate in vivo into conventional effector TH cells, with or 
without concomitant downregulation of Foxp3.” (Corthay, 2009). Thus, in our study the Foxp3+ CD8+ T cells 
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could be recently activated T cells explaining that more Foxp3 gene expression in those probably effector 
CD8+ T cells, hence alloreactive T cells against the host, was connected with more aGVHD. However, this did 
not explain why CD4+ T cells of patients with aGVHD did not express more Foxp3 than patients without 
aGVHD in our study, except at one timepoint (21 days after HSCT), which may was by chance. One possible 
explication could be that only Foxp3+ CD8+ T cells and not Foxp3+ CD4+ T cells could react as alloreactive T 
cells in case of aGVHD, or that aGVHD was mostly CD8+ T cell-mediated. Very little is known about Foxp3+ 
CD8+ T cells, hence these opinions have to be verified in further experimental and clinical trails. 
 
 
     6.8 ICOS Gene Expression and its Correlation to aGVHD Development 
 
In our study the correlation between ICOS gene expression levels in both CD4+ and CD8+ T cells at day 21 (p 
= 0.029 and 0.038 respectively) suggested that decreased ICOS levels were connected with reduced GVHD 
development. This indicated that low ICOS levels on the verge of GVHD onset (median of onset 30 days after 
HSCT) were important for the prevention of the disease. 
 
Most of the studies have been done in mice and not human regarding ICOS and the outcome of GVHD after 
HSCT. Those results cannot be adopted one-to-one to humans, but they give a hint which role ICOS play in 
human GVHD development. Different studies have observed that the blockade of ICOS by either using ICOS 
deficient mice as donors or recipients or anti-ICOS mononuclear antibodies lead to reduced GVHD 
(Hubbard et al., 2005; Taylor et al., 2005; Yu et al., 2006). Furthermore alloreactive donor T cells express more 
ICOS during GVHD in mice, confirming our results (Hubbard et al., 2005). This is regardless of whether the 
alloresponse is CD4+ or CD8+ mediated (Taylor et al., 2005). There are varying debated mechanisms how 
ICOS suppresses an alloresponse in case of GVHD. It has been detected in mouse models that the number of 
effector T celles is reduced in “some lymphoid organs and GVHD target organs early after transplantation” 
(Taylor et al., 2005), thus effecting T cell migration and homing, but not their activation, if the costimulatory 
molecule is blocked. Other results indicate that alloreactive effector T cells are inhibited or that T cells are 
turned to TH2 differentiation, without altering their activation, proliferation, homing or cytotoxicity in case of 
ICOS blockade (Hubbard et al., 2005; Yu et al., 2006). However, in mice also impaired T cell proliferation 
caused by ICOS deficiency has been observed due to decreased IL-2 production after activation (Dong et al., 
2001; Taylor et al., 2005). If reduced ICOS expression is connected with less IL-2 production leading to 
decreased GVHD development in patients have to be studied further in clinical trials. In case of a correlation 
between ICOS and IL-2 expression, blocking the costimulatory molecule may be a good approach in GVHD 
treatment. But also a reduced expression of FasL has been associated with ICOS deficiency in murine models 
leading to reduced effector functions of alloreactive donor T cells as well as less GVHD (Yu et al., 2006).  
Also converse results have been received from different groups, where ICOS blocking has been seen to 
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exacerbate aGVHD and reduce only cGVHD in mice. This has been observed in non-irradiated as well as in 
sublethally irradiated mice (Ogawa et al., 2001; Taylor et al., 2005; Yu et al., 2006). If ICOS costimulates T cell 
response is probably affected by “the nature of immune response, such as the strength of the TCR signal, 
involvement of innate immunity, and CD28 costimulation” (Yu et al., 2006). A strong antigen recognition may 
lead to a costimulation of CD28 and involvement of the innate immunity, thus to more AICD through ICOS 
leading to a negative correlation between ICOS expression and GVHD development, whereas a weak antigen 
recognition may does not involve the innate immunity or CD28 costimulation leading to enhanced activity of 
the T cells and accelerated GVHD (Wallin et al., 2001; Yu et al., 2006). 
 
Our results that higher ICOS gene expression levels were connected with the development of GVHD have to 
be confirmed in further clinical studies. It is also of interest if the gene expression levels are correlating with 
the protein levels, which could be done by FACS analysis. ICOS probably does not always accelerate GVHD 
depending on the strength of alloantigen recognition and maybe IL-2 plays a central role in ICOS-mediated 
GVHD development. 
 
 
     6.9 FuT7 Gene Expression in CD8+ T Cells in Case of aGVHD 
 
FuT7 expression plays an important role in the onset of an inflammatory response leading to leukocytes’ 
homing to sites of infection by upregulating the expression of E- and P-selectin ligands and L-selectin on 
leukocytes (Bengtson et al., 2002; Dudda et al., 2008; Martinez et al., 2005). We detected a significant 
correlation between decreased FuT7 gene expression in CD8+ T cells in the peripheral blood and the 
development of aGVHD 21 days (p = 0.001) and 28 days (p = 0.023) after HSCT. 
 
Murine studies have shown that the interaction between selectins and their ligands are crucial for GVHD 
development so that the alloreactive donor T cells can role on the endothelial cells and migrate to mucosal 
lymphoid tissues (Dutt et al., 2005; Li et al., 2004; Petrovic et al., 2004). In a GVHD mouse model it has been 
detected that P-selectin ligand levels are increased, whereas L-selectin levels are decreased on activated CD8+ 
T cells in case of GVHD (Asaduzzaman et al., 2009). Those cells have been measured in GVHD target tissues 
and not in the peripheral blood as in our study. This could suggest that a lower FuT7 gene expression in CD8+ 
T cells in the peripheral blood may be connected with increased GVHD development, as we could show, 
because the alloreactive CD8+ FuT7+ T cells have already migrated to GVHD target tissues. As our results 
indicated the CD8+ FuT7+ T cells remained in the blood, if no aGVHD occurred that was possible due to a 
loss of E-selectin and P-selectin expression on the endothelium thus prohibiting leukocyte rolling. 
Other clinical studies have shown that serum levels of soluble E-selectin are elevated in patients, who develop 
aGVHD (grade II – IV) around aGVHD onset (day 30), as well as E-selectin expression on endothelial cells is 
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connected with aGVHD (Matsuda et al., 2001; Norton et al., 1992 and 1993). This proves the theory that 
CD8+ FuT7+ T cells remains in the blood without aGVHD due to reduced E-selectin expression. Activation 
and damage of the endothelium are seen to be connected with the appearance of aGVHD and also cGVHD 
(Matsuda et al., 2001). 
Elevated E-selectin expression levels on endothelial cells are probably as well as a decreased P- and E-selectin 
ligand expressions on CD8+ T cells in the peripheral blood, indicated by reduced FuT7 gene expression, good 
markers for the onset of aGVHD, whereas it is supposable not that easy to engage in this mechanism for 
treating GVHD. As detected in murine studies E-selectin “inhibition has no effect on GVHD-induced CD8+ T 
cell endothelium interactions” (Asaduzzaman et al., 2009) and alloreactive donor T cells can migrate to GVHD 
target tissues “independently of P- and E-selectin ligand” (Eom et al., 2005). Thus FuT7 may be used as 
molecular marker for diagnosing aGVHD.   
 
 
     6.10 Hypothesis about CD8+ T cell-mediated aGVHD 
 
The interpretation of our results led to the hypothesis that aGVHD was mainly mediated by CD8+ T cells. 
Concerning that CD8+ FuT7+ but not CD4+ FuT7+ T cells were recruited to GVHD target tissues in case of 
aGVHD probably indicated that the disease was CD8+-mediated. This could be fortified regarding that 
elevated CD8+ Foxp3+ T cells, seen as recently activated T cells, in the peripheral blood were correlating with 
increased aGVHD development. However, if the CD8+ Foxp3+ T cells would be seen as Tregs, the CD8+ T cells 
were maybe not only mediating aGVHD development, but also suppressing it, because less CD8+ Foxp3+ T 
cells in the peripheral blood, as it was detected in case of aGVHD, would be seen to be connected with more 
CD8+ Foxp3+ T cells in GVHD target tissues, where they could suppress alloreactive responses.  
No such correlations between aGVHD development and CD4+ T cell gene expressions could be detected in 
our studies, besides elevated IL-18 levels at day 21 in case of aGVHD, which was probably the consequence of 
aGVHD and not causing the disease. 
 
     6.11 Outlook 
 
Further studies have do be done to confirm our results and before the gained knowledge can be implemented 
in GVHD prophylaxsis and diagnosis. The administration of IFN-γ or IL-12 has to be tested in clinical trials 
to see if they ameliorate the outcome of GVHD before they can be used as prophylaxis against the disease. It is 
important to be conscious of the fact that cytokines can influence, compensate or suppress each other. Thus a 
cytokine can act differently in diverse cytokine surroundings. Furthermore, different cytokine gene 
polymorphisms can lead to variable cytokine productions. This is crucial to think of and test, if any cytokine-
dependent therapeutic setting is perfomed to avoid the outcome of contrary results. 
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7 Conclusions 
 
• Higher IFN-γ plasma levels (> 200 pg/ml) at the day of HSCT are connected with a reduced risk for 
aGVHD development. Thus low IFN-γ plasma levels at the day of HSCT are a molecular marker for 
aGVHD. 
• The application of IFN-γ or IL-12 immediately before HSCT, or an in vitro stimulation of NK or T 
cells before HSCT to produce more IFN-γ could probably lower the occurrence of aGVHD. 
 
• Elevated IL-18 plasma levels at the day of aGVHD onset could be used as a marker for diagnosing 
aGVHD leading to an early therapy initiation. 
• Higher Foxp3 gene expressions in CD8+ T cells at the day of HSCT as well as 28 days after 
transplantation in case of aGVHD could indicate the disease development. 
• FuT7 may be a capable diagnostic marker for aGVHD as well, because its gene expression is 
enhanced in CD8+ T cells 21 and 28 days after HSCT in case of aGVHD. 
• ICOS may also be a possible molecular diagnostic marker for aGVHD, because its gene expression is 
enhanced in CD4+ and CD8+ T cells in aGVHD patients 21 days after HSCT. 
  
• Gene expression levels in CD4+ and CD8+ T cells are altered through ATG administration. The 
expression levels of Foxp3, IFN-γ, ICOS and B7-int are mainly affected. 
• Foxp3, IFN-γ, IL-10, IL-18, ICOS, FuT7 and B7-int gene expression levels of donor grafts differ 
between stem cells deriving from bone marrow and from peripheral blood. However, no significant 
gene expression differences occur in patients with diverse stem cell grafts. 
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9 List of abbreviations 
 
aGVHD     acute GVHD 
AICD       Activation-induced cell death 
AML       Acute myeloid leukemia 
ALL       Acute lymphoblastic leukemia 
AP-1       Activator protein-1 
APC       Antigen-presenting cell 
ATG       Antithymocyte globulins 
Bcl-2       B cell lymphoma-2 
BMSC      Bone marrow stem cells 
BMT       Bone marrow transplantation 
BSA       Bovine serum albumin 
CBSC       Cord blood stem cells 
CCR       Chemokine (cystein-cystein motif) receptor 
CD       Cluster of differentiation 
cDNA       Complementary DNA 
cGVHD     Chronic GVHD 
CLA       Cutaneous lymphocyte antigen 
CLL       Chronic lymphoblastic leukemia 
CML       Chronic myeloid leukemia 
CMV       Cytomegalovirus 
CR       Complete remission 
CS-1/FN   Connecting segment-1 region of fibronectin 
Ct       Threshold cycle 
CTL       Cytotoxic T lymphocyte 
CTLA       Cytotoxic T lymphocyte antigen 
CVID       Common variable immunodeficiency 
DBY       Dead box RNA helicase Y 
DFFRY     Drosophila fat-facets related Y gene 
DNA       Deoxyribonucleic acid 
dNTP       Deoxyribonucleotide-triphosphate 
DTT       Dithiothreidol 
dTTP       Deoxythymidin-triphosphate 
dUTP      Deoxyuridine-triphosphate 
ELISA       Enzyme-linked immunosorbent assay 
ESL-1       E-selectin ligand-1 
FAM       6-carboxy fluorescein 
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FGF-7        Fibroblast growth factor-7 
Foxp3        Forkhead box P3 
FuT        Fucosyltransferase 
GADD45   Growth arrest and DNA damage-45 
GALT        Gut-associated lymphoid tissues 
G-CSF       Granulocyte colony-stimulating factor 
GITR       Glucocorticoid-induced tumor necrosis factor receptor 
GM-CSF   Granulocyte macrophage colony-stimulating factor 
G6PD       Glucose-6-phosphate dehydrogenase 
GVHD       Graft-versus-host disease 
GVL       Graft-versus-leukemia 
GVT       Graft-versus-tumor 
HCl      Hydrogen chloride 
HEVs       High endothelial venules 
HLA       Human leukocyte antigens 
HPE  High performance ELISA 
HRP       Horseradish peroxidase 
HSC       Hematopoietic stem cells 
HSCT       Hematopoietic stem cell transplantation 
H2SO4      Sulfuric acid 
HSV       Herpes simplex virus 
HVG       Host-versus-graft 
ICOS       Inducible costimulator 
IDO       Indoleamine 2,3-Dioxygenase 
IFN       Interferon 
IFNR       Interferon receptor 
Ig       Immunoglobulin 
IL       Interleukin 
Int       Integrin 
IRF-1       Interferon regulatory factor-1 
JAK       Janus kinase 
KCl       Potassium chloride 
KGF       Keratinocyte growth factor 
KIR       Killer immunoglobulin-like receptors 
LPAM-1    Lymphocyte Peyer’s patch adhesion molecule-1 
LPS       Lipopolysaccharide 
MAdCAM-1 Mucosal addressin cell adhesion molecule-1 
MAPKinase Mitogen-activated protein kinase 
M-CSF      Macrophage colony-stimulating factor 
MDS  Myelodisplastic syndromes 
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MgCl2       Magnesium chloride 
MHC       Major histocompatibility complex 
MiHAs      Minor histocompatibility antigens 
MMF        Mycophenolate mofetil 
mRNA      Messenger RNA  
MUD       Matched unrelated donor 
MyD88     Myeloid differentiation primary response gene 88 
NaCl       Sodium chloride 
NFAT       Nuclear factor of activated T cells 
NF-κB       Nuclear factor kappa light chain enhancer of activated B cells 
NK cell      Natural killer cell 
NKT cell   Natural killer T cell 
NO       Nitric oxide 
PBS       Phosphate buffered saline 
PBSC       Peripheral blood stem cells 
PCR  Polymerase chain reaction 
PD-1       Programmed death-1 
PD-L1       Programmed deat-ligand 1 
pdN6       Random hexamer primer 
PGE2        Prostaglandin E2 
Ph       Philadelphia 
PSGL-1     P-selectin glycoprotein ligand-1 
RIC       Reduced-intensity conditioning 
RNA       Ribonucleic acid 
ROR          Retinoic acid-related orphan receptor 
Rpm  Rounds per minute 
RQ-PCR   Real time quantitative-PCR 
RT       Reverse Transcriptase 
SFN       Scurfin 
sLex       Sialyl Lewis x 
STAT       Signal transducers and activators of transcription 
TAMRA    6-carboxy-tetramethyl rhodamine 
T-bet       T-box, expressed in T cells 
TBI       Total body irradiation 
TCR       T cell receptor 
TGF       Transforming growth factor 
TH        T helper cell 
TLR       Toll-like receptor 
TNF       Tumor nicrosis factor 
TRAF6      TNF receptor-associated factor 6 
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TRAIL       TNF-related apoptosis-inducing ligand 
TRM       Transplantation-related mortality 
Treg       Regulatory T cell 
Tyk       Tyrosine kinase 
UCB       Umbilical cord blood 
UNG       Uracil-DNA-glycosylase 
UTY       Ubiquitously transcribed tetratricopeptide repeat gene, Y-linked  
VCAM-1   Vascular cell adhesion molecule-1 
ZAP70       Zeta-chain-associated protein kinase 70 
 94 
10 References 
 
Abbas AK and Lichtman AH (2003). "Cellular and Molecular Immunology" Saunders. Fifth Edition. 
Abbott BL (2004). "Advances in the diagnosis and treatment of chronic lymphocytic leukemia." Clin Adv Hematol 
Oncol. 2(7): 448-454. 
Abbott BL (2006). "Chronic lymphocytic leukemia: recent advances in diagnosis and treatment." Oncologist. 11(1): 21-
30. 
Abramson S, Miller RG, et al. (1977). "The identification in adult bone marrow of pluripotent and restricted stem cells 
of the myeloid and lymphoid systems." J Exp Med. 145(6): 1567-1579. 
Allan SE, Crome SQ, et al. (2007). "Activation-induced FOXP3 in human T effector cells does not suppress proliferation 
or cytokine production." Int Immunol. 19(4): 345-354. 
Allen RD, Staley TA, et al. (1993). "Differential cytokine expression in acute and chronic murine graft-versus-host-
disease." Eur J Immunol. 23(2): 333-337. 
Anargyrou K, Vassilakopoulos TP, et al. (2010). "Incorporating novel agents in the treatment of myelodysplastic 
syndromes." Leuk Res. 34(1): 6-17. 
Anderson BE, Taylor PA, et al. (2008). "Effects of donor T-cell trafficking and priming site on graft-versus-host disease 
induction by naive and memory phenotype CD4 T cells." Blood. 111(10): 5242-5251. 
Aractingi S, Gluckman E, et al. (1996). "Lymphocytes, cytokines and adhesion molecules in chronic graft versus host 
disease." Clin Mol Pathol. 49(4): M225-M231. 
Armand P, Gannamaneni S, et al. (2008). "Improved survival in lymphoma patients receiving sirolimus for graft-versus-
host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity 
conditioning." J Clin Oncol. 26(35): 5767-5774. 
Arnold D, Wasem C, et al. (2002). "IL-18-independent cytotoxic T lymphocyte activation and IFN-gamma production 
during experimental acute graft-versus-host disease." Int Immunol. 14(5): 503-511. 
Aul C, Giagounidis A, et al. (2002). "Myelodysplastic syndromes. Diagnosis and therapeutic strategies. (Article in 
German)" Med Klin (Munich). 97(11): 666-676. 
Asaduzzaman M, Mihaescu A, et al. (2009). "P-selectin and P-selectin glycoprotein ligand 1 mediate rolling of activated 
CD8+ T cells in inflamed colonic venules." J Investig Med. 57(7): 765-768. 
Atkinson K, Horowitz MM, et al. (1990). "Risk factors for chronic graft-versus-host disease after HLA-identical sibling 
bone marrow transplantation." Blood. 75(12): 2459-2464. 
Bach EA, Szabo SJ, et al. (1995). "Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T 
helper cell subsets." Science. 270(5239): 1215-1218. 
Bacigalupo A (2005). "Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side 
effects." Bone Marrow Transplant. 35(3): 225-231. 
Badovinac VP, Tvinnereim AR, et al. (2000). "Regulation of antigen-specific CD8+ T cell homeostasis by perforin and 
interferon-gamma." Science. 290(5495): 1354-1358. 
 95 
Barker JN, Davies SM, et al. (2001). "Survival after transplantation of unrelated donor umbilical cord blood is 
comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-
pair analysis." Blood. 97(10): 2957-2961. 
Barkholt L and Ringdén O (2004). "Allogen hematopoetisk stamcelltransplantation (Article in Swedish)." Centrum för 
Allogen Stamcellstransplantation och Avdelningen för Klinisk Immunologi, Huddinge Universitetssjukhus: 1-
46. 
Beebe AM, Cua DJ, et al. (2002). "The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus 
(SLE) and multiple sclerosis (MS)." Cytokine Growth Factor Rev. 13(4-5): 403-412. 
Bengtson P, Lundblad A, et al. (2002). "Polymorphonuclear leukocytes from individuals carrying the G329A mutation 
in the alpha 1,3-fucosyltransferase VII gene (FUT7) roll on E- and P-selectins." J Immunol. 169(7): 3940-3946. 
Bennett CL, Christie J, et al. (2001). "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
(IPEX) is caused by mutations of FOXP3." Nat Genet. 27(1): 20-21. 
Bensinger WI, Martin PJ, et al. (2001). "Transplantation of bone marrow as compared with peripheral-blood cells from 
HLA-identical relatives in patients with hematologic cancers." N Engl J Med. 344(3): 175-181. 
Bensinger WI, Price TH, et al. (1993). "The effects of daily recombinant human granulocyte colony-stimulating factor 
administration on normal granulocyte donors undergoing leukapheresis." Blood. 81(7): 1883-1888. 
Bettelli E, Korn T, et al. (2008). "Induction and effector functions of TH17 cells." Nature. 453: 1051-1057. 
Blazar BR, Taylor PA, et al. (1995). "Interleukin-10 administration decreases survival in murine recipients of major 
histocompatibility complex disparate donor bone marrow grafts." Blood. 85(3): 842-851. 
Bogunia-Kubik K, Mlynarczewska A, et al. (2006). "The presence of IFNG 3/3 genotype in the recipient associates with 
increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation." Br J 
Haematol. 132(3): 326-332. 
Böhm W, Thoma S, et al. (1998). "T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas." J 
Immunol. 161(2): 897-908. 
Brandacher G, Margreiter R, et al. (2008). "Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and 
transplantation." Curr Opin Organ Transplant. 13(1): 10-15. 
Brodsky RA and Jones RJ (2005). "Aplastic anaemia." Lancet. 365(9471): 1647-1656. 
Brok HP, Heidt PJ, et al. (1993). "Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow 
transplantation in mice." J Immunol. 151(11): 6451-6459. 
Bross DS, Tutschka PJ, et al. (1984). "Predictive factors for acute graft-versus-host disease in patients transplanted with 
HLA-identical bone marrow." Blood. 63(6): 1265-1270. 
Bunjes D, Theobald M, et al. (1995). "Presence of host-specific interleukin 2-secreting T helper cell precursors correlates 
closely with active primary and secondary chronic graft-versus-host disease." Bone Marrow Transplant. 15(5): 
727-732. 
Caspi RR, Chan CC, et al. (1994). "Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity 
in mice." J Immunol. 152(2): 890-899. 
Cavet J, Dickinson AM, et al. (2001). "Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-
versus-host disease in HLA-matched sibling bone marrow transplantation." Blood. 98(5): 1594-1600. 
 96 
Chen J and Liu X (2009). "The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications." Cell 
Immunol. 254(2): 85-90. 
Chen W, Liang X, et al. (2008). "The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid 
dendritic cell-induced adaptive T regulatory cell generation." J Immunol. 181(8): 5396-5404. 
Chen X, Vodanovic-Jankovic S, et al. (2007). "Absence of regulatory T-cell control of TH1 and TH17 cells is responsible 
for the autoimmune-mediated pathology in chronic graft-versus-host disease." Blood. 110(10): 3804-3813. 
Chesler DA and Reiss CS (2002). "The role of IFN-gamma in immune responses to viral infections of the central 
nervous system." Cytokine Growth Factor Rev. 13(6): 441-454. 
Chiaretti S and Foà R (2009). "T-cell acute lymphoblastic leukemia." Haematologica. 94(2): 160-162. 
Colombo MP and Trinchieri G (2002). "Interleukin-12 in anti-tumor immunity and immunotherapy." Cytokine Growth 
Factor Rev. 13(2): 155-168. 
Corthay A (2009). "How do regulatory T cells work?" Scand J Immunol. 70(4): 326-336. 
Cosmi L, Liotta F, et al. (2003). "Human CD8+CD25+ thymocytes share phenotypic and functional features with 
CD4+CD25+ regulatory thymocytes." Blood. 102(12): 4107-4114. 
Crespo M, Bosch F, et al. (2003). "ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in 
chronic lymphocytic leukemia." N Engl J Med. 2003 348(18): 1764-1775. 
Dander E, Balduzzi A, et al. (2009). "Interleukin-17-producing T-helper cells as new potential player mediating graft-
versus-host disease in patients undergoing allogeneic stem-cell transplantation." Transplantation. 88(11): 1261-
1272. 
Davies SM, Ruggieri L, et al. (2002). "Evaluation of KIR ligand incompatibility in mismatched unrelated donor 
hematopoietic transplants. Killer immunoglobulin-like receptor." Blood. 100(10): 3825-3827. 
Dazzi F, Szydlo RM, et al. (2000). "Comparison of single-dose and escalating-dose regimens of donor lymphocyte 
infusion for relapse after allografting for chronic myeloid leukemia." Blood. 95(1): 67-71. 
Deeg HJ, Storb R, et al. (1985). "Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in 
patients undergoing marrow transplantation for acute nonlymphoblastic leukemia." Blood. 65(6): 1325-1334. 
Deininger MW, Goldman JM, et al. (2000). "The molecular biology of chronic myeloid leukemia." Blood. 96(10): 3343-
3356. 
Dey BR, Yang YG, et al. (1998). "Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism 
associated with alterations in donor T-cell activation and expansion." Blood. 91(9): 3315-3322. 
Dong C, Juedes AE, et al. (2001). "ICOS co-stimulatory receptor is essential for T-cell activation and function." Nature. 
409(6816): 97-101. 
Dudda JC, Perdue N, et al. (2008). "Foxp3+ regulatory T cells maintain immune homeostasis in the skin." J Exp Med. 
205(7): 1559-1565. 
Dutt S, Ermann J, et al. (2005). "L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration 
to host mesenteric lymph nodes and acute colitis of graft-versus-host disease." Blood. 106(12): 4009-4015. 
Eom HS, Rubio MT, et al. (2005). "T-cell P/E-selectin ligand alpha(1,3)fucosylation is not required for graft-vs-host 
disease induction." Exp Hematol. 33(12): 1564-1573. 
 97 
Farag SS, Bacigalupo A, et al. (2006). "The effect of KIR ligand incompatibility on the outcome of unrelated donor 
transplantation: a report from the center for international blood and marrow transplant research, the European 
blood and marrow transplant registry, and the Dutch registry." Biol Blood Marrow Transplant. 12(8): 876-884. 
Fefer A, Einstein AB, et al. (1974). "Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical 
twins." N Engl J Med. 290(25): 1389-1393. 
Ferber IA, Brocke S, et al., (1996). "Mice with a disrupted IFN-gamma gene are susceptible to the induction of 
experimental autoimmune encephalomyelitis (EAE)." J Immunol. 156(1): 5-7. 
Ferrara JL (2007). "Novel strategies for the treatment and diagnosis of graft-versus-host-disease." Best Pract Res Clin 
Haematol. 20(1): 91-97. 
Ferrara JL, Levy R, et al., (1999). "Pathophysiologic mechanisms of acute graft-vs.-host disease." Biol Blood Marrow 
Transplant. 5(6): 347-356. 
Fontenot JD, Gavin MA, et al. (2003). "Foxp3 programs the development and function of CD4+CD25+ regulatory T 
cells." Nat Immunol. 4(4): 330-336. 
Forman SJ, Blume KG, et al. (1987). "A prospective randomized study of acute graft-v-host disease in 107 patients with 
leukemia: methotrexate/prednisone v cyclosporine A/prednisone." Transplant Proc. 19(1 Pt 3): 2605-2607. 
Fujimori Y, Takatsuka H, et al. (2000). "Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after 
allogeneic bone marrow transplantation." Br J Haematol. 109(3): 652-657. 
Gallardo D, de la Cámara R, et al. (2009). "Is mobilized peripheral blood comparable with bone marrow as a source of 
hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control 
study." Haematologica. 94(9): 1282-1288. 
Gatti RA, Meuwissen HJ, et al. (1968). "Immunological reconstitution of sex-linked lymphopenic immunological 
deficiency." Lancet. 2(7583): 1366-1369. 
Gluckman E, Rocha V, et al. (1997). "Outcome of cord-blood transplantation from related and unrelated donors. 
Eurocord Transplant Group and the European Blood and Marrow Transplantation Group." N Engl J Med. 
337(6): 373-381. 
Gora-Tybor J and Robak T (2008). "Targeted drugs in chronic myeloid leukemia." Curr Med Chem. 15(29): 3036-3051. 
Goulmy E, Gratama JW, et al. (1983). "A minor transplantation antigen detected by MHC-restricted cytotoxic T 
lymphocytes during graft-versus-host disease." Nature. 302(5904): 159-161. 
Grosskreutz C, Ross V, et al. (2003). "Low-dose total body irradiation, fludarabine, and antithymocyte globulin 
conditioning for nonmyeloablative allogeneic transplantation." Biol Blood Marrow Transplant. 9(7): 453-459. 
Grüllich C, Ziegler C, et al. (2009). "Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood 
mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant." Biol 
Blood Marrow Transplant. 15(2): 173-182. 
Haraguchi K, Takahashi T, et al. (2005). "Host-residual invariant NK T cells attenuate graft-versus-host immunity." J 
Immunol. 175(2): 1320-1328. 
Higman MA and Vogelsang GB (2004). "Chronic graft versus host disease." Br J Haematol. 125(4): 435-454. 
Hochberg J, Waxman IM, et al. (2009). "Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the 
science." Br J Haematol. 144(1): 24-40. 
Holler E (2002). "Cytokines, viruses, and graft-versus-host disease." Curr Opin Hematol. 9(6): 479-484. 
 98 
Hori S, Nomura T, et al. (2003). "Control of regulatory T cell development by the transcription factor Foxp3." Science. 
299(5609): 1057-1061. 
Hubbard VM, Eng JM, et al. (2005). "Absence of inducible costimulator on alloreactive T cells reduces graft versus host 
disease and induces Th2 deviation." Blood. 106(9): 3285-3292. 
Ikeda H, Old LJ, et al. (2002). "The roles of IFN gamma in protection against tumor development and cancer 
immunoediting." Cytokine Growth Factor Rev. 13(2): 95-109. 
Kappel LW, Goldberg GL, et al. (2009). "IL-17 contributes to CD4-mediated graft-versus-host disease." Blood. 113(4): 
945-952. 
Kashiwamura S, Ueda H, et al. (2002). "Roles of interleukin-18 in tissue destruction and compensatory reactions." J 
Immunother. 25(1): 4-11. 
Kastelein RA, Hunter CA, et al. (2007). "Discovery and biology of IL-23 and IL-27: related but functionally distinct 
regulators of inflammation." Annu Rev Immunol. 25: 221-242. 
Keohane EM (2004). "Acquired aplastic anemia." Clin Lab Sci. 17(3): 165-171. 
Klimpel GR, Annable CR, et al. (1990). "Immunosuppression and lymphoid hypoplasia associated with chronic graft 
versus host disease is dependent upon IFN-gamma production." J Immunol. 144(1): 84-93. 
Knibbs RN, Craig RA, et al. (1996). "The fucosyltransferase FucT-VII regulates E-selectin ligand synthesis in human T 
cells." J Cell Biol. 133(4): 911-920. 
Kollman C, Howe CW, et al. (2001). "Donor characteristics as risk factors in recipients after transplantation of bone 
marrow from unrelated donors: the effect of donor age." Blood. 98(7): 2043-2051. 
Krenger W and Ferrara JL (1996). "Graft-versus-host disease and the Th1/Th2 paradigm." Immunol Res. 15(1): 50-73. 
Krenger W, Hill GR, et al. (1997). "Cytokine cascades in acute graft-versus-host disease." Transplantation. 64(4): 553-
558. 
Krenger W, Snyder KM, et al. (1994). "Effects of exogenous interleukin-10 in a murine model of graft-versus-host 
disease to minor histocompatibility antigens." Transplantation. 58(11): 1251-1257. 
Krenger W, Snyder KM, et al. (1995). "Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce 
experimental acute graft-versus-host disease." J Immunol. 155(2): 585-593. 
Kurtzberg J, Laughlin M, et al. (1996). "Placental blood as a source of hematopoietic stem cells for transplantation into 
unrelated recipients." N Engl J Med. 335(3): 157-166. 
Kurzrock R, Gutterman JU, et al. (1988). "The molecular genetics of Philadelphia chromosome-positive leukemias." N 
Engl J Med. 319(15):990-998. 
Kurzrock R, Kantarjian H, et al. (2001). "Chronic myelogenous leukemia in chronic phase." Curr Treat Options Oncol. 
2(3): 245-252. 
Lane SW, Scadden DT, et al. (2009). "The leukemic stem cell niche: current concepts and therapeutic opportunities." 
Blood. 114(6): 1150-1157. 
Laster SM, Wood JG, et al. (1988). "Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis." J 
Immunol. 141(8): 2629-2634. 
Laughlin MJ, Eapen M, et al. (2004). "Outcomes after transplantation of cord blood or bone marrow from unrelated 
donors in adults with leukemia." N Engl J Med. 351(22): 2265-2275. 
 99 
Lee I, Wang L, et al. (2005). "Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the 
CCR4 chemokine receptor." J Exp Med. 201(7): 1037-1044. 
Léger CS and Nevill TJ (2004). "Hematopoietic stem cell transplantation: a primer for the primary care physician." 
CMAJ. 170(10): 1569-1577. 
Li B, New JY, et al. (2004). "Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating 
donor cells with antibodies directed at l-selectin and alpha4-integrin prior to infusion." Scand J Immunol. 
59(5): 464-468. 
Liu S, Zhang Y, et al. (2008). "FUT7 antisense sequence inhibits the expression of FUT7/sLeX and adhesion between 
embryonic and uterine cells." IUBMB Life. 60(7): 461-466. 
Lotze MT, Tahara H, et al. (2002). "Interleukin-18 as a novel, distinct, and distant member of the interleukin-1 family 
promoting development of the adaptive immune response: the interleukin-18 issue of the Journal of 
Immunotherapy." J Immunother. 25(1): 1-3. 
Lum LG (1987). "The kinetics of immune reconstitution after human marrow transplantation." Blood. 69(2): 369-380. 
Lynch EL, Little FF, et al. (2003). "Immunomodulatory cytokines in asthmatic inflammation." Cytokine Growth Factor 
Rev. 14(6): 489-502. 
Mackinnon S, Papadopoulos EB, et al. (1995). "Adoptive immunotherapy evaluating escalating doses of donor 
leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-
versus-leukemia responses from graft-versus-host disease." Blood. 86(4): 1261-1268. 
Martin PJ, Schoch G, et al. (1990). "A retrospective analysis of therapy for acute graft-versus-host disease: initial 
treatment." Blood. 76(8): 1464-1472. 
Martinez M, Joffraud M, et al. (2005). "Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role 
of human fucosyltransferase-IV and -VII." J Biol Chem. 280(7): 5378-5390. 
Matsuda Y, Hara J, et al. (2001). "Serum levels of soluble adhesion molecules in stem cell transplantation-related 
complications." Bone Marrow Transplant. 27(9): 977-982. 
Matte CC, Liu J, et al. (2004). "Donor APCs are required for maximal GVHD but not for GVL." Nat Med. 10(9): 987-
992.  
Mauro MJ and Maziarz RT (2006). "Stem cell transplantation in patients with chronic myelogenous leukemia: when 
should it be used?" Mayo Clin Proc. 81(3): 404-416. 
McKenzie SB (2005). "Advances in understanding the biology and genetics of acute myelocytic leukemia." Clin Lab Sci. 
18(1): 28-37. 
McSweeney PA and Storb R (1999). "Mixed chimerism: preclinical studies and clinical applications." Biol Blood Marrow 
Transplant. 5(4): 192-203. 
Meisel R, Laws HJ, et al. (2007). "Comparable long-term survival after bone marrow versus peripheral blood progenitor 
cell transplantation from matched unrelated donors in children with hematologic malignancies." Biol Blood 
Marrow Transplant. 13(11): 1338-1345. 
Mielke S, Rezvani K, et al. (2007). "Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted 
allotransplantation in elderly patients and association with acute graft-versus-host disease." Blood. 110(5): 
1689-1697. 
Miklos DB, Kim HT, et al. (2004). "Antibody response to DBY minor histocompatibility antigen is induced after 
allogeneic stem cell transplantation and in healthy female donors." Blood. 103(1): 353-359. 
 100 
Miles A, Liaskou E, et al. (2008). "CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of 
lymphocytes to MAdCAM-1 under shear flow." Am J Physiol Gastrointest Liver Physiol. 294(5): G1257-1267. 
Min CK, Maeda Y, et al. (2004). "Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease 
mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation." Blood. 
104(10): 3393-3399. 
Miura Y, Thoburn CJ, et al. (2004). "Association of Foxp3 regulatory gene expression with graft-versus-host disease." 
Blood. 104(7): 2187-2193. 
Mlynarczewska A, Wysoczanska B, et al. (2004). "Lack of IFN-gamma 2/2 homozygous genotype independently of 
recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-
matched sibling haematopoietic stem cell transplantation." Bone Marrow Transplant. 34(4): 339-344. 
Mohty M (2007). "Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond." Leukemia. 
21(7):1387-94. 
Mohty M, Blaise D, et al. (2005). "Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity 
conditioning allogeneic stem cell transplantation." Blood. 106(13): 4407-4411. 
Moore KW, de Waal Malefyt R, et al. (2001). "Interleukin-10 and the interleukin-10 receptor." Annu Rev Immunol. 19: 
683-765. 
Morgan ME, van Bilsen JH, et al. (2005). "Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory 
cells in humans." Hum Immunol. 66(1): 13-20. 
Mortimer J, Blinder MA, et al. (1989). "Relapse of acute leukemia after marrow transplantation: natural history and 
results of subsequent therapy." J Clin Oncol. 7(1): 50-57. 
Moseley TA, Haudenschild DR, et al. (2003). "Interleukin-17 family and IL-17 receptors." Cytokine Growth Factor Rev. 
14(2): 155-174. 
Mowat AM (1989). "Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-
versus-host reaction." Immunology. 68(1): 18-23. 
Murphy WJ, Welniak LA, et al. (1998). "Differential effects of the absence of interferon-gamma and IL-4 in acute graft-
versus-host disease after allogeneic bone marrow transplantation in mice." J Clin Invest. 102(9): 1742-1748. 
Nakamura H, Komatsu K, et al. (2000). "Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients 
with acute graft-versus-host disease after allogeneic bone marrow transplantation." J Allergy Clin Immunol. 
106(1 Pt 2): 45-50. 
Nakanishi K, Yoshimoto T, et al. (2001). "Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 
responses depending on its cytokine milieu." Cytokine Growth Factor Rev. 12(1): 53-72. 
Niederwieser D, Herold M, et al. (1990). "Endogenous IFN-gamma during human bone marrow transplantation. 
Analysis of serum levels of interferon and interferon-dependent secondary messages." Transplantation. 50(4): 
620-625. 
Nishikawa H, Kato T, et al. (2005). "IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells 
in antitumor immune response." J Immunol. 175(7): 4433-4440. 
Norton J, Sloane JP, et al. (1992) "Expression of adhesion molecules in human intestinal graft-versus-host disease." Clin 
Exp Immunol. 87(2): 231-236. 
Norton J, Sloane JP, et al. (1993). "Reciprocal expression of CD34 and cell adhesion molecule ELAM-1 on vascular 
endothelium in acute cutaneous graft-versus-host disease." J Pathol. 170(2): 173-177. 
 101 
O'Brien S, del Giglio A, et al. (1995). "Advances in the biology and treatment of B-cell chronic lymphocytic leukemia." 
Blood. 85(2): 307-318. 
O'Garra A, Stockinger B, et al. (2008). "Differentiation of human TH-17 cells does require TGF-beta!" Nat Immunol. 
9(6):588-590. 
Ogawa S, Nagamatsu G, et al. (2001). "Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory 
molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host 
disease." J Immunol. 167(10): 5741-5748. 
Okamoto I, Kohno K, et al. (2000). "IL-18 prevents the development of chronic graft-versus-host disease in mice." J 
Immunol. 164(11): 6067-6074. 
Onciu M (2009). "Acute lymphoblastic leukemia." Hematol Oncol Clin North Am. 23(4): 655-674. 
Pachynski RK, Wu SW, et al. (1998). "Secondary lymphoid-tissue chemokine (SLC) stimulates integrin alpha 4 beta 7-
mediated adhesion of lymphocytes to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) under flow." J 
Immunol. 161(2): 952-956. 
Pallandre JR, Brillard E, et al. (2007). "Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: 
implications in graft-versus-host disease and antitumor immunity." J Immunol. 179(11): 7593-7604. 
Parfrey NA, El-Sheikh A, et al. (1999). "Interferon-gamma gene expression during acute graft-versus-host disease: 
relationship to MHC induction and tissue injury." J Pathol. 189(1): 99-104. 
Paulin T, Ringdén O, et al. (1987). "Variables predicting bacterial and fungal infections after allogeneic marrow 
engraftment." Transplantation. 43(3): 393-398. 
Pernis A, Gupta S, et al. (1995). "Lack of interferon gamma receptor beta chain and the prevention of interferon gamma 
signaling in TH1 cells." Science. 269(5221): 245-247. 
Petrovic A, Alpdogan O, et al. (2004). "LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive 
T cells in the development of intestinal graft-versus-host disease." Blood. 103(4): 1542-1547. 
Piller G (2001). "Leukaemia - a brief historical review from ancient times to 1950." Br J Haematol. 112(2): 282-292. 
Pinkoski MJ, Brunner T, et al. (2000). "Fas and Fas ligand in gut and liver." Am J Physiol Gastrointest Liver Physiol. 
278(3): G354-366. 
Pravica V, Asderakis A, et al. (1999). "In vitro production of IFN-gamma correlates with CA repeat polymorphism in 
the human IFN-gamma gene." Eur J Immunogenet. 26(1): 1-3. 
Przepiorka D, Weisdorf D, et al. (1995). "1994 Consensus Conference on Acute GVHD Grading." Bone Marrow 
Transplant. 15(6): 825-828. 
Pui CH, Schrappe M, et al. (2004). "Childhood and adolescent lymphoid and myeloid leukemia." Hematology Am Soc 
Hematol Educ Program.:118-145. 
Quintás-Cardama A and Cortes JE (2006). "Chronic myeloid leukemia: diagnosis and treatment." Mayo Clin Proc. 
81(7): 973-988. 
Radich JP, Sanders JE, et al. (1993). "Second allogeneic marrow transplantation for patients with recurrent leukemia 
after initial transplant with total-body irradiation-containing regimens." J Clin Oncol. 11(2): 304-313. 
Randolph SS, Gooley TA, et al. (2004). "Female donors contribute to a selective graft-versus-leukemia effect in male 
recipients of HLA-matched, related hematopoietic stem cell transplants." Blood. 103(1): 347-352. 
 102 
Reddy P and Ferrara JL (2003). "Immunobiology of acute graft-versus-host disease." Blood Rev. 17(4): 187-194. 
Reddy P, Teshima T, et al. (2001). "Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated 
donor T cell apoptosis." J Exp Med. 194(10): 1433-1440. 
Reddy P, Teshima T, et al. (2003). "Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host 
disease via STAT6 and preserves graft-versus-leukemia effects." Blood. 101(7): 2877-2885. 
Refaeli Y, Van Parijs L, et al. (2002). "Interferon gamma is required for activation-induced death of T lymphocytes." J 
Exp Med. 196(7): 999-1005. 
Renneville A, Roumier C, et al. (2008). "Cooperating gene mutations in acute myeloid leukemia: a review of the 
literature." Leukemia. 22(5): 915-931. 
Rezvani K, Mielke S, et al. (2006). "High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low 
risk of GVHD following HLA-matched allogeneic SCT." Blood. 108(4): 1291-1297. 
Rieger K, Loddenkemper C, et al. (2006). "Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and 
chronic GvHD." Blood. 107(4): 1717-1723. 
Robertson MJ and Ritz J (1990). "Biology and clinical relevance of human natural killer cells." Blood. 76(12): 2421-2438. 
Rosloniec EF, Latham K, et al. (2002). "Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity." 
Arthritis Res. 4(6): 333-336. 
Rowe V, Banovic T, et al. (2006). "Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic 
bone marrow transplantation." Blood. 108(7): 2485-2492. 
Sala-Torra O, Martin PJ, et al. (2008). "Serious acute or chronic graft-versus-host disease after hematopoietic cell 
transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens." Bone Marrow 
Transplant. 41(10): 887-893.  
Sather BD, Treuting P, et al. (2007). "Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific 
inflammatory disease." J Exp Med. 204(6): 1335-1347. 
Sawitzki B, Kingsley CI, et al. (2005). "IFN-gamma production by alloantigen-reactive regulatory T cells is important for 
their regulatory function in vivo." J Exp Med. 201(12): 1925-1935. 
Sayers TJ, Brooks AD, et al. (1998). "Molecular mechanisms of immune-mediated lysis of murine renal cancer: 
differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells." J 
Immunol. 161(8): 3957-3965. 
Schmitz N, Dreger P, et al. (1995). "Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by 
filgrastim (granulocyte colony-stimulating factor)" Blood. 85(6): 1666-1672. 
Schubert LA, Jeffery E, et al. (2001). "Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell 
activation." J Biol Chem. 276(40): 37672-37679. 
Segal BM, Dwyer BK, et al. (1998). "An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to 
autoimmune disease." J Exp Med. 187(4): 537-546. 
Sehgal SN (1998). "Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results 
from blockade of signal transduction and inhibition of cell cycle progression." Clin Biochem. 31(5): 335-340. 
Shaw SK and Brenner MB (1995). "The beta 7 integrins in mucosal homing and retention." Semin Immunol. 7(5): 335-
342. 
 103 
Sillaber C, Mayerhofer M, et al. (2003). "Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and 
current treatment concepts." Wien Klin Wochenschr. 2003 115(13-14): 485-504. 
Simpson D (2003). "T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow 
transplantation?" BioDrugs. 17(3): 147-154. 
Sims JE (2002). "IL-1 and IL-18 receptors, and their extended family." Curr Opin Immunol. 14(1): 117-122. 
Slavin S, Nagler A, et al. (1998). "Nonmyeloablative stem cell transplantation and cell therapy as an alternative to 
conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and 
nonmalignant hematologic diseases." Blood. 91(3): 756-763. 
Stone RM, O'Donnell MR, et al. (2004). "Acute myeloid leukemia." Hematology Am Soc Hematol Educ Program.: 98-
117. 
Storb R, Deeg HJ, et al. (1989). "Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-
versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a 
controlled trial." Blood. 1989 73(6): 1729-1734. 
Storb R, Prentice RL, et al. (1983). "Predictive factors in chronic graft-versus-host disease in patients with aplastic 
anemia treated by marrow transplantation from HLA-identical siblings." Ann Intern Med. 98(4): 461-466. 
Storb R and Thomas ED (1983). "Allogeneic bone-marrow transplantation." Immunol Rev. 71: 77-102. 
Sykes M, Romick ML, et al. (1990). "Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-
leukemia effect of allogeneic T cells." Proc Natl Acad Sci U S A. 87(15): 5633-5637. 
Sykes M, Sheard MA, et al. (1988). "Graft-versus-host-related immunosuppression is induced in mixed chimeras by 
alloresponses against either host or donor lymphohematopoietic cells." J Exp Med. 168(6): 2391-2396. 
Takahashi S, Ooi J, et al. (2007). "Comparative single-institute analysis of cord blood transplantation from unrelated 
donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with 
hematologic malignancies after myeloablative conditioning regimen." Blood. 109(3): 1322-1330. 
Takahashi T, Kuniyasu Y, et al. (1998). "Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and 
suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state." Int 
Immunol. 10(12): 1969-1980. 
Takami K, Takuwa N, et al. (2002). "Interferon-gamma inhibits hepatocyte growth factor-stimulated cell proliferation of 
human bronchial epithelial cells: upregulation of p27(kip1) cyclin-dependent kinase inhibitor." Am J Respir 
Cell Mol Biol. 26(2): 231-238. 
Taylor PA, Panoskaltsis-Mortari A, et al. (2005). "Targeting of inducible costimulator (ICOS) expressed on alloreactive 
T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone 
marrow (BM)." Blood. 105(8): 3372-3380. 
Teitell MA, Pandolfi PP, et al. (2009). "Molecular genetics of acute lymphoblastic leukaemia." Annu Rev Pathol. 4: 175-
198. 
Tenen DG (2003). "Disruption of differentiation in human cancer: AML shows the way." Nat Rev Cancer. 3(2): 89-101. 
Tesciuba AG, Shilling RA, et al. (2008). "ICOS costimulation expands Th2 immunity by augmenting migration of 
lymphocytes to draining lymph nodes." J Immunol. 181(2): 1019-1024. 
Teshima T and Ferrara JL (2002). "Understanding the alloresponse: new approaches to graft-versus-host disease 
prevention." Semin Hematol. 39(1): 15-22. 
 104 
Thomas ED, Lochte HL Jr, et al. (1959). "Supralethal whole body irradiation and isologous marrow transplantation in 
man." J Clin Invest. 38: 1709-1716. 
Thomas ED, Storb R, et al. (1975). "Bone-marrow transplantation (first of two parts)." N Engl J Med. 292(16): 832-43; 
895-902. 
Trinchieri G (1995). "Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate 
resistance and antigen-specific adaptive immunity." Annu Rev Immunol. 13: 251-276. 
Uzunel M (2003). "The Methodology and Significance of Minimal Residual Disease Detection after Allogeneic Stem Cell 
Transplantation" Karolinska Institute Stockholm. 
Van Vlierberghe P, Pieters R, et al. (2008). "Molecular-genetic insights in paediatric T-cell acute lymphoblastic 
leukaemia." Br J Haematol. 143(2): 153-168. 
Via CS and Shearer GM (1988). "T-cell interactions in autoimmunity: insights from a murine model of graft-versus-host 
disease." Immunol Today. 9(7-8): 207-213. 
Vogt MH, de Paus RA, et al. (2000). "DFFRY codes for a new human male-specific minor transplantation antigen 
involved in bone marrow graft rejection." Blood. 95(3): 1100-1105. 
Wagner JE, Kernan NA, et al. (1995). "Allogeneic sibling umbilical-cord-blood transplantation in children with 
malignant and non-malignant disease." Lancet. 346(8969): 214-219. 
Waller EK, Langston AA, et al. (2003). "Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in 
recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation." Biol Blood Marrow 
Transplant. 9(7): 460-471. 
Wallin JJ, Liang L, et al. (2001). "Enhancement of CD8+ T cell responses by ICOS/B7h costimulation." J Immunol. 
167(1): 132-139. 
Wang J, Ioan-Facsinay A, et al. (2007). "Transient expression of FOXP3 in human activated nonregulatory CD4+ T 
cells." Eur J Immunol. 37(1): 129-138. 
Wang W, Meadows LR, et al. (1995). "Human H-Y: a male-specific histocompatibility antigen derived from the SMCY 
protein." Science. 269(5230): 1588-1590. 
Warnatz K, Bossaller L, et al. (2006). "Human ICOS deficiency abrogates the germinal center reaction and provides a 
monogenic model for common variable immunodeficiency." Blood. 107(8): 3045-3052. 
Watford WT, Moriguchi M, et al. (2003). "The biology of IL-12: coordinating innate and adaptive immune responses." 
Cytokine Growth Factor Rev. 14(5): 361-368. 
Watanabe M, Takagi Y, et al. (2008). "Down-regulation of ICOS ligand by interaction with ICOS functions as a 
regulatory mechanism for immune responses." J Immunol. 180(8): 5222-5234. 
Weaver CT, Hatton RD, et al. (2007). "IL-17 family cytokines and the expanding diversity of effector T cell lineages." 
Annu Rev Immunol. 25: 821-852. 
Weiden PL, Sullivan KM, et al. (1981). "Antileukemic effect of chronic graft-versus-host disease: contribution to 
improved survival after allogeneic marrow transplantation." N Engl J Med. 304(25): 1529-1533. 
Welniak LA, Blazar BR, et al. (2000). "Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host 
disease: effects of conditioning." Biol Blood Marrow Transplant. 6(6): 604-612. 
Welniak LA, Blazar BR, et al. (2007). "Immunobiology of allogeneic hematopoietic stem cell transplantation." Annu Rev 
Immunol. 25: 139-170. 
 105 
Wiestner A, Rosenwald A, et al. (2003). "ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with 
unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile." Blood. 
101(12): 4944-4951. 
Williamson E, Garside P, et al. (1997). "Neutralizing IL-12 during induction of murine acute graft-versus-host disease 
polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from 
disease." J Immunol. 159(3): 1208-1215. 
Wright N, Hidalgo A, et al. (2002). "The chemokine stromal cell-derived factor-1 alpha modulates alpha 4 beta 7 
integrin-mediated lymphocyte adhesion to mucosal addressin cell adhesion molecule-1 and fibronectin." J 
Immunol. 168(10): 5268-5277. 
Yang YG, Dey BR, et al. (1998). "Donor-derived interferon gamma is required for inhibition of acute graft-versus-host 
disease by interleukin 12." J Clin Invest. 102(12): 2126-2135. 
Yang YG, Qi J, et al. (2002). "Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-
host disease induced by donor CD8 T cells." Blood. 99(11): 4207-4215. 
Yang YG, Wang H, et al. (2005). "Role of Interferon-gamma in GVHD and GVL." Cell Mol Immunol. 2(5): 323-329. 
Yang J, Zhu H, et al. (2001). "IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-
gamma production." Nat Immunol. 2(2): 157-164. 
Young HA and Hardy KJ (1995). "Role of interferon-gamma in immune cell regulation." Journal of Leukocyte Biology. 
58 (4): 373-381. 
Young NS (2006). "Pathophysiologic mechanisms in acquired aplastic anemia." Hematology Am Soc Hematol Educ 
Program.:72-77. 
Yu XZ, Liang Y, et al. (2006). "Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T 
cells." J Immunol. 176(12): 7394-7401. 
Zecchina G, Novick D, et al., (2001). "Interleukin-18 binding protein in acute graft versus host disease and engraftment 
following allogeneic peripheral blood stem cell transplants." J Hematother Stem Cell Res. 10(6): 769-776. 
Zeeb H and Blettner M (1998). "Adult leukaemia: what is the role of currently known risk factors?" Radiat Environ 
Biophys. 36(4): 217-228. 
 
 
 
"I exerted myself for seeking after all owners of the picture rights and got their agreement for using the 
pictures in my work. However, if any copyright infringement should emerge, please contact me." 
 
 
 
 
 106 
11 Cirrculum vitae 
 
Personal Information: 
Name:   Sylvia Ruhm 
Date of Birth:   November 17th, 1983 
Place of Birth:   Feldkirch 
Citizenship:  Austria 
 
Education: 
2009 – 2010: Project Work "The immunosuppressive effects of skin fibroblasts, cord and placenta-
derived cells" in Olle Ringdén’s group at the Karolinska Institute, Huddinge 
University Hospital in Stockholm, Sweden 
2008 – 2009: Diploma Thesis in the group of Mehmet Uzunel and Olle Ringdén at the Karolinska 
Institute, the Division of Clinical Immunology at the Department Laboratory 
Medicine, Huddinge University Hospital in Stockholm 
2007 – 2008: Immunology Course at the University of Stockholm and Laboratory Practice at the 
Karolinska Institute, Huddinge University Hospital in Stockholm 
2004 – 2007: Study of Genetics with Immunology as major study subject at the University of 
Vienna 
2003 – 2004: Basic Study of Biology at the University of Vienna 
2002 – 2003: Study of Civil Engineering at the Technical University of Vienna 
2002, June: Final Examination (Matura) 
1994 – 2002: Grammar School with humanistic education, Bundesgymnasium Feldkirch 
1990 – 1994: Elementary School in Feldkirch/Tosters 
 
Languages: 
German (mother tongue) 
English (very well understanding and speaking fluently) 
Swedish (very well understanding and speaking fluently) 
French (quite well understanding and writing, but out of practice) 
Spanish (basic understanding and speaking) 
 107 
12 Zusammenfassung auf Deutsch 
 
Die Transplantation von hämatopoetischen Stammzellen (HSCT) ist eine häufig angewandte Therapieform 
bei Patienten mit blutbildenden Störungen, bei denen konventionelle Chemotherapie nicht durchgeführt 
werden konnte bzw. erfolglos war. Die Hauptkomplikation nach HSCT ist neben Rezidiv (Rückfall der 
Krankheit) graft-versus-host Reaktion (GVHD), bei der immunokompetente Donatorzellen Wirtszellen als 
fremd erkennen können und eine Immunantwort gegen den Wirt starten. Diese Erkennung erfolgt durch 
Unterschiede in den humanen Leukozytenantigenen (HLA) zwischen Donator und Wirt. GVHD führt zu 
Gewebeschäden, die zuerst den Thymus, sekundäre lymphoide Gewebe, die Haut, Leber und den 
Verdauungstrakt schädigen, aber auch zum Tod führen kann. Es ist daher von großem Interesse GVHD so 
früh wie möglich zu diagnostizieren um rasch mit einer Behandlung beginnen zu können und den weiteren 
Verlauf der Reaktion zu unterbinden. Heutzutage wird GVHD nur über klinische Symptome diagnostiziert. 
Das Ziel unserer Studie ist es molekulare Marker zu finden um GVHD diagnostizieren und prognostizieren 
zu können bevor Symptome auftreten, sowie den Ausgang von HSCT in weiteren Studien verbessern zu 
können, indem GVHD durch die Beeinflussung von regulatorischen Molekülen verringert wird. 
Bei unserer Studie waren 76 Patienten, die alle mit allogenetischer HSCT behandelt wurden, mit einem 
Durchschnittsalter von 45 Jahern beteiligt. Leukämie und Myelodysplastisches Syndrom (MDS) waren die 
Haupterkrankungen der Patienten. Knochenmarksstammzellen (BMSC) und periphere Blutstammzellen 
(PBSC) waren die am meisten verwendeten Stammzellenquellen für HSCT, wobei 7 Patienten 
Nabelschnurstammzellen (CBSC) als Transplantat erhielten. Wir analysierten die Genexpressionsniveaus von 
IFN-γ, IL-10, IL-18, ICOS, Foxp3, FuT7 und B7-int in CD4+ und CD8+ T Zellen vor der HSCT und zu 
unterschiedlichen Zeitpunkten danach, sowie die Genexpressionsniveaus der Donatorzellen mithilfe von 
Realzeit quantitativer-PCR (RQ-PCR). Mittels enzyme-linked immunosorbent assay (ELISA) maßen wir die 
Cytokinproteinniveaus der Donatoren und Patienten (zu unterschiedlichen Zeitpunkten) von IFN-γ, IL-10, 
IL-18, IL-12, IL-17 und IL-23 im Plasma. Die Genexpressions- und Proteinplasmaniveaus wurden analysiert 
um eine Korrelation zwischen diesen Niveaus und dem Auftreten von GVHD zu finden. 
Schlussfolgernd könnte IFN-γ als molekularer Prognosemarker für eine GVHD-Entwicklung verwendet 
werden und IL-18, Foxp3, FuT7 sowie ICOS als mögliche Diagnosemarker. Am Tag der HSCT korrelieren 
höhere IFN-γ Plasmaniveaus (> 200 pg/ml) mit einem verringerten Auftreten von aGVHD (p = 0.009) und 
die Plasmaniveaus von IL-18 sind am Entstehungstag von GVHD erhöht (p < 0.001). Die 
Genexpressionsniveaus von Foxp3 (p = 0.005 – 0.020), FuT7 (p = 0.001 – 0.023) und ICOS (p = 0.005 – 
0.029) sind zu unterschiedlichen Zeitpunkten nach der HSCT im Falle von GVHD erhöht. 
IFN-γ ist möglicherweise ein Schlüsselcytokin. Durch das Eingreifen in die Produktion von IFN-γ könnte 
vielleicht das Auftreten von aGVHD verringert werden. 
 
